Common use of Terms Defined Elsewhere Clause in Contracts

Terms Defined Elsewhere. The following is a list of additional terms used in this Agreement and a reference to the Section hereof in which such term is defined: Agreement Preamble Biogen Idec License Agreement Section 4.7 Biogen Idec Supply Agreement Section 4.7 Books and Records Section 2.12(f)(2) Claim Notice Section 8.3(a) Closing Section 2.3 Closing Date Section 2.3 Company Preamble Company Common Stock Section 2.8 Company Disclosure Schedule Article IV Company Expenses Schedule Section 2.13 Company Indemnified Parties Section 8.2(a)(ii) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g)

Terms Defined Elsewhere. The following is a list of additional Other than the terms used defined in this Agreement and a reference to Exhibit B, the following terms are defined elsewhere in the Agreement, as indicated below: Additional Issuer SEC Reports Section hereof in which such term is defined: 2.7(a) Agreement Preamble Biogen Idec License Agreement Aggregate Principal Amount Section 4.7 Biogen Idec Supply Agreement 1.1 Bankruptcy and Equity Exception Section 4.7 Books and Records 2.3(a) BCA Recitals Change in Recommendation Section 2.12(f)(2) Claim Notice Section 8.3(a7.11(a) Closing Section 2.3 1.4(a) Closing Conditions Article VI Closing Date Section 2.3 1.4(a) Closing Notice Section 1.4(b) Company Preamble Company Common Stock Disclosure Schedule(s) Article III Company Fundamental Representations Section 2.8 5.1(a) Company Disclosure Schedule Article IV Leased Real Property Section 3.18(b) Company Expenses Schedule Owned Real Property Section 2.13 3.18(a) Company Indemnified Parties Property Section 8.2(a)(ii3.18(b) Contracts Company Real Property Lease Section 4.8(a3.18(b) Covered Company Related Party (PartiesSection 3.21 Company Related Party Transactions Section 3.21 Contract Property Section 3.18(e) Conversant Investor Recitals Conversant Subscription Agreement Recitals Convertible Notes Recitals Current Credit Agreement Section 8.2(a)(ii7.8(f) Damages Section 8.2(a)(i9.2(a)(i) DGCL Designated Court(s) Section 2.1 9.16 Disclosure Document Retention Period Section 2.12(f)(27.5(a) Drug Regulatory Agency Disclosure Schedule(s) Article III Effectiveness Date Section 4.25 Effective Time 7.3(a) Election Notice Section 2.2 ERISA 7.7(c) Filing Deadline Section 4.13(a7.3(a) ERISA Affiliate Final Offer Notice Section 4.13(a7.7(b) Finally Determined Financial Statements Section 8.5(b3.4(a) First Milestone Indemnified Breaches Section 2.10(e) First Milestone Payment Amount Section 2.10(e9.2(a)(i) Indemnifying Party Section 8.3(a9.2(a)(i) Instrument Initial Offer Notice Section 2.12(c7.7(b) Merger Insurance Policies Section 2.1 Merger Certificate 3.15 Interim Financial Statements Section 2.2 Merger Sub 3.4(a) Investor Indemnified Persons Section 9.2(a)(i) Investor Subscription Agreement Recitals Investor(s) Preamble Parent Preamble Parent Disclosure Schedule Investor’s Closing Conditions Article V Parent IPO Prospectus Section 7.6(a) Issuance Approval Section 2.2(b) Issuance Approval Meeting Section 7.11(a) Issuance Approval Meeting Deadline Section 7.11(a) Issuance Approval Proxy Statement Section 7.11(a) Issuer Preamble Issuer Board Section 2.2(b) Issuer Board Recommendation Section 2.2(b) Issuer Companies Recitals Issuer Disclosure Schedule(s) Article II Issuer Fundamental Representations Section 5.1(a) Issuer Indemnified Parties Persons Section 8.2(a)(i9.2(b) parties Preamble Payee Issuer Related Party Section 8.5 Payor 2.9 Issuer Related Party Transactions Section 8.5 Per Diem Taxes 2.9 Issuer SEC Reports Section 8.7(a2.7(a) Proceeding Issuer’s and Company’s Closing Conditions Article VI Latest Balance Sheet Section 4.17 Royalties 3.4(a) Material Contracts Section 2.10(h3.7(a) Second Milestone Material Permits Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g)3.6

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: 401(k) Plan Section hereof in which such term is defined: 5.07(d) Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 5.03(d)(i) Book-Entry Shares Section 4.7 Books and Records 2.02(b) Capitalization Date Section 2.12(f)(23.02(a) Claim Notice Certificate of Merger Section 8.3(a1.02 Certificates Section 2.02(b) Change of Board Recommendation Section 5.03(a)(v) Closing Section 2.3 1.02 Closing Date Section 2.3 1.02 Company Preamble Company Common Stock Section 2.8 Board Recitals Company Board Recommendation Recitals Company Disclosure Schedule Article IV ARTICLE III Company Expenses Schedule Employees Section 2.13 5.07(a) Company Indemnified Parties Financial Statements Section 8.2(a)(ii3.07(a) Contracts Company Material Contract Section 4.8(a3.13(a) Covered Party (PartiesCompany Permits Section 3.05(a) Company Preferred Stock Section 8.2(a)(ii3.02(a) Damages Company Representatives Section 8.2(a)(i5.02(a) Company SEC Documents Section 3.06(a) Company Stockholder Approval Section 3.21 Confidentiality Agreement Section 5.02(c) D&O Indemnification Agreements Section 5.08(a) D&O Runoff Insurance Section 5.08(c) DGCL Recitals Dispute Section 2.1 Document Retention Period 3.15(l) Dissenting Shares Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 2.03 Effective Time Section 2.2 ERISA 1.02 Electronic Delivery Section 4.13(a8.13 Employment Practices Section 3.12(a) ERISA Affiliate Exon-▇▇▇▇▇▇ Filing Section 4.13(a5.04(c) Finally Determined Export Approvals Section 8.5(b3.05(e) First Milestone Full Value Award Section 2.10(e2.04(b) First Milestone Payment Fundamental Representations Section 6.02(a)(ii) Guarantee Section 8.15(c) Guaranteed Obligations Section 8.15(a) Guarantor Section 8.15(a) Indentures Section 5.14 Independent Director Section 3.12(h) Insurance Policies Section 3.17 Intercompany Contracts Section 3.13(a)(vii) Intervening Event Notice Period Section 5.03(e)(i) Leased Real Property Section 3.18(c) LGPL Section 3.15(f) Maximum Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c5.08(c) Merger Section 2.1 Recitals Merger Certificate Section 2.2 Consideration Recitals Merger Sub Preamble Most Recent Balance Sheet Section 3.09(a)(i) New Plans Section 5.07(a) Parent Preamble Parent Disclosure Schedule Article V Representatives Section 5.02(a) Parent Indemnified Parties Subsidiary Section 8.2(a)(i4.03(a) parties Preamble Payee Parent Welfare Plan Section 8.5 Payor 5.07(a) Paying Agent Section 8.5 Per Diem Taxes 2.02(a) Proxy Statement Section 8.7(a1.03(a) Proceeding Replacement Right Section 4.17 Royalties 2.04(b) ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 2.10(h3.06(a) Second Milestone Section 2.10(f16 Section 5.10 Shares Recitals Significant Customer Section 3.23 Special Meeting Section 1.03(e) Second Milestone Payment Amount Superior Proposal Notice Period Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b5.03(d)(i) Surviving Corporation Recitals Takeover Law Section 2.1 Third Milestone 3.03(b) Termination Fee Section 2.10(g7.02(b) Third Milestone Payment Amount U.S. Continuing Employees Section 2.10(g5.07(a) Voting Agreement Recitals WARN Act Section 3.12(e) Worker List Section 3.12(f)

Terms Defined Elsewhere. The Each of the following is a list of additional terms used in this Agreement and a reference has the meaning ascribed to the Section hereof in which such term is definedin the Article or Section set forth opposite such term: Accounts Receivable Section 3.23(a) Additional Parent Filings Section 5.05(f) Affiliate Transactions Section 3.26(a) Agent Section 7.04(a) Agreed Claims Section 7.03(c) Agreement Preamble Biogen Idec License Agreement Alternative Acquisition Section 4.7 Biogen Idec Supply Agreement 5.01(f) Attorney Section 4.7 Books and Records 7.04(g) Bid Section 2.12(f)(23.19(a) Board Recitals Booked Revenue Section 3.09(e) Bridge Notes Section 2.04(b) Change in Recommendation Section 5.05(f) Claim Notice Section 8.3(a7.04(k) Claim Certificate Section 7.03(a) Closing Section 2.3 2.01(c) Closing Date Section 2.3 2.01(c) Closing Form 8-K Section 5.05(g) Closing Press Release Section 5.05(g) Collateral Source Section 7.02 Communication Policy Section 5.01(h) Company Preamble Company Common Stock Employee Benefit Plan Section 2.8 3.14(a) Company Disclosure Schedule Article IV Government Contract Section 3.19(a) Company Expenses Schedule Government Subcontract Section 2.13 3.19(a) Company Indemnified Parties Group Section 8.2(a)(ii8.15(a) Contracts Company Prepared Returns Section 4.8(a5.04(a) Covered Party (PartiesCompany Unitholder Approval Recitals Control Section 1.01 Copyrights Section 1.01 D&O Beneficiary Section 5.09(b) D&O Claim Section 8.2(a)(ii5.09(b) Damages D&O Provisions Section 8.2(a)(i5.09(a) DGCL Data Room Section 2.1 Document Retention Period 8.05 Deductible Section 2.12(f)(27.01(b) Drug Regulatory Agency Deposit Materials Section 4.25 2.02(b) Director Nomination Agreement Section 2.04(b) DLLCA Recitals Earn Out Shares Section 2.06(a) Effective Time Section 2.2 ERISA 2.01(d) Environmental Permits Section 4.13(a3.17 Eos Companies Interim Financial Statements Section 3.04(a) ERISA Affiliate Escrow Agent Section 4.13(a2.04(b) Finally Determined Excluded Units Section 8.5(b2.02(a)(ii) Financial Statements Section 3.04(a) First Milestone Certificate of Merger Section 2.10(e2.01(d) First Milestone Payment Amount Merger Recitals First Surviving Company Recitals Formula Section 2.10(e2.02(b) Indemnified Matters Section 7.01(a) Indemnified Persons Section 5.09(a) Indemnifying Party Section 8.3(a7.03(c) Instrument Intended Tax Treatment Recitals Internal Controls Section 2.12(c3.04(a) Merger IRS Section 2.1 Merger Certificate 3.14(a) Latest Balance Sheet Section 2.2 3.04(a) LTIP Section 5.01(e) Material Customer Section 3.09(c) Material Contract Section 3.09(b) Mergers Recitals Merger Sub I Preamble Merger Sub II Preamble New Customer Contracts Section 3.09(a) Newco Section 5.14(a) Newco Merger Sub Section 5.14(a) Non-Party Affiliate Section 5.11 Obligations Section 7.04(a) Ordinary Course of Business Section 8.05 Outside Date Section 6.01(c) Parent Preamble Parent Disclosure Schedule Article V Class A Common Section 4.05(a) Parent Indemnified Class B Common Section 4.05(a) Parent Warrants Section 4.05(a) Parent SEC Reports Section 4.08 Parent Stockholder Group Section 8.15 Party Preamble Patents Section 1.01 Permits Section 3.16(b) Pledged Collateral Section 7.04(a) Pledged Shares Section 7.04(a) Pledgor Section 7.04(a) Pre-Closing Period Section 5.01(a) Pre-Closing Reorganization Section 5.14(a) Privileged Communications Section 8.15 Purchaser Indemnitees Section 7.01(a) Registration Rights Agreement Section 2.04(b) Second Certificate of Merger Section 2.01(d) Second Effective Time Section 2.01(d) Second Merger Recitals Securityholder Representative Preamble Signing Press Release Section 5.05(b) Sponsor Section 2.04(b)(x) Sponsor Earn Out Agreement Section 2.04(b)(x) Trademarks Section 1.01 Transfer Taxes Section 5.04(e) Triggering Event Section 2.06(a) UCC Section 7.04(b) Ultimate Surviving Company Recitals Unitholder Letter of Transmission Section 2.03(b) Waiving Parties Section 8.2(a)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g)8.15

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: Adverse Recommendation Change Section hereof in which such term is defined: 6.2(c) Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 6.2(c) Arbitrator Section 4.7 Books and Records 10.8(b) Base Premium Section 2.12(f)(27.4(d) Claim Notice CICA Section 8.3(a) 2.1 Closing Section 2.3 2.2 Closing Date Section 2.3 2.2 Company Preamble Company Common Stock Benefit Plans Section 2.8 4.12(a) Company Disclosure Schedule Article IV Board Recitals Company Expenses Schedule Board Recommendation Recitals Company Equity Interests Section 2.13 4.2(a) Company Indemnified Parties Group Section 8.2(a)(ii9.2(h) Contracts Company Material Properties Section 4.8(a4.19(b) Company Permits Section 4.18(b) Company Termination Fee Section 9.2(e) Competing Proposal Section 6.2(g) Contract Section 4.15(a) Covered Party (PartiesPersons Section 7.4(a) Data Protection Laws Section 8.2(a)(ii4.17(j) Damages Dissenting Shareholders Section 8.2(a)(i3.5(a) DGCL Dissenting Shares Section 2.1 Document Retention Period 3.5(a) Dollars Section 2.12(f)(21.3(c) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA 2.3 Enforceability Exceptions Section 4.13(a4.3 EP toxicity Section 1.1 Equity Commitment Letters Section 5.5(a) ERISA Affiliate Equity Financing Section 4.13(a5.5(a) Finally Determined Exchange Act Section 8.5(b4.5 Exchange Fund Section 3.4(a) First Milestone FCPA Section 2.10(e4.18(c) First Milestone Payment Amount Financial Statements Section 2.10(e4.6(b) Indemnifying Party GAAP Section 8.3(a4.6(b) Instrument Governmental Entity Section 2.12(c4.5 HKIAC Section 10.8(b) Indemnification Agreements Section 7.4(a) Intervening Event Section 6.2(d) IP Rights Agreements Section 4.17(d) Legal Proceeding Section 4.11 Limited Guarantee Recitals Material Contract Section 4.15(b) Merger Recitals Merger Consideration Section 3.4(a) Merger Sub Recitals NASDAQ Section 4.5 Open Source Materials Section 4.17(j) Parent Parent Parent Group Section 9.2(h) Parent Group Contracts Section 5.8 Parent Termination Fee Section 9.2(f) Party Preamble Paying Agent Section 3.4(a) Per Share Merger Consideration Section 3.1(a) Plan of Merger Section 2.3 PRC Subsidiaries Section 4.10(a) Protected Information Section 4.17(i) Proxy Statement Section 4.5 Record Date Section 6.4(a) Registrar of Companies Section 2.3 Risk Factors Article IV Rules Section 10.8(b) Sanctions Section 4.18(c) ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 4.6(a) Schedule 13E-3 Section 6.3(a) SEC Section 4.5 SEC Documents Section 4.6(a) Securities Act Section 4.6(a) Share Certificates Section 3.4(b)(i) Special Committee Recitals Superior Proposal Section 6.2(h) Support Agreement Recitals Surviving Entity Section 2.1 Merger Certificate Takeover Statute Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties 4.25 Transaction Litigation Section 8.2(a)(i7.7 Transactions Recitals Uncertificated Shares Section 3.4(b)(i) parties Preamble Payee VIE Contracts Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g4.10(c)

Terms Defined Elsewhere. The following is a list of additional terms used in this Agreement and a reference to the Section Article hereof in which such term is defined: Actual Closing Balance Sheet Section 3.4(d) Actual Closing Date Cash Section 3.4(d) Actual Closing Date Indebtedness Section 3.4(d) Actual Working Capital Section 3.4(d) Acquisition Transaction Section 7.6(a) Adjusted Merger Consideration Section 3.4(f) Agreement Preamble Biogen Idec License Agreement Assumed Option Recitals Bankruptcy and Equity Exception Section 4.7 Biogen Idec Supply Agreement 4.2 Base Balance Sheet Section 4.7 Books 4.6 Base Merger Consideration Section 3.2(a)(i) Cash, Indebtedness and Records Expenses Schedule Section 2.12(f)(23.1(h) Claim Notice Certificate of Merger Section 8.3(a) 2.2 Closing Section 2.3 Closing Date Section 2.3 Common Stock Section 3.1(b) Company Preamble Company Common Stock Dissenting Shares Section 2.8 3.5 Company Terminating Breach Section 9.1(d) Continuing Employee Section 7.14(a) Deductible Section 10.4(a) DGCL Section 2.1 Disclosure Schedule Article IV Company Expenses Schedule Section 2.13 Company Indemnified Parties Section 8.2(a)(ii) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 Employee Benefit Program Section 4.18(a) ERISA Section 4.13(a4.18(a) ERISA Affiliate Escrow Account Section 4.13(a3.3(a) Finally Determined Escrow Agent Section 8.5(b3.3(a) First Milestone Escrow Agreement Section 2.10(e3.3(a) First Milestone Payment Escrow Amount Section 2.10(e3.3(a) Estimated Closing Balance Sheet Section 3.4(a) Estimated Closing Date Cash Section 3.4(a) Estimated Closing Date Indebtedness Section 3.4(a) Estimated Working Capital Section 3.4(a) Excepted Representations Section 10.1 Final Closing Balance Sheet Section 3.4(b) Final Closing Date Cash Section 3.4(b) Final Closing Date Indebtedness Section 3.4(b) Final Working Capital Section 3.4(b) Financial Information Section 4.6 Firm Section 3.4(c) Fundamental Representations Section 10.1 HSR Act Section 4.2 Indemnified Party Section 10.3 Indemnifying Party Section 8.3(a10.3 Initial Merger Consideration Section 3.2(a) Instrument Interim Period Section 2.12(c7.1(a) Investor Restricted Period Section 7.7(b) Investor Restricted Stockholder Section 7.7(b) Losses Section 10.2 Management Restricted Period Section 7.7(b) Management Restricted Stockholder Section 7.7(b) Material Contract Section 4.13 Material Stockholder Preamble Merger Section 2.1 Merger Certificate Section 2.2 Recitals Merger Sub Preamble Parent Preamble Parent Disclosure Net Working Capital Target Section 3.2(a)(iii) November 30, 2007 Unaudited Financials Section 4.6 Objection Notice Section 3.4(c) Other Stockholders Recitals Parachute Payment Waiver Section 7.14(e) Payment Schedule Article V Parent Indemnified Parties Section 8.2(a)(i3.1(g) parties Preamble Payee Preferred Stock Section 8.5 Payor 3.1(b) Privacy Policy Section 8.5 Per Diem Taxes 4.13(d) Released Persons Section 8.7(a7.9 Reserve Account Section 3.2(e) Proceeding Special Representations Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent 10.1 Stockholders Recitals Stockholder Stockholders’ Representative Preamble Super Majority Stockholder Indemnified Party Section 2.12(b) 10.3 Stockholder Indemnifying Party Section 10.2 Surviving Corporation Section 2.1 Third Milestone Tax Reduction Section 2.10(g7.11(b) Third Milestone Payment Amount Termination Date Section 2.10(g)9.1(f) Ticketmaster Preamble Ticketmaster Indemnified Party Section 10.2 Ticketmaster Indemnifying Party Section 10.3 Ticketmaster Plans Section 7.14(b) Ticketmaster Shares Section 6.3(a) Ticketmaster Terminating Breach Section 9.1(e) Transactions Section 2.1

Terms Defined Elsewhere. The following is a list of additional terms used in this Agreement and a reference to the Section hereof in which such term is defined: 20-20 Purchase Agreement 4.37 Agreement Preamble Biogen Idec License Agreement Benefit Plan(s) Section 4.7 Biogen Idec Supply Agreement 4.14(a) CERCLA Section 4.7 Books and Records Section 2.12(f)(2) 4.13 Claim Notice Section 8.3(a9.3(a) Closing Section 2.3 Closing Date Section 2.3 Company Preamble Company Common Stock Dissenting Shares Section 2.8 2.11 Company Disclosure Schedule Article IV Marks Section 4.20(b) Company Expenses Schedule Patents Section 2.13 4.20(c) Company Indemnified Parties Registered Copyrights Section 8.2(a)(ii4.20(d) Contracts Company Registered IP Section 4.8(a4.20(g) Company SEC Reports Section 4.10(a) Company Software Section 4.20(l) Company Stockholder Meeting Section 6.9(d) Copyrights Section 4.20(a) Covered Matter Section 9.2(a) Covered Party (PartiesSection 9.2(a) D&O Insurance Section 8.2(a)(ii6.12(a) Damages Section 8.2(a)(i9.2(a) Principal Stockholder Representative Section 2.13(a) DGCL Section 2.1 Document Retention Period Dispute Notice Section 2.12(f)(29.3(b) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 Employee Loans Section 4.8(a) ERISA Section 4.13(a4.14(a) ERISA Affiliate Section 4.13(a4.14(a) Finally Determined Escrow Account Section 8.5(b2.9(a) First Milestone Escrow Earnings Section 2.10(e2.9(a) First Milestone Payment Excess D&O Policy Amount Section 2.10(e6.12(a) Indemnifying Party Exchange Act Section 8.3(a4.10(a) Instrument Final Aggregate Outstanding Claims Section 2.12(c2.9(d) Final Retained Escrow Amount Section 2.9(d) Financial Statement Section 4.10(b) Hazardous Materials Section 4.13 Inbound License Agreements Section 4.20(i) Initial Aggregate Outstanding Claims Section 2.9(b) Initial Retained Escrow Amount Section 2.9(b) Intellectual Property Section 4.20(a) IRS Section 4.14(d) Kinderhook Section 2.9(a) Marks Section 4.20(a) Material Contracts Section 4.8(a) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Most Recent Balance Sheet Section 4.10(c) Outside Date Section 8.1(b) Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Patents Section 8.2(a)(i4.20(a) parties Preamble Payee Personal Element Section 8.5 Payor 4.20(p)(v) Principal Stockholder Representative Section 8.5 Per Diem Taxes 2.13 Privacy Policies Section 8.7(a4.20(p)(i) Proceeding Section 4.18 Pro Rata Portion Section 9.5(d) Proxy Statement Section 4.17 Royalties Real Property Section 2.10(h4.5(c) Second Milestone SEC Section 2.10(f4.10(a) Second Milestone Payment Securities Act Section 4.10(a) Software Section 4.20(l) Subsequent Aggregate Outstanding Claims Section 2.9(c) Subsequent Retained Escrow Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b2.9(c) Surviving Corporation Section 2.1 Third Milestone Tax(es) Section 2.10(g4.12(a)(i) Third Milestone Payment Tax Return Section 4.12(a)(ii) Taxable Section 4.12(a)(i) Termination Fee Section 8.2(b) Threshold Amount Section 2.10(g)9.5(a) Trade Secrets Section 4.20(a) Transaction Fee Schedule Section 2.14 Unaccrued Litigation and Consumer Complaints Section 4.36 User Data Section 4.20(p)(v) Unique Identifying Number Section 4.20(p)(v) Voting Agreement Recitals

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: Action Section hereof in which such term is defined: 4.09 Agreement Preamble Biogen Idec License Agreement Arbitrator Section 4.7 Biogen Idec Supply Agreement 10.08(b) Base Premium Section 4.7 Books and Records Section 2.12(f)(2) Claim Notice Section 8.3(a7.04(d) Closing Section 2.3 2.02 Closing Date Section 2.3 2.02 Company Preamble Company Common Stock Board Recitals Company Equity Interests Section 2.8 4.02(a) Company Disclosure Schedule Article IV Group Section 9.02(d) Company Expenses Schedule Termination Fee Section 2.13 Company Indemnified Parties 9.02(b) Competing Proposal Section 8.2(a)(ii) Contracts Section 4.8(a6.02(d) Covered Party (PartiesPersons Section 7.04(a) Deposit Agreement Section 8.2(a)(ii3.05 Depositary Section 3.05 Dissent Notice Section 3.06(d) Damages Dissent Right Section 8.2(a)(i3.06(d) DGCL Dissenting Shareholders Section 2.1 Document Retention Period 3.06(a) Dissenting Shares Section 2.12(f)(23.06(a) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA 2.03 Enforceability Exceptions Section 4.13(a4.03 Equity Commitment Letter Section 5.05(a) ERISA Affiliate Equity Commitment Letters Section 4.13(a5.05(a) Finally Determined Equity Financing Section 8.5(b5.05(a) First Milestone GAAP Section 2.10(e4.06(b) First Milestone Payment Amount Governmental Entity Section 2.10(e4.05 HKIAC Section 10.08(b) Indemnifying Party HKIAC Rules Section 8.3(a10.08(b) Instrument Indemnification Agreements Section 2.12(c7.04(a) Intervening Event Section 6.02(h) Intervening Event Termination Section 6.02(h) Legal Proceeding Section 5.06 Limited Guarantee Recitals Merger Recitals Merger Consideration Section 3.02(a) Merger Consideration Fund Section 2.1 Merger Certificate Section 2.2 3.02(a) Merger Sub Preamble Non-Required Remedy Section 7.02(d) NYSE Section 4.02(a) OTC Market Section 4.02(a) Parent Preamble Parent Disclosure Group Section 9.02(d) Parent Termination Fee Section 9.02(c) Parties Preamble Party Preamble Paying Agent Section 3.02(a) Per ADS Merger Consideration Section 3.01(b) Per Share Merger Consideration Section 3.01(a) Plan of Merger Section 2.03 Record ADS Holders Section 6.03(c) Record Date Section 6.03(c) Rollover Agreements Recitals Rollover Shareholders Recitals ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 4.06(a) Schedule Article V Parent Indemnified Parties 13E-3 Section 8.2(a)(i6.03(a) parties Preamble Payee SEC Documents Section 8.5 Payor 4.06(a) Securities Act Section 8.5 Per Diem Taxes 4.06(a) Share Certificates Section 8.7(a3.02(b)(i) Proceeding Special Committee Recitals Superior Proposal Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b6.02(f) Surviving Corporation Company Section 2.1 Third Milestone 2.01 Takeover Statute Section 2.10(g) Third Milestone Payment Amount 7.05 Transaction Litigation Section 2.10(g7.07 Transactions Recitals Uncertificated Shares Section 3.02(b)(i)

Terms Defined Elsewhere. The Each of the following is a list of additional terms used in this Agreement and a reference has the meaning ascribed to the Section hereof in which such term is definedin the Article or Section set forth opposite such term: Accounts Receivable Section 3.23(a) Additional Parent Filing Section 6.7(f) Agreement Preamble Biogen Idec License Alta Companies Interim Financial Statements Section 3.4(a) Altenative Acquisition Section 6.1(e) Alternative Financing Section 6.15(c) Antitrust Laws Section 6.2(c) Applicable Limitation Date Section 6.4(c) Bid Section 3.19(a) Binder Agreement Section 4.7 Biogen Idec Supply Agreement 6.3(a) Board Recitals Cash Consideration Section 4.7 Books and Records 1.1 Certificate of Merger Section 2.12(f)(22.1(d) Claim Notice Change in Recommendation Section 8.3(a6.7(f) Closing Section 2.3 2.1(c) Closing Date Section 2.3 2.1(c) Closing Form 8-K Section 6.7(g) Closing Press Release Section 6.7(g) Communication Policy Section 6.1(g) Company Preamble Company Common Stock Employee Benefit Plan Section 2.8 3.14(a) Company Disclosure Schedule Article IV Government Contract Section 3.19(a) Company Expenses Schedule Government Subcontract Section 2.13 3.19(a) Company Indemnified Parties Shareholder Approval Recitals Control Section 8.2(a)(ii1.1 Data Room Section 8.5 Debt Commitment Letters Section 5.6 Debt Financing Section 5.6 Definitive Debt Agreement Section 6.15(a) Contracts D&O Provisions Section 4.8(a6.11(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA 2.1(d) Environmental Permits Section 4.13(a3.17 EquityHolder Preamble Equityholder Prepared Returns Section 6.6(a) ERISA Affiliate Excluded Shares Section 4.13(a2.2(b) Finally Determined Fee Letter Section 8.5(b5.6 Financial Statements Section 3.4(a) First Milestone Indemnified Persons Section 2.10(e6.11(a) First Milestone Payment Amount Indemnitee Section 2.10(e6.5(e) Indemnifying Party Indemnitor Section 8.3(a6.5(e) Instrument Intended Tax Treatment Recitals Interim Financial Statement Section 2.12(c3.4(a) Internal Controls Section 3.4(b) IRS Section 3.14(a) Latest Balance Sheet Section 3.4(a) LTIP Section 6.1(d) Material Customer Section 3.9(c) Material Contract Section 3.9(b) Merger Section 2.1 Merger Certificate Section 2.2 Recitals Merger Sub Preamble NITCO Section 3.4(a) Non-Party Affiliate Section 6.14 Ordinary Course of Business Section 8.5 Outside Date Section 7.1(c) Parent Preamble Parent Disclosure Schedule Article V Prepared Returns Section 6.6(a) Parent Indemnified Parties Related party Section 8.2(a)(i7.3(b) parties Party Preamble Payee Permits Section 8.5 Payor 3.16(b) Per Share Merger Consideration Section 8.5 Per Diem 2.2(a) Pre-Closing Period Section 6.1(a) Registration Rights Agreement Section 2.4(b)(v)(I) Restrictive Covenants Section 6.16(d) R&W Deductible Section 6.3(a) R&W Insurance Company Section 6.3(a) R&W Insurance Policy Section 6.3(a) Signing Form 8-K Section 6.7(b) Signing Press Release Section 6.7(b) Stock Consdieration Section 1.1 Surviving Company Section 2.1(a) Tail Policy Section 6.11(b) Tax Contest Section 6.6(b) Third-Party Recovery Proceeds Section 6.5(d) Trade Controls Section 3.23(a) Trademarks Section 1.1 Transfer Taxes Section 8.7(a6.6(d) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g)Article II TRANSACTION

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: 510(k) Section hereof in which such term is defined: 5.6(b) Acceptance Time Section 2.4(a) Action Section 5.15 Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 7.5(c)(ii) Bankruptcy Exception Section 4.7 Books and Records 5.13(b) Board Appointment Date Section 2.12(f)(22.4(a) Claim Notice Certificate of Merger Section 8.3(a3.3 Certificates Section 4.2(b) Closing Section 2.3 3.2 Closing Date Section 2.3 3.2 Company Preamble Company Adverse Recommendation Change Section 7.5(c)(i) Company Board Recommendation Section 2.3(a)(iv) Company Common Stock Recitals Company Disclosing Party Section 2.8 1.1 Company Disclosure Schedule Article IV Documents Section 5.10(a) Company Expenses Schedule Financial Advisor Section 2.13 5.3(c) Company Indemnified Parties Financial Statements Section 8.2(a)(ii5.7(b) Contracts Company Intellectual Property Section 4.8(a5.17(b) Covered Party (PartiesCompany Material Contract Section 5.13(a) Company Person Section 5.21(b) Company Plan(s) Section 8.2(a)(ii5.11(a) Damages Company Preferred Stock Section 8.2(a)(i5.2(a) Company Related Party Section 5.21(b) Company Representatives Section 7.4(a) Company SEC Filings Section 5.7(a) Company Stockholder Approval Section 5.3(b) Company Stockholders’ Meeting Section 7.2(a) Company Subsidiary Section 5.1 Compensation Committee Section 5.24 Continuing Directors Section 2.4(a) DGCL Section 2.1 Document Retention Period 3.1 Dissenting Shares Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 4.3 Effective Time Section 2.2 3.3 Employment Compensation Arrangement Section 5.24 End Date Section 9.1(b) ERISA Section 4.13(a5.11(a) ERISA Affiliate Section 4.13(a5.11(a) Finally Determined Exchange Fund Section 8.5(b4.2(a) First Milestone FDA Section 2.10(e5.6(a) First Milestone Payment Amount FDCA Section 2.10(e5.6(a) Indemnifying Party Improvements Section 8.3(a5.20(b) Instrument Indemnified Parties Section 2.12(c7.12(a) Independent Directors Section 2.4(b) Investments Section 5.2(d) IRS Section 5.11(b) JV Partner Section 5.21(b) Merger Recitals Merger Consideration Section 2.1 Merger Certificate Section 2.2 4.1(a) Merger Sub Preamble Minimum Condition Section 2.1(b) Notice Period Section 7.5(d)(iii) Offer Recitals Offer Documents Section 2.1(g) Offer Price Recitals Parent Preamble Parent Disclosure Expenses Section 9.4(c) Parent Plans Section 7.18(a) Parent Share Price Section 1.1 Parent Representatives Section 7.4(a) Party Preamble Paying Agent Section 4.2(a) Proxy Statement Section 7.2(b) Registered Company Intellectual Property Section 5.17(a) Reimbursable Expenses Section 9.4(c) Related Party Financing Section 5.21(b) Schedule Article V Parent Indemnified Parties TO Section 8.2(a)(i2.1(g) parties Preamble Payee Schedule 14D-9 Section 8.5 Payor 2.3(b) Software Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent 1.1 Support Agreement Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone 3.1 Tail Period Section 2.10(g7.12(c) Third Milestone Payment Amount Takeover Provisions Section 2.10(g)2.3(a)(iii) Top-Up Option Section 2.2(a) Top-Up Option Shares Section 2.2(d) Transaction Litigation Section 7.8

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement Agreement, as indicated below: Acquired Companies Acquired Company Interests Acquired Entity Deferred Compensation Plans Antitrust Division Recitals Recitals Section 5.2(g)(ii) Section 5.5(b) -22- Applicable Severance Plan Approval Section 5.2(c)(i) Section 5.7(c) Asset Basis Section 5.16(g)(i) Bankruptcy and a reference to the Equity Principles Section hereof in which such term is defined: Agreement 3.2 Basis Information Section 5.16(g)(i) Business CBA Section 3.19(a) Business Environmental Reports Section 5.25 Business Reports Section 3.11 Buyer Preamble Biogen Idec License Buyer 401(k) Plan Section 5.2(f)(i) Buyer Controlled Action Section 5.19(a) Buyer Deferred Compensation Plans Section 5.2(g)(i) Buyer Employee DCP Participants Section 5.2(g)(i) Buyer Indemnified Parties Section 8.2 Buyer Parent Recitals Buyer Parent Guarantee Recitals Buyer’s Allocation Section 5.16(a)(i) Cap Section 8.5(a)(i) Casualty Event Section 2.5(b) Casualty Event Notice Section 2.5(b) Casualty Loss Adjustment Site Section 2.5(c) Chosen Courts Section 9.1 claim Section 1.1 Claim Notice Section 8.4(b) Closing Section 2.3(a) Closing Cash Amounts Section 2.4(b) Closing Date Section 2.3(a) Closing Indebtedness Section 2.4(b) Closing Month Section 1.1 Closing Net Working Capital Section 2.4(b) Closing Section 338(h)(10) Election Amount Section 2.4(b) Collective Bargaining Agreement Section 4.7 Biogen Idec 3.19(a) Competing Business Section 5.26(b)(ii) Condemnation Action Section 5.28(a) Confidential Business Information Section 5.4(b) Continuation Period Section 5.2(c)(i) Corporate Policies Section 5.13 Covered Parties Section 5.17 COVID-19 Conditions Section 1.1 Current Representation Section 9.17(a) Cutoff Date Section 8.1(a) Damaged Retail Site Section 2.5(b) debt Section 1.1 Debt Financing Section 5.27(a) Deemed Section 338(h)(10) Election Transactions Section 5.16(e) Designated Person -23- Section 9.17(a) Disagreement Notice Section 2.4(c) Disclosing Party Section 5.4(c) Disputed Item Section 2.4(c) Divestiture Actions Section 5.5(c) Divestiture Event Section 5.26(d) DOL Section 3.21(c) Effective Time Section 2.3(a) Estimated Closing Cash Amounts Section 2.4(a)(i) Estimated Closing Indebtedness Section 2.4(a)(i) Estimated Net Working Capital Section 2.4(a)(i) Excluded Businesses Section 1.1 Excluded Marks Section 5.14(a) Excluded Retail Operations Section 5.26(b)(iv) Expenses Schedule Section 9.4(b) Final Allocation Section 5.16(a)(i) Final Cash Amounts Section 2.4(h) Final Closing Adjustment Section 2.4(j) Final Indebtedness Section 2.4(h) Final Net Working Capital Section 2.4(h) Final Purchase Price Section 2.4(j) Final Section 338(h)(10) Election Amount Section 2.4(h) FLSA Section 3.19(b) FTC Section 5.5(b) Governmental Filings Section 3.4 Grandfathered Participants Section 5.2(f)(ii) Incremental Fuel Supply Agreement Section 4.7 Books and Records 5.30(b) Indemnified Party Section 2.12(f)(2) Claim Notice Section 8.3(a) Closing Section 2.3 Closing Date Section 2.3 Company Preamble Company Common Stock Section 2.8 Company Disclosure Schedule Article IV Company Expenses Schedule Section 2.13 Company Indemnified Parties Section 8.2(a)(ii) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e8.4(a) Indemnifying Party Section 8.3(a8.4(a) Instrument Independent Accounting Firm Section 2.12(c2.4(e) Merger Initial Purchase Price Section 2.4(a)(ii) Interim Financial Statements Section 5.22(a) IRS Section 3.21(b) Like-Kind Exchange Section 5.16(l) Losses Section 8.2 Marketing Materials Section 5.27(a) Material Contract Section 3.18(a) Monetization Transaction Section 5.27(d) New Price Section 5.26(d) New Seller Deferred Compensation Plans Section 5.2(g)(ii) Non-Business Employee DCP Participants Section 5.2(g)(ii) Notice Period Section 8.4(b) Offer Notice Section 5.26(d) Offer Price Section 5.26(d) Outside Date Section 7.1(b) Partial Condemnation Actions Section 5.28(a) PBGC -24- Section 3.21(d) Permits Section 3.20(b) Post-Closing Representation Section 9.17(a) Pre-Closing Separate Tax Return Section 5.16(i)(i) Preliminary Adjustment Statement Section 2.4(b) Privileged Communications Section 9.17(b) R&W Insurance Policy Section 5.24 Resolution Period Section 2.4(e) Restricted Activities Section 5.26(a) Restricted Area Section 5.26(a) Restricted Parties Section 5.26(a) Retained Deferred Compensation Plans Section 5.2(g)(iii) Review Period Section 2.4(c) ROFO Section 5.26(d) ROFO Event Section 5.26(d) ROFO Notice Section 5.26(d) RSSP Section 5.2(f)(i) Sale Section 2.1 Merger Certificate Sale Notice Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent 5.26(d) Section 338(h)(10) Election Section 5.16(g)(i) Section 338(h)(10) Election Accounting Firm Section 5.16(g)(i) Section 338(h)(10) Election Amount Section 5.16(g)(i) Section 338(h)(10) Forms Section 5.16(g)(iii) Seller Controlled Action Section 5.19(a) Seller Deferred Compensation Plans Section 5.2(g)(i) Seller Guarantors Section 5.20(a) Seller Indemnified Parties Section 8.2(a)(i8.3 Seller Parent Preamble Seller Surviving Representations Section 8.1(a) parties Seller Thrift Plan Section 5.2(f)(i) Sellers Preamble Payee Separation Activities Section 8.5 Payor 5.7(a) Separation Plan Section 8.5 Per Diem Taxes 5.7(a) Service Credits Section 8.7(a5.2(c)(ii) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Signing Date Preamble Speedway Retirement Plan Sharing Amount Section 2.10(f5.2(e) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Stock Basis Section 2.12(b5.16(g)(i) Surviving Corporation Stock Purchase Subsidiaries Section 2.1 Third Milestone 5.16(g)(i) Straddle Period Section 2.10(g5.16(h)(i) Support Services Section 5.12 Tax Claim Section 5.16(k)(i) Tax Clearance Certificates Section 5.16(m) Terminating Contracts Section 5.11(a) Third Milestone Payment Amount Party Claim Section 2.10(g)8.4(b) Threshold Section 8.5(a)(i) Total Condemnation Actions Section 5.28(b) Transaction Accounting Principles -25- Section 1.1 Transferred Employees Transition Services Agreement Transportation Services Agreements Unclaimed Property Reports Section 5.2(a)(iii) Section 5.30(a) Section 5.30(c) Section 3.31 Union Section 3.19(a) Unresolved Items Section 2.4(f) willful and material breach -26- Section 7.2

Terms Defined Elsewhere. The following is a list of additional terms used in this Agreement and a reference to the Section hereof in which such term is defined: Acquisition Sub Preamble Aggregate Loss Threshold Section 8.3(a) Agreement Preamble Biogen Idec License Agreement Available NOL Amount Section 4.7 Biogen Idec Supply Agreement 2.15(c) CIC Amendment Section 4.7 Books and Records Section 2.12(f)(25.14(b) Claim Notice Section 8.3(a8.4(a) Closing Section 2.3 2.3(a) Closing Date Section 2.3 2.3(a) Closing Working Capital Section 2.13(a)(i) Company Preamble Company Common Stock Section 2.8 Company Disclosure Schedule Article IV III Company Expenses Schedule Intellectual Property Section 2.13 Company Indemnified Parties 3.17(a) Credits Section 8.2(a)(ii) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii2.15(a) Damages Section 8.2(a)(i8.2(a), (c) Decline Date Section 2.13(d) DGCL Section 2.1 Document Retention Period Dispute Notice Section 2.12(f)(28.4(b) Drug Regulatory Agency Disputed Line Items Section 4.25 2.13(d) Dissenting Shares Section 2.16(a) Dissenting Shares Reduction Amount Section 2.16(b) Effective Time Section 2.2 ERISA Equityholder Indemnified Parties Section 4.13(a8.2(b) ERISA Affiliate Estimated Working Capital Section 4.13(a2.13(b) Finally Determined Estimated Working Capital Adjustment Section 8.5(b2.13(b) First Milestone Final Working Capital Adjustment Section 2.10(e2.13(e) First Milestone Payment Amount Form Working Capital Statement Section 2.10(e2.13(a)(i) Indemnifying General Survival Date Section 8.1 Hireworks Section 5.15 Indemnified Officers Section 5.10 Indemnified Party Section 8.3(a8.4(a) Instrument Indemnitor Section 2.12(c8.4(b) Initial Calculation Section 2.13(c) Kenexa Indemnified Parties Section 8.2(a) Kenexa Technology Preamble Labor Union Section 3.16(a)(i) Letter of Transmittal Section 2.10(b) Material Contracts Section 3.6(a) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Net Adjustment Amount Section 2.13(f) NOL Adjustment Amount Section 2.15(c) NOL Study Section 2.15(b) NOLs Section 2.15(a) Notice of Disagreement Section 2.13(d) Notice of NOL Disagreement Section 2.15(c) Option Cancellation Agreement Section 2.11 Option Holder Section 3.4(c) Outside Date Section 7.1(b) Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Pre-Closing Taxes Section 5.11(a) Relevant Group Section 3.10(a)(i) Representative Preamble Representative Agreement Section 8.8(a) Representative Parties Section 8.2(a)(i8.8(f)(iii) parties Preamble Payee Settlement Accountants Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f2.13(d) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Approval Section 2.12(b3.3(b) Straddle Period Section 5.11(a) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Targeted Credit Amount Section 2.10(g2.15(a) Targeted NOL Amount Section 2.15(a) Tax or Taxes Section 3.10(a)(ii) Tax Return Section 3.10(a)(iii) Terminated Plan Section 3.16(b)(i) Transaction Expense Statement Section 2.9(a) Transfer Taxes Section 3.10(a)(iv)

Terms Defined Elsewhere. The For purposes of this Agreement, the following is a list of additional terms (as capitalized below) will have the following meanings when used in this Agreement and a reference to the Agreement: Action Section hereof in which such term is defined: 5.10(b) Agreement Preamble Biogen Idec License Agreement Appraisal Rights Section 4.7 Biogen Idec Supply Agreement 2.1(b) Board of Directors Recitals Book-Entry Shares Section 4.7 Books and Records 2.2(a) Cancelled Shares Section 2.12(f)(22.1(a)(ii) Claim Notice Certificate of Merger Section 8.3(a1.3 Certificates Section 2.2(a) Change of Recommendation Section 5.4(e) Closing Section 2.3 1.2 Closing Date Section 2.3 1.2 Code Section 2.2(b)(iii) Common Stock Section 2.1(a)(i) Company Preamble Company Common Stock Disclosure Letter Article 3 Company Employees Section 2.8 5.6(a) Company Disclosure Schedule Article IV Post-Signing RSU Award Section 2.3(c) Company Expenses Schedule Section 2.13 Company Indemnified Related Parties Section 8.2(a)(ii7.3(a) Contracts Company SEC Reports Section 4.8(a3.5(a) Covered Party (PartiesCompany Stockholders’ Meeting Section 5.5(b) Company Termination Fee Section 8.2(a)(ii7.3(a) Damages Confidentiality Agreement Section 8.2(a)(i5.3(b) Development Real Property Section 3.9(e) DFARS Section 3.20(c) DGCL Recitals Dissenting Shares Section 2.1 Document Retention Period 2.1(b) EAR Section 2.12(f)(23.15(d) Drug Regulatory Agency Section 4.25 E▇▇▇▇ Article 3 Effective Time Section 2.2 ERISA 1.3 End Date Section 4.13(a7.1(b) ERISA Affiliate ESPP Section 4.13(a3.2(b)(i) Finally Determined Exchange Fund Section 8.5(b2.2(a) First Milestone Filed SEC Reports Article 3 Financing Amounts Section 2.10(e4.12 HSR Act Section 3.4 Indemnified Party Section 5.10(b) First Milestone Payment Intervening Event Notice Section 5.4(f) Leases Section 3.9(a) Legal Restraint Section 6.1(b) Major Customer Section 3.13(a) Major Supplier Section 3.13(b) Material Contract Section 3.11(a) Maximum Amount Section 2.10(e5.10(c) Indemnifying Party Measurement Time Section 8.3(a) Instrument Section 2.12(c3.2(a) Merger Recitals Merger Consideration Section 2.1 Merger Certificate Section 2.2 2.1(a)(i) Merger Sub Preamble New Plans Section 5.6(b) Old Plans Section 5.6(b) Owned Real Property Section 3.9(a) Parent Preamble Parent Approvals Section 4.2(b) Parent Disclosure Schedule Letter Article V 4 Parent Indemnified Material Adverse Effect Section 4.1 Parent Related Parties Section 8.2(a)(i7.3(a) parties Preamble Payee Parent RSU Award Section 8.5 Payor 2.3(c)(i) Paying Agent Section 8.5 Per Diem Taxes 2.2(a) Proposed Dissenting Shares Section 8.7(a2.1(b) Proceeding Recommendation Section 4.17 Royalties 3.3 Remedial Action Section 2.10(h5.7(b) Second Milestone Representatives Section 2.10(f5.3(a) Second Milestone Payment Amount Required Company Stockholder Vote Section 2.10(f3.23 Sexual Misconduct Allegation Section 3.18(c) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Share Section 2.12(b2.1(a)(i) Specified Approvals Section 3.4 Standards Organization Section 3.10(b) Superior Proposal Notice Section 5.4(e) Surviving Corporation Section 2.1 Third Milestone 1.1 Takeover Statute Section 2.10(g3.22 Termination Date Section 5.1(a) Third Milestone Payment Amount WARN Act Section 2.10(g3.18(a)

Terms Defined Elsewhere. The following is a list of additional terms used in this Agreement and a reference to the Section hereof in which such term is defined: Accelerated Options Section 2.12(a) Acquisition Sub Preamble Affected Employees Section 6.9 Agreement Preamble Biogen Idec License Agreement Amended Severance Policy Section 4.7 Biogen Idec Supply Agreement 6.9 BRINC Preamble BRLLC Preamble BRLLC Expenses Section 4.7 Books and Records 2.10(a) Certificate of Merger Section 2.12(f)(22.3 Change of Control Payment Statement Section 2.10(c) Change of Control Payments Section 2.10(c) Claim Notice Section 8.3(a10.4(a) Closing Section 2.3 2.4(a) Closing Date Section 2.3 Company Preamble Company Common Stock 2.4(a) Closing Working Capital Section 2.8 Company 2.14(a)(i) Confidential Information Section 6.5(a)(i) Copyright Office Section 6.16(b) Customer Information Section 3.16 D&O Tail Section 6.19(b) Damages Section 10.2(a) Decline Date Section 2.14(e) Delivering Party Section 6.5(a)(ii) DGCL Recitals Disclosure Schedule Article IV Company Expenses Schedule III Dispute Notice Section 2.13 Company 10.4(b) Disputed Line Items Section 2.14(e) Dissenting Shares Section 2.16(a) Dissenting Shares Reduction Amount Section 2.16(b) DOJ Section 6.6 Effective Time Section 2.3 Environmental Costs Section 3.14(c)(ii) Equityholder Indemnified Parties Section 8.2(a)(ii10.2(b) Estimated Working Capital Section 2.14(b) Estimated Working Capital Deficiency Section 2.14(c) EU Personal Data Section 5.8 Excess Negative Adjustment Amount Section 2.14(g) Expense Statement Section 2.10(a) Final Tax Returns Section 9.2(a)(i) Form Working Capital Statement Section 2.14(a)(i) FTC Section 6.6 Fundamental Representation Distributions Section 10.2(d) Funded Indebtedness Statement Section 2.10(d) Gannett Preamble General Survival Date Section 10.1 Indemnified Executive Section 6.19(a) Indemnity Escrow Amount Shortfall Section 2.14(g) Information Statement Section 6.3(a) Initial Calculation Section 2.14(d) Insolvent Section 5.6 Kenexa Indemnified Parties Section 10.2(a) Kenexa Technology Preamble Labor Union Section 3.11(a)(i) Letter of Transmittal Section 2.11(b) Material Client Contract Section 3.10(a)(i) Material Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c3.10(a) Merger Section 2.1 Merger Certificate 2.2 Negative Adjustment Amount Section 2.2 Merger Sub Preamble 2.14(f) Notice of Disagreement Section 2.14(e) Off-the-Shelf Software Section 3.15(c) Organizational Documents Section 2.4(c)(ii) Outside Date Section 8.1(b) Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Positive Adjustment Amount Section 2.10(f2.14(f) Stockholder Consent Recitals Stockholder Post Preamble Privacy Policy Section 3.16 Qualified Plan Section 3.11(b)(ii)(I) Receiving Party Section 6.5(a)(iii) Registered Intellectual Property Section 3.15(e) Regulatory Agreements Section 3.25(b) Relevant Group Section 3.13(a)(i) Representative Preamble Super Majority Required Exchange Documents Section 2.12(b2.11(b) Requisite BRINC Vote Section 3.3(b) Safe Harbor Section 5.8 Selling Members Recitals Settlement Accountants Section 2.14(e) Severance Payment Statement Section 2.10(b) Severance Payments Section 2.10(b) Straddle Periods Section 9.2(a)(ii) Surviving Corporation Section 2.2 Takeover Statutes Section 3.25(a)(iii) Tax or Taxes Section 3.13(a)(ii) Tax Return Section 3.13(a)(iii) Terminated Plan Section 3.11(b)(i) Transactions Section 2.4(a) Transfer Section 2.1 Third Milestone Transfer Taxes Section 2.10(g3.13(a)(iv) Third Milestone Payment Amount Tribune Preamble USPTO Section 2.10(g6.16(b) WARN Act Section 3.11(a)(i)

Terms Defined Elsewhere. The following is a list of additional terms used have the meanings set forth in this Agreement and a reference to the Section hereof in which such term is definedSections set forth below: Agreement Preamble Biogen Idec License Agreement Arbitrator Section 4.7 Biogen Idec Supply Agreement 10.8(b) Available Cash Section 4.7 Books and Records 7.13 Base Premium Section 2.12(f)(27.4(d) Claim Notice Change in Recommendation Section 8.3(a6.2(d) Closing Section 2.3 Closing Date Section 2.3 Company Preamble Company Common Stock Board Recitals Company Group Section 2.8 9.2(d) Company Disclosure Schedule Article IV Company Expenses Schedule Termination Fee Section 2.13 Company Indemnified Parties 9.2(b) Confidential Information Section 8.2(a)(ii) Contracts Section 4.8(a10.11(c) Covered Party (PartiesPersons Section 7.4(a) Deposit Agreement Section 8.2(a)(ii3.5 Depositary Section 3.5 Deposited Available Cash Section 7.13 Dissent Notice Section 3.6(b)(ii) Damages Dissent Right Section 8.2(a)(i3.6(b) DGCL Dissenting Shareholders Section 2.1 Document Retention Period 3.6(a) Dissenting Shares Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 3.6 Effective Time Section 2.2 ERISA 2.3 Enforceability Exceptions Section 4.13(a4.3 Financing Section 5.6(a) ERISA Affiliate GAAP Section 4.13(a4.6(d) Finally Determined Governmental Entity Section 8.5(b4.5 HKIAC Section 10.8(b) First Milestone HKIAC Rules Section 2.10(e10.8(b) First Milestone Payment Amount Indemnification Agreements Section 2.10(e7.4(a) Indemnifying Party Intervening Event Section 8.3(a6.2(e) Instrument Intervening Event Termination Section 2.12(c6.2(e) Limited Guarantee Recitals Loan Agreement Section 5.6(a) Material Company Permits Section 4.8 Merger Recitals Merger Consideration Section 3.2(a) Merger Consideration Fund Section 2.1 Merger Certificate Section 2.2 3.2(a) Merger Sub Preamble NASDAQ Section 4.2(b) Notice of Recommendation Change Section 6.2(d) Notice Period Section 6.2(d) Option Consideration Section 3.3(a)(i) Parent Preamble Parent Disclosure Group Section 9.2(d) Parent Termination Fee Section 9.2(c) Parties Preamble Paying Agent Section 3.2(a) Per ADS Merger Consideration Section 3.1(b) Per Share Merger Consideration Section 3.1(a) Plan of Merger Section 2.3 Record ADS Holders Section 6.3(c) Record Date Section 6.3(c) Rollover Agreement Recitals Rollover Shareholders Recitals Ruhnn1106 Section 5.6(a) ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 4.6(a) Schedule Article V Parent Indemnified Parties 13E-3 Section 8.2(a)(i6.3(a) parties Preamble Payee SEC Documents Section 8.5 Payor 4.6(a) Securities Act Section 8.5 Per Diem Taxes 4.6(a) Share Certificates Section 8.7(a3.2(c)(i) Proceeding Special Committee Recitals Subscription Agreement Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b5.6(a) Surviving Corporation Company Section 2.1 Third Milestone Takeover Statute Section 2.10(g7.5 Transaction Litigation Section 7.8 Transactions Recitals Uncertificated Shares Section 3.2(c)(i) Third Milestone Payment Amount Vista Section 2.10(g5.6(a)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Section hereof in which such term is definedAgreement, as indicated below: Agreement Preamble Biogen Idec License Agreement Arbitrator Section 4.7 Biogen Idec Supply Agreement 10.08(b) Base Premium Section 4.7 Books and Records 7.04(d) Change in Recommendation Section 2.12(f)(2) Claim Notice Section 8.3(a6.02(f) Closing Section 2.3 2.02 Closing Date Section 2.3 2.02 Company Preamble Company Common Stock Board Recitals Company Equity Interests Section 2.8 4.02(a) Company Disclosure Schedule Article IV Group Section 9.02(d) Company Expenses Schedule Termination Fee Section 2.13 Company Indemnified Parties 9.02(b) Competing Proposal Section 8.2(a)(ii6.02(e) Contracts Competition Laws Section 4.8(a4.05 Covered Persons Section 7.04(a) Covered Party (Parties) Deposit Agreement Section 8.2(a)(ii) Damages 3.05 Depositary Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 3.05 Effective Time Section 2.2 ERISA 2.03 Enforceability Exceptions Section 4.13(a4.03 GAAP Section 4.06(b) ERISA Affiliate Governmental Entity Section 4.13(a4.05 HKIAC Section 10.08(b) Finally Determined HKIAC Rules Section 8.5(b10.08(b) First Milestone Indemnification Agreements Section 2.10(e7.04(a) First Milestone Payment Amount Intervening Event Section 2.10(e6.02(h) Indemnifying Party Intervening Event Termination Section 8.3(a6.02(h) Instrument Legal Proceeding Section 2.12(c5.06 Limited Guarantee Recitals Merger Recitals Merger Consideration Section 3.02(a) Merger Consideration Fund Section 2.1 Merger Certificate Section 2.2 3.02(a) Merger Sub Preamble NASDAQ Section 4.02(a) Non-Required Remedy Section 7.02(e) Option Consideration Section 3.03(a) Parent Preamble Parent Disclosure Group Section 9.02(d) Parent Termination Fee Section 9.02(c) Parties Preamble Party Preamble Paying Agent Section 3.02(a) Per ADS Merger Consideration Section 3.01(b) Per Share Merger Consideration Section 3.01(a) Plan of Merger Section 2.03 Record ADS Holders Section 6.03(c) Record Date Section 6.03(c) Rollover Agreement Recitals Rollover Shareholders Recitals RSU Consideration Section 3.03(c) ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 4.06(a) Schedule Article V Parent Indemnified Parties 13E-3 Section 8.2(a)(i6.03(a) parties Preamble Payee SEC Documents Section 8.5 Payor 4.06(a) Securities Act Section 8.5 Per Diem Taxes 4.06(a) Special Committee Recitals Superior Proposal Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b6.02(g) Surviving Corporation Company Section 2.1 Third Milestone 2.01 Takeover Statute Section 2.10(g) Third Milestone Payment Amount 7.05 Transaction Litigation Section 2.10(g7.07 Transactions Recitals Uncertificated Shares Section 3.02(b)(i)

Terms Defined Elsewhere. The Each of the following is a list of additional terms used in this Agreement and a reference has the meaning ascribed to the Section hereof in which such term is definedin the Article or Section set forth opposite such term: ACA Section 4.15(c) Additional Buyer Filings Section 8.10(f) Affiliated Transactions Section 4.19 Agreement Preamble Biogen Idec License Agreement Allocation Section 4.7 Biogen Idec Supply Agreement 4.19 Audited Financial Statements Section 4.7 Books and Records 4.4(a)(i) Blocker Affiliated Transactions Section 2.12(f)(25.8 Blocker Bring-Down Certificate Section 11.2(b)(iii) Claim Notice Blocker Certificates of Merger Section 8.3(a2.2(b) Blocker Dissenting Shareholders Section 3.6 Blocker Dissenting Shares Section 3.6 Blocker Effective Time Section 2.2(b) Blocker Letter of Transmittal Section 3.5(a) Blocker Merger Closing Section 2.2(a) Blocker Merger Sub 1 Preamble Blocker Merger Sub 2 Preamble Blocker Merger Sub 3 Preamble Blocker Merger Subs Preamble Blocker Mergers Recitals Blockers Preamble Buyer Preamble Buyer Balance Sheet Section 6.10(c) Buyer Bring-Down Certificate Section 11.3(d) Buyer Contribution Amount Section 2.4(c) Buyer Parties Preamble Buyer Preferred Stock Section 6.3(a) Buyer Public Securities Section 6.9 Buyer SEC Documents Section 6.8(a) Buyer Warrants Section 6.3(a) Cancelled Equity Interests Section 3.1(d) CBA Section 4.9(a)(i) Certificates of Merger Section 2.2(c) Closing Section 2.3 2.2(a) Closing Date Section 2.3 2.2(a) Closing Form 8-K Section 8.10(g) Closing Press Release Section 8.10(g) Company Preamble Company Common Stock A&R LLCA Recitals Company Bring-Down Certificate Section 2.8 11.2(a)(iv) Company Disclosure Schedule Article IV Certificate of Merger Section 2.2(c) Company Expenses Schedule Merger Recitals Company Merger Closing Section 2.13 2.1(a) Company Indemnified Parties Merger Sub Preamble Company Unitholder Letter of Transmittal Section 8.2(a)(ii4.3(a) Contracts Competing Buyer Section 4.8(a8.21(a) Covered Party (PartiesData Room Section 13.5 Delaware Corporation Section 8.22 DGCL Recitals DLLCA Recitals D&O Provisions Section 8.13(a) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA 2.2(c) EIP Section 4.13(a8.3(c) ERISA Affiliate Environmental Permits Section 4.13(a4.18 ESPP Section 8.4(b) Finally Determined Estimated Blocker Closing Statement Section 8.5(b3.2(c) First Milestone Estimated Company Closing Statement Section 2.10(e3.2(a) First Milestone Payment Execution Date Preamble Failed Blocker Merger Section 2.2(a) Financial Statements Section 4.4(a) Foreign Plan Section 4.15(e) Group Company Processor Section 4.10(h) Indemnified Persons Section 8.13(a) Insurance Policies Section 4.16 Intended Tax Treatment Section 10.1(e) Internal Controls Section 4.4(c) IRS Section 4.15(a) IVP Blocker Preamble IVP Blocker Merger Preamble JOBS Act Section 8.3(b) KPCB Blocker Preamble KPCB Blocker Merger Recitals Material Contract Section 4.9(b) Mergers Recitals Merger Subs Preamble New Equity Plans Section 8.4(b) Outside Date Section 12.1(c) Parties Preamble Party Preamble PCAOB Financial Statements Section 8.10(h) Permits Section 4.17(b) Permitted Equity Financing Proceeds Section 8.15(b)(i) PIPE Investment Recitals PIPE Investors Recitals Pre-Closing Period Section 7.1 Premium Cap Section 8.13(b)(ii) Recipient Section 1.1 Registration Rights Agreement Recitals Rollover Option Section 3.1(c)(iii) Rollover Warrant Section 3.1(c)(iv) Sale Section 10.1(e) Signing Form 8-K Section 8.10(b) Signing Press Release Section 8.10(b) Sponsor Side Letter Recitals Standard Form Agreements Section 4.10(d) Subscription Agreements Recitals Surviving Company Section 2.1(e) Surviving IVP Merger Sub Section 2.1(b) Surviving KPCB Merger Sub Section 2.1(a) Surviving Merger Subs Section 2.1(c) Surviving W Capital Merger Sub Section 2.1(c) Tail Policy Section 8.13(b)(ii) Tax Positions Section 10.1(g) Tax Receivable Agreement Recitals Trade Controls Section 4.20(a) Transaction Litigation Section 8.20 Transaction Support Agreement Recitals Trust Amount Section 2.10(e6.7 Trust Distributions Section 13.9 Unaudited Balance Sheet Section 4.4(a)(ii) Indemnifying Party Unaudited Financial Statements Section 8.3(a4.4(a)(ii) Instrument Unitholder Materials Section 2.12(c3.5(b) W Capital Blocker Recitals W Capital Blocker Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g)Recitals

Terms Defined Elsewhere. The Each of the following is a list of additional terms used in this Agreement and a reference has the meaning ascribed to the Section hereof in which such term is definedin the Article or Section set forth opposite such term: A&R GGPPA Section 6.1(f) Acquired Entity Benefit Plan Section 3.14(a) Affiliate Transaction Section 3.21 Agreement Preamble Biogen Idec License Agreement Antitrust Laws Section 4.7 Biogen Idec Supply Agreement 6.2(c) Balance Sheet Date Section 4.7 Books and Records 3.5(a) Buyers Preamble Carlsbad CIV Preamble Casualty Loss Section 2.12(f)(2) Claim Notice Section 8.3(a) 6.4 Closing Section 2.3 2.4 Closing Date Section 2.3 Company 2.4 control Section 1.1 D&O Provisions Section 6.10(a) ECP III Preamble Company Common Stock ECP III CIV Preamble ECP III-A Preamble ECP III-B Preamble ECP III-C Preamble ECP Parties Preamble Excess Payment Section 2.8 Company Disclosure Schedule Article IV Company Expenses Schedule 2.3(f)(i) Final Adjustment Certificate Section 2.13 Company 2.3(d) Final Settlement Date Section 2.3(c) Financial Statements Section 3.5(a) First Lien Debt Payoff Amount Section 2.5(b)(iii)(C) General Partner Preamble GP Buyer Preamble GP Interests Recitals Guarantee Section 8.14(a) Guarantor Preamble Holdings Recitals Indemnified Persons Section 6.10(a) Intended Tax Treatment Section 2.6(a) ▇▇▇▇▇▇ & ▇▇▇▇▇▇▇ Section 8.11(a) LP Buyer Preamble LP Interest Sellers Preamble LP Interests Recitals Material Contract Section 3.10(b) Maximum D&O Premium Section 6.10(a) MOP Section 6.1(f) Multiemployer Plan Section 3.14(a) New Plans Section 6.13 Non-Continuing Employee Section 6.13 Nonparty Affiliates Section 6.17 Notice of Disagreement Section 2.3(c) Outside Date Section 7.1(c) Partnership Preamble Partnership Proprietary Rights Section 3.11(a) Party and Parties Section 8.2(a)(ii) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Preamble Purchase Price Section 2.2 ERISA Purchase Price Allocation Section 4.13(a2.6(b) ERISA Affiliate R&W Insurance Policy Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment 6.3 Second Lien Debt Payoff Amount Section 2.10(e2.5(b)(iii)(D) Indemnifying Party Seller Representative Section 8.3(a8.13(a) Instrument Seller Representative Expense Account Section 2.12(c8.13(c) Merger Seller Tax Returns Section 2.1 Merger Certificate 6.5(a) Sellers Preamble Sendero Carlsbad Finance Recitals Sendero Carlsbad Midstream Recitals Sendero Management Preamble Shortfall Payment Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties 2.3(f)(i) Subject Interests Recitals Tail Policy Section 8.2(a)(i6.10(a) parties Preamble Payee Tax Contest Section 8.5 Payor Section 8.5 Per Diem 6.5(c) Transfer Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g6.5(f)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: Acceptance Time Section hereof in which such term is defined: 2.01(e) Agreement Preamble Biogen Idec License Agreement Alternative Financing Section 4.7 Biogen Idec Supply Agreement 8.09(b) Alternative Financing Documents Section 4.7 Books and Records 8.09(b) Arbitrator Section 2.12(f)(211.08(b) Claim Notice Base Premium Section 8.3(a8.04(d) Change in the Company Recommendation Section 7.02(b) Closing Section 2.3 3.02 Closing Date Section 2.3 3.02 Company Preamble Company Common Stock Board Recitals Company Board Actions Recitals Company Board Recommendation Recitals Company Equity Interests Section 2.8 5.02(a) Company Disclosure Schedule Article IV Group Section 10.02(d) Company Expenses Schedule Termination Fee Section 2.13 Company Indemnified Parties 10.02(b) Competing Proposal Section 8.2(a)(ii7.02(d) Contracts Competition Laws Section 4.8(a5.05 Covered Persons Section 8.04(a) Covered Party (PartiesDebt Commitment Letter Section 6.05(a) Debt Financing Source Section 8.2(a)(ii6.05(a) Damages Deposit Agreement Section 8.2(a)(i) DGCL 4.05 Depositary Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 4.05 Effective Time Section 2.2 ERISA 3.03 Enforceability Exceptions Section 4.13(a5.03(a) ERISA Affiliate Expiration Time Section 4.13(a2.01(c)(ii)(B) Finally Determined Financing Section 8.5(b6.05(a) First Milestone Financing Condition Annex A Financing Document Section 2.10(e8.09(b) First Milestone Payment Amount GAAP Section 2.10(e5.06(b) Indemnifying Party Governmental Entity Section 8.3(a5.05 HKIAC Section 11.08(b) Instrument HKIAC Rules Section 2.12(c11.08(b) Indemnification Agreements Section 8.04(a) Intervening Event Section 7.02(g) Intervening Event Termination Section 7.02(g) Legal Proceeding Section 6.06 ▇▇▇ Preamble Merger Recitals Merger Consideration Section 2.1 Merger Certificate 4.02(a) Minimum Condition Annex A Non-Required Remedy Section 2.2 Merger Sub Preamble 8.02(e) Offer Recitals Offer Conditions 2.01(a) Offer Documents Section 2.01(f) Offer Price Recitals Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Termination Fee Section 10.02(c) Parties Preamble Party Preamble Paying Agent Section 8.2(a)(i4.02(a) parties Preamble Payee Payment Fund Section 8.5 Payor 4.02(a) Per ADS Merger Consideration Section 8.5 4.01(b) Per Diem Taxes Share Merger Consideration Section 8.7(a4.01(a) Proceeding Plan of Merger Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment 3.03 Required Amount Section 2.10(f6.05(c) Stockholder Consent ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 5.06(a) Schedule TO Section 2.01(f) Schedule 13E-3 Section 2.02(b) Schedule 14D-9 Section 2.02(b) SEC Documents Section 5.06(a) Securities Act Section 5.06(a) Share Certificates Section 4.02(b)(i) Special Committee Recitals Stockholder Representative Special Committee Recommendation Recitals Super ROI Preamble Super Majority ROI Group Section 2.12(b10.02(d) Superior Proposal Section 7.02(f) Surviving Corporation Company Section 2.1 Third Milestone 3.01 Takeover Statute Section 2.10(g) Third Milestone Payment Amount 8.05 Transaction Litigation Section 2.10(g8.07 Transactions Recitals Uncertificated Shares Section 4.02(b)(i)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement Agreement, as indicated below: Acquired Companies Recitals Acquired Company Interests Recitals Acquired Entity Deferred Compensation Plans Section 5.2(g)(ii) Antitrust Division Section 5.5(b) Applicable Severance Plan Section 5.2(c)(i) Approval Section 5.7(c) Asset Basis Section 5.16(g)(i) Bankruptcy and a reference to the Equity Principles Section hereof in which such term is defined: Agreement 3.2 Basis Information Section 5.16(g)(i) Business CBA Section 3.19(a) Business Environmental Reports Section 5.25 Business Reports Section 3.11 Buyer Preamble Biogen Idec License Buyer 401(k) Plan Section 5.2(f)(i) Buyer Controlled Action Section 5.19(a) Buyer Deferred Compensation Plans Section 5.2(g)(i) Buyer Employee DCP Participants Section 5.2(g)(i) Buyer Indemnified Parties Section 8.2 Buyer Parent Recitals Buyer Parent Guarantee Recitals Buyer’s Allocation Section 5.16(a)(i) Cap Section 8.5(a)(i) Casualty Event Section 2.5(b) Casualty Event Notice Section 2.5(b) Casualty Loss Adjustment Site Section 2.5(c) Chosen Courts Section 9.1 claim Section 1.1 Claim Notice Section 8.4(b) Closing Section 2.3(a) Closing Cash Amounts Section 2.4(b) Closing Date Section 2.3(a) Closing Indebtedness Section 2.4(b) Closing Month Section 1.1 Closing Net Working Capital Section 2.4(b) Closing Section 338(h)(10) Election Amount Section 2.4(b) Collective Bargaining Agreement Section 4.7 Biogen Idec 3.19(a) Competing Business Section 5.26(b)(ii) Condemnation Action Section 5.28(a) Confidential Business Information Section 5.4(b) Continuation Period Section 5.2(c)(i) Corporate Policies Section 5.13 Covered Parties Section 5.17 COVID-19 Conditions Section 1.1 Current Representation Section 9.17(a) Cutoff Date Section 8.1(a) Damaged Retail Site Section 2.5(b) debt Section 1.1 Debt Financing Section 5.27(a) Deemed Section 338(h)(10) Election Transactions Section 5.16(e) Designated Person Section 9.17(a) Disagreement Notice Section 2.4(c) Disclosing Party Section 5.4(c) Disputed Item Section 2.4(c) Divestiture Actions Section 5.5(c) Divestiture Event Section 5.26(d) DOL Section 3.21(c) Effective Time Section 2.3(a) Estimated Closing Cash Amounts Section 2.4(a)(i) Estimated Closing Indebtedness Section 2.4(a)(i) Estimated Net Working Capital Section 2.4(a)(i) Excluded Businesses Section 1.1 Excluded Marks Section 5.14(a) Excluded Retail Operations Section 5.26(b)(iv) Expenses Schedule Section 9.4(b) Final Allocation Section 5.16(a)(i) Final Cash Amounts Section 2.4(h) Final Closing Adjustment Section 2.4(j) Final Indebtedness Section 2.4(h) Final Net Working Capital Section 2.4(h) Final Purchase Price Section 2.4(j) Final Section 338(h)(10) Election Amount Section 2.4(h) FLSA Section 3.19(b) FTC Section 5.5(b) Governmental Filings Section 3.4 Grandfathered Participants Section 5.2(f)(ii) Incremental Fuel Supply Agreement Section 4.7 Books and Records 5.30(b) Indemnified Party Section 2.12(f)(2) Claim Notice Section 8.3(a) Closing Section 2.3 Closing Date Section 2.3 Company Preamble Company Common Stock Section 2.8 Company Disclosure Schedule Article IV Company Expenses Schedule Section 2.13 Company Indemnified Parties Section 8.2(a)(ii) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e8.4(a) Indemnifying Party Section 8.3(a8.4(a) Instrument Independent Accounting Firm Section 2.12(c2.4(e) Merger Initial Purchase Price Section 2.4(a)(ii) Interim Financial Statements Section 5.22(a) IRS Section 3.21(b) Like-Kind Exchange Section 5.16(l) Losses Section 8.2 Marketing Materials Section 5.27(a) Material Contract Section 3.18(a) Monetization Transaction Section 5.27(d) New Price Section 5.26(d) New Seller Deferred Compensation Plans Section 5.2(g)(ii) Non-Business Employee DCP Participants Section 5.2(g)(ii) Notice Period Section 8.4(b) Offer Notice Section 5.26(d) Offer Price Section 5.26(d) Outside Date Section 7.1(b) Partial Condemnation Actions Section 5.28(a) PBGC Section 3.21(d) Permits Section 3.20(b) Post-Closing Representation Section 9.17(a) Pre-Closing Separate Tax Return Section 5.16(i)(i) Preliminary Adjustment Statement Section 2.4(b) Privileged Communications Section 9.17(b) R&W Insurance Policy Section 5.24 Resolution Period Section 2.4(e) Restricted Activities Section 5.26(a) Restricted Area Section 5.26(a) Restricted Parties Section 5.26(a) Retained Deferred Compensation Plans Section 5.2(g)(iii) Review Period Section 2.4(c) ROFO Section 5.26(d) ROFO Event Section 5.26(d) ROFO Notice Section 5.26(d) RSSP Section 5.2(f)(i) Sale Section 2.1 Merger Certificate Sale Notice Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent 5.26(d) Section 338(h)(10) Election Section 5.16(g)(i) Section 338(h)(10) Election Accounting Firm Section 5.16(g)(i) Section 338(h)(10) Election Amount Section 5.16(g)(i) Section 338(h)(10) Forms Section 5.16(g)(iii) Seller Controlled Action Section 5.19(a) Seller Deferred Compensation Plans Section 5.2(g)(i) Seller Guarantors Section 5.20(a) Seller Indemnified Parties Section 8.2(a)(i8.3 Seller Parent Preamble Seller Surviving Representations Section 8.1(a) parties Seller Thrift Plan Section 5.2(f)(i) Sellers Preamble Payee Separation Activities Section 8.5 Payor 5.7(a) Separation Plan Section 8.5 Per Diem Taxes 5.7(a) Service Credits Section 8.7(a5.2(c)(ii) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Signing Date Preamble Speedway Retirement Plan Sharing Amount Section 2.10(f5.2(e) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Stock Basis Section 2.12(b5.16(g)(i) Surviving Corporation Stock Purchase Subsidiaries Section 2.1 Third Milestone 5.16(g)(i) Straddle Period Section 2.10(g5.16(h)(i) Support Services Section 5.12 Tax Claim Section 5.16(k)(i) Tax Clearance Certificates Section 5.16(m) Terminating Contracts Section 5.11(a) Third Milestone Payment Amount Party Claim Section 2.10(g)8.4(b) Threshold Section 8.5(a)(i) Total Condemnation Actions Section 5.28(b) Transaction Accounting Principles Section 1.1 Transferred Employees Section 5.2(a)(iii) Transition Services Agreement Section 5.30(a) Transportation Services Agreements Section 5.30(c) Unclaimed Property Reports Section 3.31 Union Section 3.19(a) Unresolved Items Section 2.4(f) willful and material breach Section 7.2

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below. Location of AAA Section hereof in which such term is defined: 12.5(c) Affiliates Section 7.17 Agreement Preamble Biogen Idec License Agreement of Merger Section 2.3 ▇▇▇▇▇▇ Employment Agreement Section 4.7 Biogen Idec Supply Agreement 11.3(w) Basket Section 4.7 Books and Records 12.2(c)(i) CCC Recital B CERCLA Section 2.12(f)(2) Claim Notice Section 8.3(a12.2(c)(iii) Closing Section 2.3 2.2 Closing Date Section 2.3 2.2 Closing Date Severance Working Capital Section 3.11(a) Closing Date Working Capital Section 3.3(a) COBRA Section 7.14(e) Company Preamble Company 401(K) Plan Section 10.7(d) Company Board Recommendation Section 7.3(a) Company Common Stock Section 2.8 Company Disclosure Schedule Article IV Company Expenses Schedule Section 2.13 Recital A Company Indemnified Parties Section 8.2(a)(ii12.2(b) Contracts Company Indemnified Party Section 4.8(a12.2(b) Covered Company Indemnifying Parties Section 12.2(a) Company Indemnifying Party (PartiesSection 12.2(a) Contingent Purchase Price Payment Section 8.2(a)(ii3.4(d) CTS Section 11.3(v) Customers Section 7.11(a) Damage Payment Section 12.2(d) Damages Section 8.2(a)(i12.2(a) DGCL Determination Date Section 2.1 Document Retention Period 3.3(b) Disclosure Letter Article VII Dispute Notice Section 2.12(f)(23.4(b) Drug Regulatory Agency Dissenting Shareholder Section 4.25 3.6(a) Dissenting Shares Section 3.6(a) Effective Time Section 2.2 2.3 Environmental Law Section 7.18 ERISA Section 4.13(a7.14(a) ERISA Affiliate Section 4.13(a7.14(a) Finally Determined Escrow Section 8.5(b3.7(a) Escrow Agreement Section 3.7(a) Estimated Severance Working Capital Section 3.10 Estimated Severance Working Capital Statement Section 3.10 Estimated Working Capital Section 3.2 Estimated Working Capital Statement Section 3.2 Excess Payments Section 3.6(d) Expenses Section 10.6 Final Net Sales Statement Section 3.4(c) First Milestone Release Date Section 2.10(e3.7(a)(i) First Milestone Payment Amount GAAP Section 2.10(e7.4(b) Indemnifying Party Governmental Entity Section 8.3(a7.3(b) Instrument Hazardous Substance Section 2.12(c7.18 Insurance Policies Section 9.1 Intellectual Property Rights Section 7.19(a) Interim Balance Sheet Section 7.4(a) Interim Financial Statements Section 7.4(a) KLO Preamble KLO Agreement of Merger Section 2.1 4.3 KLO Board Recommendation Section 7.3(a) KLO Dissenting Shareholder Section 4.9(a) KLO Dissenting Shares Section 4.9(a) KLO Excess Payments Section 4.9(d) KLO Merger Certificate Recital D KLO Merger Effective Time Section 2.2 4.3 KLO Merger Sub Preamble KLO Required Shareholder Vote Section 7.12 KLO Surviving Entity Section 4.1 Liens Section 7.2(f) Material Agreement Section 7.13(a) Merger Recital B Merger Sub Preamble MT Recital E MT Payment Date Section 5.2(b) MT Purchase Agreement Section 5.1 MT Purchase Price Section 5.2(a) MT Stock Section 5.1 Net Sales Statement Section 3.4(a) Notice Section 12.3(a) Notice of Set-Off Dispute Section 3.5 Objection Notice Section 12.3(c) Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i12.2(a) parties Preamble Payee Parent Indemnified Party Section 8.5 Payor 12.2(a) Parent Indemnifying Parties Section 8.5 Per Diem 12.2(b) Parent Indemnifying Party Section 12.2(b) Parent Objection Notice Section 12.3(d) Percentage of Contingent Purchase Price Payment Section 3.4(d) Permits Section 7.8(a) Post-Closing Tax Period Section 9.2(d) Pre-Closing Return Section 9.2(d) Real Property Section 7.16(a) Required Shareholder Vote Section 7.12 Second Release Date Section 3.7(a)(ii) Seller Representative Letter Section 3.8(g) Selling Entity Employees Section 7.20(b) Set-Off Notice Section 3.5 Set-Off Review Period Section 3.5 Severance Working Capital Statement Section 3.11(a) Straddle Period Section 12.2(a)(vi) Surviving Entity Section 2.1 Tax Contest Section 9.2(d) Third Party Claim Section 12.4(a) Third Party Notice Section 12.4(a) Transfer Taxes Section 8.7(a9.2(e) Proceeding Violation Section 4.17 Royalties 7.3(c) Working Capital Statement Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g3.3(a)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: 2004 Plan Section hereof in which such term is defined: 2.4 2009 Plan Section 2.4 Acceptance Time Section 1.1(b) Agreement Preamble Biogen Idec License Agreement Annex I Section 4.7 Biogen Idec Supply Agreement 1.1(a) ARRA Section 4.7 Books and Records 3.14(k) Balance Sheet Section 2.12(f)(23.9(b) Claim Notice Book-Entry Shares Section 8.3(a2.2(b) Breakup Fee Section 7.3(b) Certificate of Merger Section 1.5 Certificates Section 2.2(b) Change of Board Recommendation Section 5.4(b) Closing Section 2.3 1.5 Closing Date Section 2.3 1.5 COBRA Section 3.14(k) Company Preamble Company Board Recitals Company Board Recommendation Recitals Company Bylaws Section 3.2 Company Charter Section 3.2 Company Common Stock Section 2.8 Recitals Company Disclosure Schedule Preamble to Article IV III Company Expenses Schedule Representatives Section 2.13 5.3(a) Company Securities Section 3.3(a) Company Stockholder Approval Section 3.4(b) Comparable Carrier Section 5.16 Continuing Directors Section 1.3(b) DGCL Recitals Dissenting Shares Section 2.3 DOJ Section 5.8 D&O Insurance Section 5.16 Effective Time Section 1.5 Equivalent Coverage Section 5.16 ERISA Affiliate Section 3.14(a) Exchange Act Section 1.1(a) Expiration Date Section 1.1(d) Financial Advisor Section 3.22 FTC Section 5.8 Go-Shop Party Section 5.4(b) Go-Shop Period Termination Date Section 5.4(a) Holding Company Recitals Indemnification Agreements Section 5.16 Indemnified Parties Section 8.2(a)(ii5.16 Initial Expiration Date Section 1.1(d) Insurance Policies Section 3.20 Insured Persons Section 5.16 IP Contracts Section 4.8(a3.19(e) Covered Party (PartiesLeased Real Property Section 3.16(b) Material Contracts Section 8.2(a)(ii3.13(a) Damages Material Leased Real Property Section 8.2(a)(i3.16(b) DGCL Material Real Property Leases Section 2.1 Document Retention Period Section 2.12(f)(23.16(d) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Maximum Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g)5.16

Terms Defined Elsewhere. The Each of the following is a list of additional terms used in this Agreement and a reference has the meaning ascribed to the Section hereof in which such term is definedin the Article or Section set forth opposite such term: Accounts Receivable Section 3.4(e) Adverse Recommendation Section 6.2 Agreement Preamble Biogen Idec License Agreement Alternative Company Acquisition Section 4.7 Biogen Idec Supply Agreement 6.3(g)(ii) Alternative Financing Section 4.7 Books and Records 6.11(c) Alternative Vistas Acquisition Section 2.12(f)(26.3(f)(i) Claim Notice Anghami Merger Sub Preamble Anghami Merger Surviving Company Section 8.3(a2.1(b) Cayman Plan of Merger for the Anghami Merger Section 2.1(b) Cayman Plan of Merger for the Vistas Merger Section 2.1(a) CFO Section 2.2(b)(i) Closing Section 2.3 2.2 Closing Date Section 2.3 2.2 Closing Form 8-K Section 6.4(c) Closing Press Release Section 6.4(c) Communication Policy Section 6.3(h) Company Preamble Company Common Stock Acquisition Proposal Section 2.8 6.3(g)(ii) Company Disclosure Schedule Article IV Class A Shares Section 3.3 Company Expenses Schedule Class C Shares Section 2.13 3.3 Company Closing Statement Section 2.4(a)(i) Company Employee Benefit Plan Section 3.15(a) Company Permits Section 3.17(b) Company Seed Preferred Shares Section 3.3 Company Series A Preferred Shares Section 3.3 Company Series A+ Preferred Shares Section 3.3 Company Shareholders Section 3.3 D&O Claim Section 6.9(a) D&O Entity Section 6.9(a) D&O Indemnification Obligation Section 6.9(d) D&O Indemnified Parties Person Section 8.2(a)(ii6.9(a) Contracts Data Room Section 4.8(a) Covered Party (Parties) 10.5 Dispute Section 8.2(a)(ii) Damages 10.9 Dispute Notice Section 8.2(a)(i) DGCL Section 2.1 Document Retention 10.9 Dispute Resolution Period Section 2.12(f)(210.9 Equity Financing Section 6.11 Financial Statements Section 3.4(a) Drug Regulatory Agency ICDR Section 4.25 Effective Time 10.9 ICDR Rules Section 2.2 ERISA 10.9 Latest Balance Sheet Section 4.13(a3.4(a) ERISA Material Contract Section 3.10(a) Non-Party Affiliate Section 4.13(a10.7 Other Indemnitors Section 6.9(d) Finally Determined Outside Date Section 8.5(b9.1(c) First Milestone Party, Parties Preamble Post-Closing Pubco Board Section 2.10(e2.1(d) First Milestone Payment Amount Pre-Closing Period Section 2.10(e6.3 Registration Statement Section 6.1(a) Indemnifying Party Pubco Preamble Pubco Assumed Option Section 8.3(a2.3(b)(ii) Instrument Public Stockholders Section 2.12(c10.11 Relevant Period Section 3.22 Restrictive Covenant Agreement Recitals Signing Form 8-K Section 6.4(b) Signing Press Release Section 6.4(b) Sponsor Letter Agreement Recitals Registration Rights Agreement Section 8.2(d)(iv) Tail Policy Section 6.9(c) Transactions Recitals Vistas Preamble Vistas Acquisition Proposal Section 6.3(f)(i) Vistas Benefit Plans Section 5.14 Vistas Material Contract Section 5.8 Vistas Merger Section 2.1 Merger Certificate Section 2.2 Recitals Vistas Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Vistas Merger Surviving Company Section 8.2(a)(i2.1(a) parties Preamble Payee Vistas Preferred Shares Section 8.5 Payor 5.2 Vistas Public Securities Section 8.5 Per Diem Taxes 5.15 Vistas Record Date Section 8.7(a6.1(a) Proceeding Vistas SEC Documents Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g)5.5

Terms Defined Elsewhere. The For the purposes of this Agreement, the following is a list terms have the meanings specified in the indicated Sections of additional terms used in this Agreement and a reference to the Agreement: Additional Individual Parties Preamble Additional Individual Party HoldCos Preamble Additional Number Section hereof in which such term is defined: 3.2(b) Agreement Preamble Biogen Idec License Agreement Board Section 4.7 Biogen Idec Supply Agreement 1.2(a) Business Opportunity Section 4.7 Books and Records 11.7 CEO Section 2.12(f)(21.3 CFC Section 10.4 Chairman Section 1.2(c) Claim Company Preamble Compensation Committee Section 1.2(e) Confidential Information Section 8.1 Covered Transaction Section 3.5 Co-Sale Notice Section 8.3(a6.1 Co-Sale Pro Rata Portion Section 6.1(a) Closing Co-Sale Right Period Section 2.3 Closing 6.1 Director Section 1.2(a) Disclosing Party Section 8.4 Disposal Event Section 11.1(c)(i) Exercising ROFR Holder Section 5.2(b) First Participation Notice Section 3.2(a) First Refusal Expiration Notice Section 5.2(c) First Refusal Period Section 5.2(a) Founders Preamble Founder HoldCos Preamble HKIAC Section 12.12(b) HKIAC Rules Section 12.12(b) Information Rights Holder Section 1.1(a) Initiating Holders Section 2.2(b) Inspection Rights Section 1.1(c) Investors Preamble IPO Section 2.11(c) IPO Event Section 11.1(c)(i) Key Group Company Preamble Loan Outside Date Section 2.3 Company Preamble Company Common Stock Section 2.8 Company Disclosure 11.1(c)(i) MGJ OpCo Schedule Article IV Company Expenses A-1 MLS Schedule Section 2.13 Company Indemnified Parties Section 8.2(a)(ii) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention A-1 MLS OpCo Schedule A-1 Non-Competition Period Section 2.12(f)(211.4 Offered Shares Section 5.1 Onshore Equity Transfer Section 11.12 Onshore Personnel Replacement Section 11.12 Ordinary Director/Ordinary Directors Section 1.2(c) Drug Regulatory Agency Overallotment New Securities Section 4.25 Effective Time 3.2(b) Oversubscribing Right Participants Section 2.2 ERISA 3.2(b) Participation Rights Holder Section 4.13(a3.1 Party/Parties Preamble Permitted Transferee Section 4.4 PFIC Section 10.3 PFIC Shareholder Section 10.3 Preferred Director/Preferred Directors Section 1.2(b) ERISA Affiliate Prior Shareholders Agreement Recital (A) Re-allotment Period Section 4.13(a5.2(b) Finally Determined Re-allotment Share Number Section 8.5(b5.2(b) First Milestone Request Notice Section 2.10(e2.2(a) First Milestone Payment Amount Right of Participation Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g)3.1

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: "Agreement" Preamble "Certificate of Merger" Section hereof in which such term is defined: Agreement 1.2 "Certificates" Section 2.2.2 "Company" Preamble Biogen Idec License Agreement "Company Benefit Plan" Section 4.7 Biogen Idec Supply Agreement 3.12.1 "Company Board" Recitals "Company By-laws" Section 4.7 Books and Records 3.2 "Company Certificate" Section 2.12(f)(2) Claim Notice Section 8.3(a) Closing Section 2.3 Closing Date Section 2.3 Company Preamble 3.2 "Company Common Stock Stock" Section 2.8 2.1.1 "Company Disclosure Schedule Schedule" Article IV 3 "Company Expenses Schedule Employees" Section 2.13 5.10 "Company Indemnified Parties Financial Advisor" Section 8.2(a)(ii) Contracts 3.17 "Company Leased Property" Section 4.8(a) Covered Party (Parties) 3.8.1 "Company Material Contract" Section 8.2(a)(ii) Damages 3.11 "Company Options" Section 8.2(a)(i) DGCL 2.5 "Company Owned Property" Section 2.1 Document Retention Period 3.8.1 "Company Permits" Section 2.12(f)(2) Drug Regulatory Agency 3.19.1 "Company Real Property" Section 4.25 3.8.1 "Company Representatives" Section 5.5 "Company SEC Filings" Section 3.5.1 "Company Stockholders' Meeting" Section 5.4 "Company Subsidiaries" Section 3.1 "D&O Insurance" Section 5.11.2 "Dissenting Stockholders" Section 2.1.1 "DGCL" Recitals 38 "Effective Time Time" Section 2.2 1.2 "ERISA" Section 3.12.1 "ERISA Affiliate" Section 4.13(a) ERISA Affiliate 3.12.1 "▇▇▇▇▇▇ Street Agreement" Section 4.13(a) Finally Determined 3.8.11 "IRS" Section 8.5(b) First Milestone 3.7.5 "Lease Documents" Section 2.10(e) First Milestone Payment Amount 3.8.3 "Material Intellectual Property" Section 2.10(e) Indemnifying Party 3.10 "Merger" Recitals "Merger Consideration" Section 8.3(a) Instrument 2.1.1 "Merger Sub" Preamble "Multiemployer Plan" Section 2.12(c) Merger 3.12.3 "Option Payment" Section 2.1 Merger Certificate 2.5 "Outside Date" Section 2.2 Merger Sub 7.1.2 "Parent" Preamble "Parent Preamble Benefit Plan" Section 5.10 "Parent Disclosure Schedule" Article 4 "Parent Representatives Section 5.5 "Parent Subsidiaries" Recitals "Paying Agent" Section 2.2.1 "Payment Fund" Section 2.2.1 "PBGC" Section 3.12.4 "Permitted Exceptions" Section 3.8.2 "Proxy Statement" Section 5.3.1 "Qualifying Acquisition Proposal" Section 5.6.1 "Regulatory Conditions" Section 7.1.2 "Requisite Stockholder Approval" Section 3.18 "Schedule Article V 13E-3" Section 5.3.1 "Separation Agreements" Recitals "Special Committee" Recitals "Surviving Corporation" Section 1.1 "Surveys" Section 3.8.2 "Taxes" Section 3.7.13 "Tax Return" Section 3.7.13 "Terminating Company Breach" Section 7.1.5 39 "Terminating Parent Indemnified Parties Breach" Section 8.2(a)(i) parties Preamble Payee 7.1.6 "Title Policies" Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g)3.8.2 "Voting Agreements" Recitals

Terms Defined Elsewhere. The For purposes of this Agreement, the following is a list of additional terms used have the meanings set forth in this Agreement and a reference to the Sections indicated: Term Section hereof in which such term is defined: 2017 Financial Statements Section 5.13(a) Acquisition Transaction Section 5.9 Agreement Preamble Biogen Idec License Agreement Agreements and Instruments Section 4.7 Biogen Idec Supply Agreement 4.12 Allocation Statement Section 4.7 Books and Records 2.7(a) Annual Financial Statements Section 2.12(f)(23.6 Antitrust Laws Section 5.4(b) Claim Notice Balance Sheet Section 8.3(a3.6 Balance Sheet Date Section 3.6 Basket Section 8.5(a) Cash Consideration Amount Section 2.2(a) Closing Section 7.4 Closing Cash Consideration Section 2.3 Closing Date Section 7.4 Closing Net Working Capital Section 2.4(a) Closing Statement Section 2.4(a) Company Released Parties Section 5.10(a) Cumulative Revenue Make Up Amount Section 2.5(a) Dispute Notice Section 2.4(b) Disputed Amount Section 2.6(b) Earnout Recipients Section 2.5(d) Earnout Statement Section 2.5 Employee Benefit Plans Section 3.14(a) Equity Interests Recitals Estimated Closing Statement Section 2.3 Company Estimated Net Working Capital Section 2.3 FCPA Section 3.17(c) Financial Statements Section 3.6 Fraud Claims Section 8.1(b) ▇. ▇▇▇▇▇▇ Guaranties Section 5.14 HSR Act Section 3.5(b) Indemnification Claim Section 8.4(a) Indemnity Cap Section 8.5(d) Insurance Policies Section 3.21 Interim Financial Statements Section 3.6 Leased Real Property Section 3.10(a) Losses Section 8.2(a) Material Contracts Section 3.13(a) Material Customers Section 3.24(a) Material Vendors Section 3.24(a) Non-Disclosure Agreement Section 5.6(a) NYSE Section 4.13 Objection Notice Section 2.5(c) Party and Parties Preamble Company Payoff Letters Section 7.1(i) Personal Property Leases Section 3.11 Purchaser Preamble Purchaser Common Stock Section 2.8 Company Disclosure Schedule Article IV Company Expenses Schedule 2.2(a) Purchaser Documents Section 2.13 Company 4.2 Purchaser Financial Statements Section 4.10 Purchaser Indemnified Parties Section 8.2(a)(ii8.2(a) Contracts Purchaser Plans Section 4.8(a6.1(b) Covered Party (PartiesPurchaser Preferred Stock Section 4.9(a) Purchaser SEC Documents Section 8.2(a)(ii4.11(a) Damages R&W Policy Premium Section 8.2(a)(i8.10 Real Property Leases Section 3.10(a) DGCL 93 Required Quarter Financial Statements Section 2.1 Document Retention Period 5.13(a) Rights-of-Way Section 2.12(f)(23.10(a) Drug Regulatory Agency SEC Section 4.25 Effective Time 4.10 Seller Documents Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent 3.2 Seller Indemnified Parties Section 8.2(a)(i8.3 Sellers Representative Section 9.1(a) parties Sellers Preamble Payee Specified Creditors Section 8.5 Payor 2.3(b) Specified Indebtedness Section 8.5 Per Diem Taxes 2.3(b) Specified Indebtedness Statement Section 8.7(a2.3(b) Proceeding Tax Matter Section 4.17 Royalties 9.2(d) Termination Date Section 2.10(h7.5(a) Second Milestone Transaction Consideration Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g)2.2

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: Adverse Recommendation Change Section hereof in which such term is defined: 6.02(c) Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 6.02(c) Arbitrator Section 4.7 Books and Records 10.08(b) Assumed Option Section 2.12(f)(23.03(b) Claim Notice Base Premium Section 8.3(a7.05(d) Benefit Plan Section 4.15(b) BlueCity Holdings Limited Section 2.06 Closing Section 2.3 2.02 Closing Date Section 2.3 2.02 Company Preamble Company Common Stock Board Recitals Company Board Recommendation Recitals Company Equity Interests Section 2.8 4.02(b) Company Disclosure Schedule Article IV Group Section 9.02(h) Company Expenses Schedule Termination Fee Section 2.13 Company Indemnified Parties 9.02(e) Competing Proposal Section 8.2(a)(ii) Contracts Section 4.8(a6.02(g) Covered Party (PartiesPersons Section 7.05(a) Deposit Agreement Section 8.2(a)(ii3.05 Depositary Section 3.05 Dissenting Shareholders Section 3.06(a) Damages Dissenting Shares Section 8.2(a)(i3.06(a) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA 2.03 Enforceability Exceptions Section 4.03 Equity Commitment Letter Section 5.05(a) Equity Financing Section 5.05(a) Exchange Ratio Section 3.03(b) Financial Statements Section 4.06(b) HKIAC Section 10.08(b) HKIAC Rules Section 10.08(b) Indemnification Agreements Section 7.05(a) Insurance Policies Section 4.18 Intervening Event Section 6.02(e) Legal Proceeding Section 5.08 Limited Guarantee Recitals Material Contracts Section 4.16(a)(xiv) Merger Recitals Merger Consideration Section 3.02(a) Merger Consideration Fund Section 3.02(a) Merger Sub Preamble Nasdaq Section 4.02(c) Non-Required Remedy Section 7.02(d) Operating Subsidiary Section 4.16(a)(xi) Parent Preamble Parent Group Section 9.02(h) Parent Termination Fee Section 9.02(f) Parties Preamble Party Preamble Paying Agent Section 3.02(a) Per ADS Merger Consideration Section 3.01(b) Per Share Merger Consideration Section 3.01(a) Plan of Merger Section 2.03 PRC Subsidiaries Section 4.09(a) Proxy Statement Section 4.05 Record ADS Holders Section 6.04(a) Record Date Section 6.04(a) Registrar of Companies Section 2.03 Rollover Shareholders Recitals S▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 4.06(a) Schedule 13E-3 Section 6.03(a) SEC Documents Section 4.06(a) Securities Act Section 4.06(a) Share Certificates Section 3.02(b)(i) Social Insurance Section 4.15(k) Special Committee Recitals Superior Proposal Section 6.02(h) Support Agreement Recitals Surviving Company Section 2.01 Takeover Statute Section 4.23 Tax Returns Section 4.13(a) ERISA Affiliate Transaction Litigation Section 4.13(a7.08 Transactions Recitals U.S. GAAP Section 4.06(b) Finally Determined Uncertificated Shares Section 8.5(b3.02(b)(i) First Milestone VIE Contracts Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g4.09(c)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: Action Section hereof in which such term is defined: 4.11(b) Agreement Preamble Biogen Idec License Agreement Anglo China Preamble Anti-Corruption Laws Section 4.7 Biogen Idec Supply Agreement 4.5(b) Table of Contents Bankruptcy and Equity Exception Section 4.7 Books and Records 4.3(a) Britain Ukan Preamble Cayman Companies Law Recitals Certificates Section 2.12(f)(2) Claim Notice Section 8.3(a3.2(c) Closing Section 2.3 2.2 Closing Date Section 2.3 2.2 Company Preamble Company Common Stock Adverse Recommendation Change Section 2.8 6.4(c)(i) Company Disclosure Schedule Article IV Board Recitals Company Expenses Schedule Financial Advisors Section 2.13 4.3(b) Company Financial Statements Section 4.6(b) Company Group Section 8.2(d) Company Intellectual Property Section 4.14(b) Company Material Contract Section 4.11(a) Company Plan(s) Section 4.9(a) Company Recommendation Section 4.3(b) Company Representatives Section 6.3(a) Company SEC Filings Section 4.6(a) Company Shareholders Meeting Section 6.2(e) Company Subsidiary Section 4.1 D&O Insurance Section 6.12(b) Dissenter Rights Section 3.1(f) Dissenting Shares Section 3.1(f) Dissenting Shareholders Section 3.1(f) Effective Time Section 2.3 End Date Section 8.1(b)(i) Exchange Fund Section 3.2(a) Financing Section 5.6 Founder Vehicle Preamble HKIAC Section 9.7(c) Indemnified Parties Section 8.2(a)(ii6.12(a) Contracts Independent Committee Recitals Investments Section 4.8(a4.2(d) Covered Party (PartiesLeased Real Property Section 4.17(b) Lender Section 8.2(a)(ii) Damages 5.6 Loan Agreement Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) 5.6 Merger Section 2.1 Merger Certificate Section 2.2 Recitals Merger Sub Preamble Notice Period Section 6.4(d)(iii) Owned Real Property Section 4.17(a) Parent Preamble Table of Contents Parent Disclosure Group Section 8.2(d) Parent Representatives Section 6.3(a) Party Preamble Paying Agent Section 3.2(a) Per ADS Merger Consideration Section 3.1(b) Per Share Merger Consideration Section 3.1(b) Plan of Merger Section 2.2 Proxy Statement Section 6.2(a) Registrar of Companies Section 2.3 Schedule Article V Parent Indemnified Parties 13E-3 Section 8.2(a)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b4.4(b) Surviving Corporation Section 2.1 Third Milestone Transaction Litigation Section 2.10(g) Third Milestone Payment Amount 6.8 Uncertificated Shares Section 2.10(g3.2(c)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: Acceptance Time Section hereof in which such term is defined: 2.4(a) Action Section 5.14 Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 7.5(c)(ii) Articles of Merger Section 4.7 Books and Records 3.3 Bankruptcy Exception Section 2.12(f)(25.3(a) Claim Board Appointment Date Section 2.4(a) Book-Entry Shares Section 4.2(b) Certificates Section 4.2(b) CFIUS Notice Section 8.3(a) 7.19 Closing Section 2.3 3.2 Closing Date Section 2.3 3.2 Company Preamble Company Adverse Recommendation Change Section 7.5(c)(i) Company Board Recitals Company Board Recommendation Section 2.3(a)(v) Company Common Stock Section 2.8 Recitals Company Disclosure Schedule Article IV Documents Section 5.10(a) Company Expenses Schedule Financial Advisor Section 2.13 5.3(c) Company Indemnified Parties Financial Statements Section 8.2(a)(ii5.7(b) Contracts Company Intellectual Property Section 4.8(a5.16 Company Material Contract Section 5.13(a) Covered Party (PartiesCompany Plan(s) Section 8.2(a)(ii5.11(a) Damages Company Preferred Stock Section 8.2(a)(i5.2(a) DGCL Company Representatives Section 2.1 Document Retention Period 7.4(a) Company SEC Filings Section 2.12(f)(25.7(a) Drug Regulatory Agency Company Shareholder Approval Section 4.25 5.3(b) Company Shareholders Recitals Company Shareholders’ Meeting Section 7.2(a) Company Subsidiary Section 5.1 Compensation Committee Section 5.23 Continuing Directors Section 2.4(a) Determination Notice Section 7.5(d)(i)(C) Dissenting Shareholder Section 4.3 Dissenting Shares Section 4.3 Effective Time Section 2.2 3.3 Employment Compensation Arrangement Section 5.23 End Date Section 9.1(b)(i) ERISA Section 4.13(a5.11(a) ERISA Affiliate Section 4.13(a5.11(a) Finally Determined Exchange Fund Section 8.5(b4.2(a) First Milestone Expiration Date Annex A FCPA Section 2.10(e5.6(b) First Milestone Payment Governmental Antitrust Entity Section 7.6(e)(i) Indemnified Parties Section 7.13(a) Independent Directors Section 2.4(b) Intervening Event Change of Recommendation Section 7.5(d)(ii) Investments Section 5.2(d) IRS Section 5.11(b) Loan Payoff Amount Section 2.10(e7.7(b) Indemnifying Party Measurement Date Section 8.3(a) Instrument Section 2.12(c5.2(a) Merger Recitals Merger Consideration Section 2.1 Merger Certificate Section 2.2 4.1(a) Merger Sub Preamble MGBCL Recitals Minimum Condition Section 2.1(b) Notes Section 7.7(a) Notice Period Section 7.5(d)(i)(C) Offer Recitals Offer Documents Section 2.1(g) Offer Price Recitals Offer to Purchase Section 2.1(g) Parent Preamble Parent Disclosure Schedule Documents Section 6.7(b) Parent Representatives Section 7.4(a) Party, Parties Preamble Paying Agent Section 4.2(a) Proxy Statement Section 7.2(b) Recent SEC Reports Article V Parent Indemnified Parties Redemption Section 8.2(a)(i7.7(a) parties Preamble Payee Schedule TO Section 8.5 Payor 2.1(g) Schedule 14D-9 Section 8.5 Per Diem Taxes 2.3(b) Short-Form Threshold Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) 7.3 Surviving Corporation Section 2.1 Third Milestone 3.1 Tail Period Section 2.10(g7.13(c) Third Milestone Payment Amount Takeover Provisions Section 2.10(g)2.3(a)(iv) Top-Up Option Section 2.2(a) Transaction Litigation Section 7.8 WARN Act Section 5.12

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: 401(k) Plan Section hereof in which such term is defined: 5.07(c) Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 5.03(d)(i) Book-Entry Shares Section 4.7 Books and Records 2.02(b) Capitalization Date Section 2.12(f)(23.02(a) Claim Notice Certificate of Merger Section 8.3(a1.02 Certificates Section 2.02(b) Change of Board Recommendation Section 5.03(a)(iv) Closing Section 2.3 1.02 Closing Date Section 2.3 1.02 Company Preamble Company Common Stock Section 2.8 Board Recitals Company Board Recommendation Recitals Company Disclosure Schedule Article IV ARTICLE III Company Expenses Schedule Employees Section 2.13 5.07(a) Company Indemnified Parties Financial Statements Section 8.2(a)(ii3.07(a) Contracts Company Material Contract Section 4.8(a3.13(a) Covered Party (PartiesCompany Permits Section 3.05(a) Company Preferred Stock Section 8.2(a)(ii3.02(a) Damages Company Representatives Section 8.2(a)(i5.02(a) Company SEC Documents Section 3.06(a) Company Stockholder Approval Section 3.21 Confidentiality Agreement Section 5.02(c) D&O Insurance Section 5.08(c) DGCL Recitals Dispute Section 2.1 Document Retention Period 3.15(i) Dissenting Shares Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 2.03 Effective Time Section 2.2 ERISA 1.02 Electronic Delivery Section 4.13(a8.13 Employment Practices Section 3.12(a) ERISA Affiliate Equity Plan Documents Section 4.13(a2.04(b) Finally Determined Equity Plan Stock Section 8.5(b2.04(b) First Milestone Exon-▇▇▇▇▇▇ Filing Section 2.10(e5.04(c) First Milestone Payment Export Approvals Section 3.05(e) Guarantee Section 8.15(c) Guaranteed Obligations Section 8.15(a) Guarantor Section 8.15(a) Insurance Policies Section 3.17 Intervening Event Notice Period Section 5.03(e)(i) Lease Agreement Section 3.18(c) Leased Real Property Section 3.18(c) LGPL Section 3.15(f) Maximum Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c5.08(c) Merger Section 2.1 Recitals Merger Certificate Section 2.2 Consideration Recitals Merger Sub Preamble Most Recent Balance Sheet Section 3.09(a)(i) New Plans Section 5.07(a) Parent Preamble Parent Disclosure Schedule Article V 401(k) Plan Section 5.07(c) Parent Indemnified Parties Representatives Section 8.2(a)(i5.02(a) parties Preamble Payee Parent Subsidiary Section 8.5 Payor 4.03(a) Parent Welfare Plan Section 8.5 Per Diem Taxes 5.07(a) Paying Agent Section 8.7(a2.02(a) Proceeding Proxy Statement Section 4.17 Royalties 1.03(a) ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 2.10(h3.06(a) Second Milestone Section 2.10(f16 Section 5.10 Shares Recitals Significant Customer Section 3.23 Special Meeting Section 1.03(e) Second Milestone Payment Amount Superior Proposal Notice Period Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b5.03(d)(i) Surviving Corporation Recitals Takeover Law Section 2.1 Third Milestone 3.03(b) Termination Fee Section 2.10(g7.02(b) Third Milestone Payment Amount Unvested Cash Section 2.10(g2.04(b) WARN Act Section 3.12(e) Worker List Section 3.12(g)

Terms Defined Elsewhere. The following is a list of additional terms used in this Agreement and a reference to the Section hereof in which such term is defined: AAA Section 9.3(b) Adjustment Event Section 2.6 Aggregate Company Consideration Section 2.2(b) Aggregate N.Z. Consideration Section 2.1(b) Aggregate U.S. Consideration Section 2.1(a) Agreement Preamble Biogen Idec License Agreement Arbitrator Section 4.7 Biogen Idec Supply Agreement 9.3(b) Australian Business Number Section 4.7 Books and Records 4.12(a) Australian Company Preamble Australian Indemnification Obligations Section 2.12(f)(29.2(a)(i) Blue Sky Laws Section 4.17 Cash Consideration Section 2.4(b) Cash Percentage Section 2.4(a) CERCLA Section 4.13 Claim Notice Section 8.3(a9.3(a) Closing Section 2.3 3.1 Closing Date Section 2.3 3.1 Company Preamble Cap Section 9.5(b) Company Common Stock Marks Section 2.8 4.20(b) Company Disclosure Schedule Article IV Patents Section 4.20(c) Company Expenses Schedule Percentage Interest Section 2.13 2.2(b) Company Registered Copyrights Section 4.20(d) Company Registered IP Section 4.20(g) Company Shareholders Recitals Company Shares Recitals Company Software Section 4.20(l) Copyrights Section 4.20(a) Damages Section 9.2(a) Disposition Section 6.9 Dispute Notice Section 9.3(b) Double Taxation Agreement Section 4.12(a) Effective Period Section 6.2(d) Employee Loans Section 4.8(a) Escrow Account Section 2.5 Escrow Agent Section 2.5 Escrow Amount Section 2.5 Escrow Shares Section 2.5 Escrow Value Section 9.6 Foreign Status Certificate Section 3.2(n) GST Section 4.12(a) Hazardous Materials Section 4.13 Holder Section 6.2(f)(iii) Inbound License Agreements Section 4.20(i) Indemnified Parties Party Section 8.2(a)(ii9.3(a) Indemnitor Section 9.3(a) Intellectual Property Section 4.20(a) Lock-up Section 6.9 Lock-up Period Section 6.9 Marks Section 4.20(a) Mask Works Section 4.20(a) Material Contracts Section 4.8(a) Covered Net Cash Deficit Section 2.7(b) Net Cash Estimate Section 2.7(a) N.Z. Company Preamble N.Z. Purchase Price Section 2.1(d) N.Z. Shareholders Recitals N.Z. Shares Recitals Net Cash Estimate Section 2.7(a) OSR Section 6.14 Outside Date Section 8.1(b) Parent Preamble Parent SEC Documents Section 5.5 Patents Section 4.20(a) Personal Element Section 4.20(p) Privacy Policies Section 4.20(p) Proceeding Section 4.18 Purchaser Preamble Purchaser Indemnified Parties Section 9.2(a) Real Property Section 4.5(c) Registration Indemnified Party (PartiesSection 6.2(g)(iii) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Registration Indemnifying Party Section 8.3(a6.2(g)(iii) Instrument Registration Statement Section 2.12(c6.2(a) Merger Share Consideration Section 2.1 Merger Certificate 2.4(b) Share Percentage Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent 2.4(a) Shareholder Indemnified Parties Section 8.2(a)(i9.2(b) parties Preamble Payee Shares Section 8.5 Payor 2.3 Software Section 8.5 Per Diem 4.20(l) Tax Section 4.12(a) Tax Return Section 4.12(a) Taxable Section 4.12(a) Taxes Section 8.7(a4.12(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Threshold Amount Section 2.10(f9.5(a) Stockholder Consent Trade Secrets Section 4.20(a) Transaction Fees Section 10.12 U.S. Company Preamble U.S. Purchase Price Section 2.1(b) U.S. Shareholder Recitals Stockholder Representative Preamble Super Majority U.S. Shares Recitals Unique Identifying Number Section 2.12(b4.20(p) Surviving Corporation Unstamped Transfers Section 2.1 Third Milestone 6.14 User Data Section 2.10(g4.20(p) Third Milestone Payment Amount Violation Section 2.10(g6.2(g)(i)

Terms Defined Elsewhere. The For purposes of this Agreement, each of the following is a list of additional terms (as capitalized below) when used in this Agreement and a reference will have the meaning ascribed to such term in the Section hereof in which set forth opposite such term is definedterm: Action Section 5.10(b) Agreement Preamble Biogen Idec License Agreement Alternative Financing Section 4.7 Biogen Idec Supply Agreement 5.16(c) Alternative Proposal Section 4.7 Books and Records 5.4(g) Appraisal Rights Section 2.12(f)(22.1(b) Claim Notice Book-Entry Shares Section 8.3(a2.2(a) Burdensome Condition Section 5.7(c) Cancelled Shares Section 2.1(a)(ii) Certificate of Merger Section 1.3 Certificates Section 2.2(a) Change of Recommendation Section 5.4(c) Closing Section 2.3 1.2 Closing Date Section 2.3 1.2 Code Section 2.2(b)(iii) Commitment Letter Section 4.6(a) Common Stock Section 2.1(a)(i) Company Preamble Company Common Stock Section 2.8 Board Recitals Company Disclosure Schedule Letter Article IV 3 Company Expenses Schedule PSU Consideration Section 2.13 2.3(c) Company Indemnified Recommendation Section 3.3 Company Registered IP Section 3.10(a) Company Related Parties Section 8.2(a)(ii7.3(d) Contracts Company RSU Consideration Section 4.8(a2.3(a) Covered Party (PartiesCompany SEC Reports Section 3.5(a) Company Stockholder Approval Section 8.2(a)(ii3.20 Company Stockholders’ Meeting Section 5.5(b) Damages Company Termination Fee Section 8.2(a)(i7.3(a) Confidentiality Agreement Section 5.3(b) Continuation Period Section 5.6(a) Data Breach Section 3.10(a) Data Protection Requirements Section 3.10(f) Definitive Agreements Section 5.16(a) DGCL Recitals Dissenting Shares Section 2.1 Document Retention Period Section 2.12(f)(22.1(b) Drug Regulatory Agency Section 4.25 ▇▇▇▇▇ Article 3 Effective Time Section 2.2 ERISA 1.3 Employee Census Section 4.13(a3.15(g) ERISA Affiliate End Date Section 4.13(a7.1(b) Finally Determined Filed SEC Reports Article 3 Financing Section 8.5(b4.6(a) First Milestone Financing Amounts Section 2.10(e4.6(d) First Milestone Payment Indemnified Party Section 5.10(b) Intervening Event Section 5.4(i) Intervening Event Notice Section 5.4(e) Intervening Event Notice Period Section 5.4(e) Leases Section 3.9(a) Legal Restraint Section 6.1(b) Lenders Section 4.6(a) Made Available to Parent Section 8.12 Material Contract Section 3.11(a) Maximum Amount Section 2.10(e5.10(c) Indemnifying Party Measurement Time Section 8.3(a) Instrument Section 2.12(c3.2(a) Merger Recitals Merger Consideration Section 2.1 Merger Certificate Section 2.2 2.1(a)(i) Merger Sub Preamble New Plans Section 5.6(b) Old Plans Section 5.6(b) Owned Real Property Section 3.9(a) Parent Preamble Parent Approvals Section 4.2(b) Parent Disclosure Schedule Letter Article V 4 Parent Indemnified Material Adverse Effect Section 4.1 Parent Related Parties Section 8.2(a)(i7.3(d) parties Preamble Payee Parent RSU Section 8.5 Payor 2.3(b) Parent Termination Fee Section 8.5 Per Diem Taxes 7.3(b)(i) Paying Agent Section 8.7(a2.2(a) Proceeding Payment Fund Section 4.17 Royalties 2.2(a) Permitted Change of Recommendation Section 2.10(h5.4(e) Second Milestone Permitted Termination Section 2.10(f5.16(b) Second Milestone Payment Amount Prohibited Modifications Section 2.10(f5.16(b) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Proposed Dissenting Shares Section 2.12(b2.1(b) Representatives Section 5.3(a) Share Section 2.1(a)(i) Subsidiary Shares Section 2.1(a)(i) Superior Proposal Section 5.4(h) Superior Proposal Notice Section 5.4(d) Superior Proposal Notice Period Section 5.4(c) Surviving Corporation Section 2.1 Third Milestone 1.1 Takeover Statute Section 2.10(g3.19 Tax Incentive Section 3.15(g) Third Milestone Payment Amount Terminating Company PSU Section 2.10(g2.3(c) Terminating Company RSU Section 2.3(a) Termination Date Section 5.1(a)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: 401(k) Plan Section hereof in which such term is defined: 5.07(d) Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 5.03(d)(i) Book-Entry Shares Section 4.7 Books and Records 2.02(b) Capitalization Date Section 2.12(f)(23.02(a) Claim Notice Certificate of Merger Section 8.3(a1.02 Certificates Section 2.02(b) Change of Board Recommendation Section 5.03(a)(iv) Closing Section 2.3 1.02 Closing Date Section 2.3 1.02 Company Preamble Company Common Stock Section 2.8 Board Recitals Company Board Recommendation Recitals Company Disclosure Schedule Article IV III Company Expenses Schedule Employees Section 2.13 5.07(a) Company Indemnified Parties Financial Statements Section 8.2(a)(ii3.07(a) Contracts Company Material Contract Section 4.8(a3.13(a) Covered Party (PartiesCompany Permits Section 3.05(a) Company Preferred Stock Section 8.2(a)(ii3.02(a) Damages Company Representatives Section 8.2(a)(i5.02(a) Company SEC Documents Section 3.06(a) Company Stockholder Approval Section 3.21 Confidentiality Agreement Section 5.02(c) D&O Indemnification Agreements Section 5.08(a) D&O Runoff Insurance Section 5.08(c) DGCL Recitals Dispute Section 2.1 Document Retention Period 3.15(l) Dissenting Shares Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 2.03 Effective Time Section 2.2 ERISA 1.02 Electronic Delivery Section 4.13(a8.13 Employment Practices Section 3.12(a) ERISA Affiliate Export Approvals Section 4.13(a3.05(e) Finally Determined Fundamental Representations Section 8.5(b6.02(a)(ii) First Milestone Guaranteed Obligations Section 2.10(e8.15(a) First Milestone Payment Guarantor Section 8.15(a) Guaranty Section 8.15(c) Indemnified Persons Section 5.08(a) Independent Director Section 3.12(f) Insurance Policies Section 3.17 Intercompany Contracts Section 3.13(a)(vii) Intervening Event Notice Period Section 5.03(e)(i) Leased Real Property Section 3.18(c) Maximum Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c5.08(c) Merger Section 2.1 Recitals Merger Certificate Section 2.2 Consideration Recitals Merger Sub Preamble Most Recent Balance Sheet Section 3.09(a)(i) New Plans Section 5.07(a) Parent Preamble Parent Disclosure Schedule Article V Representatives Section 5.02(a)(i) Parent Indemnified Parties Subsidiary Section 8.2(a)(i4.03(a) parties Preamble Payee Parent Welfare Plan Section 8.5 Payor 5.07(a) Paying Agent Section 8.5 Per Diem Taxes 2.02(a) Proxy Statement Section 8.7(a1.03(a) Proceeding PSU Award Section 4.17 Royalties 2.04(d) Replacement PSU Section 2.10(h2.04(d) Second Milestone Replacement RSU Section 2.10(f2.04(b) Second Milestone Payment Amount RSU Award Section 2.10(f2.04(b) Stockholder Consent ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 3.06(a) Section 16 Section 5.10 Shares Recitals Stockholder Representative Preamble Super Majority Significant Customer Section 2.12(b3.13(a)(xviii) Specified Antitrust Laws Section 6.01(b) Special Meeting Section 1.03(e) Superior Proposal Notice Period Section 5.03(d)(i) Surviving Corporation Recitals Takeover Law Section 2.1 Third Milestone 3.03(b) Termination Fee Section 2.10(g7.02(b) Third Milestone Payment Amount U.S. Continuing Employees Section 2.10(g5.07(b) WARN Act Section 3.12(d)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: $ Section hereof in which such term is defined: 1.3(c) Adverse Recommendation Change Section 6.2(c) Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 6.2(c) Arbitrator Section 4.7 Books and Records 10.8(b) Base Premium Section 2.12(f)(27.4(d) Claim Notice CICL Section 8.3(a) 2.1 Closing Section 2.3 2.2 Closing Date Section 2.3 2.2 Company Preamble Company Common Stock Board Recitals Company Board Recommendation Recitals Company Equity Interests Section 2.8 4.2(a) Company Disclosure Schedule Article IV Group Section 9.2(h) Company Expenses Schedule Intellectual Property Rights Section 2.13 4.11(a) Company Indemnified Parties Termination Fee Section 8.2(a)(ii9.2(e) Contracts Competing Proposal Section 4.8(a6.2(g) Covered Party (PartiesPersons Section 7.4(a) Dissenting Shareholders Section 8.2(a)(ii3.3(a) Damages Dissenting Shares Section 8.2(a)(i3.3(a) DGCL Dollars Section 2.1 Document Retention Period Section 2.12(f)(21.3(c) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA 2.3 Enforceability Exceptions Section 4.13(a4.3 Equity Commitment Letter Section 5.5(a) ERISA Affiliate Equity Financing Section 4.13(a5.5(a) Finally Determined Exchange Act Section 8.5(b4.5 Exchange Fund Section 3.2(a) First Milestone Financial Statements Section 2.10(e4.6(b) First Milestone Payment Amount Fuling Global, Inc. Section 2.10(e2.6 GAAP Section 4.6(b) Indemnifying Party Governmental Entity Section 8.3(a4.5 HKIAC Section 10.8(b) Instrument Indemnification Agreements Section 2.12(c7.4(a) Legal Proceeding Section 4.12 Merger Recitals Merger Consideration Section 2.1 Merger Certificate Section 2.2 3.2(a) Merger Sub Preamble Nasdaq Section 4.5 Non-Required Remedy Section 7.2(e) Parent Preamble Parent Disclosure Group Section 9.2(h) Parent Termination Fee Section 9.2(f) Parties Preamble Party Preamble Paying Agent Section 3.2(a) Per Share Merger Consideration Section 3.1(a) Plan of Merger Section 2.3 Proxy Statement Section 4.5 Record Date Section 6.4(a) Regulatory Filings Section 4.5 Rollover Shareholders Recitals Rules Section 10.8(b) ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 4.6(a) Schedule Article V Parent Indemnified Parties 13E-3 Section 8.2(a)(i6.3(a) parties Preamble Payee SEC Section 8.5 Payor 4.5 SEC Documents Section 8.5 Per Diem Taxes 4.6(a) Securities Act Section 8.7(a4.8 Share Certificates Section 3.2(b)(i) Proceeding Special Committee Recitals Superior Proposal Section 4.17 Royalties Section 2.10(h6.2(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Support Agreements Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Entity Section 2.1 Third Milestone Takeover Statute Section 2.10(g) Third Milestone Payment Amount 4.16 Transaction Litigation Section 2.10(g7.7 Transactions Recitals Uncertificated Shares Section 3.2(b)(i)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: Action Section hereof in which such term is defined: 4.12 Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 6.4(c)(ii) Alternative Financing Section 4.7 Books 6.6(b) Alternative Financing Agreements Section 6.6(b) Anti-Corruption Laws Section 4.5(b) Articles of Merger Section 2.3 Bankruptcy and Records Equity Exception Section 2.12(f)(24.3(a) Claim Notice BVI Companies Act Preamble Certificates Section 8.3(a3.2(c)(i) Closing Section 2.3 2.2 Closing Date Section 2.3 2.2 Company Preamble Company Common Stock Adverse Recommendation Change Section 2.8 6.4(c)(i) Company Disclosure Schedule Article IV Board Preamble Company Expenses Schedule Financial Advisor Section 2.13 4.3(b) Company Financial Statements Section 4.6(b) Company Group Section 8.2(f)(i) Company Intellectual Property Section 4.14(b) Company Material Contract Section 4.11(b) Company Plan(s) Section 4.9(a) Company Recommendation Section 4.3(b) Company Representatives Section 6.3(a) Company SEC Filings Section 4.6(a) Company Shareholders Meeting Section 6.2(e)(i) Company Subsidiary Section 4.1 Company Workers Section 4.14(e) D&O Insurance Section 6.12(b) Debt Commitment Letter Section 5.6(a) Debt Financing Agreement Section 6.6(a) Dissenter Rights Section 3.1(e) Dissenting Shareholders Section 3.1(e) Dissenting Shares Section 3.1(e) Effective Time Section 2.3 End Date Section 8.1(b)(i) Exchange Fund Section 3.2(b) Financing Section 5.6(a) Financing Agreements Section 6.6(b) Guarantor Preamble HKIAC Section 9.7(b) Indemnified Parties Section 8.2(a)(ii6.12(a) Contracts Intervening Event Section 4.8(a6.4(e)(i) Covered Party (PartiesInvestments Section 4.2(d) Leased Real Property Section 8.2(a)(ii4.17(b) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Limited Guarantee Preamble Merger Section 2.1 Merger Certificate Section 2.2 Preamble Merger Sub Preamble Notice Period Section 6.4(d)(iii) Owned Real Property Section 4.17(a) Parent Preamble Parent Disclosure Group Section 8.2(f)(i) Parent Representatives Section 6.3(a) Party Preamble Paying Agent Section 3.2(a) Per Share Merger Consideration Section 3.1(b) Plan of Merger Section 2.3 PRC VIEs Section 4.21(a) Proxy Statement Section 6.2(a) Registrar of Companies Section 2.3 Rollover Securities Preamble Rollover Securityholder Preamble SAFE Rules and Regulations Section 4.5(c) Schedule Article V Parent Indemnified Parties 13E-3 Section 8.2(a)(i4.4(b) parties Special Committee Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Support Agreement Preamble Super Majority Section 2.12(b) Surviving Corporation Company Section 2.1 Third Milestone Transaction Litigation Section 2.10(g) Third Milestone Payment Amount 6.8 Uncertificated Shares Section 2.10(g3.2(c)(i)

Terms Defined Elsewhere. The Each of the following is a list of additional terms used in this Agreement and a reference has the meaning ascribed to the Section hereof in which such term is definedin the Article or Section set forth opposite such term: ACA ‎Section 4.15(c) Additional Buyer Filings ‎Section 8.10(f) Affiliated Transactions ‎Section 4.20 Aggregate Consideration ‎Section 10.1(e) Agreement Preamble Biogen Idec License Agreement Allocation ‎Section 10.1(e) Alternative Financing Section 4.7 Biogen Idec Supply Agreement 8.13(a)(iv) Antitrust Laws ‎Section 8.8(c) Assets ‎Section 4.19 Audited Financial Statements ‎Section 4.4(a)(i) Blocker Affiliated Transactions ‎Section 5.9 Blocker Bring-Down Certificate Section 4.7 Books and Records 11.2(d) Blocker Certificates of Merger ‎Section 2.2(b) Blocker Effective Time ‎Section 2.2(b) Blocker Letter of Transmittal ‎Section 3.4(a) Blocker Merger Closing ‎Section 2.2(a) Blocker Merger Sub 1 Preamble Blocker Merger Sub 2 Preamble Blocker Merger Sub 3 Preamble Blocker Merger Sub 4 Preamble Blocker Merger Sub 5 Preamble Blocker Merger Sub 6 Preamble Blocker Merger Subs Preamble Blocker Mergers Recitals Blocker Owned Company Equity Interests ‎Section 5.4(b) Blockers Preamble Buyer Preamble Buyer Balance Sheet ‎Section 6.11(c) Buyer Bring-Down Certificate Section 2.12(f)(211.3(c) Claim Notice Buyer Certificate of Merger ‎Section 2.2(c) Buyer Certificates of Merger ‎Section 2.2(c) Buyer Contribution Amount ‎Section 3.2(e)(i) Buyer Effective Time ‎Section 2.2(c) Buyer Merger Closing ‎Section 2.2(a) Buyer Mergers Recitals Buyer Parties Preamble Buyer Preference Shares ‎Section 6.3(a) Buyer Public Securities ‎Section 6.9 Buyer SEC Documents ‎Section 6.8(a) Buyer Warrants ‎Section 6.3(a) Cancelled Equity Interests ‎Section 3.1(d) Cancelled Cash Portion Section 8.3(a3.1(c)(iii)(B) Cancelled Option Value Section 3.1(c)(iii)(B) CBA Section 4.9(a)(i) Certificates of Merger ‎Section 2.2(d) Closing Section 2.3 ‎Section 2.2(a) Closing Cash ‎Section 3.5(a) Closing Date ‎Section 2.2(a) Closing Form 8-K ‎Section 8.10(g) Closing Net Working Capital ‎Section 3.5(a) Closing Press Release ‎Section 8.10(g) Closing Statement ‎Section 3.5(a) Closing Transaction Expenses ‎Section 3.5(a) Commitment Letter Section 2.3 8.13(a)(i) Company Preamble Company Common Stock A&R LLCA Recitals Company Bring-Down Certificate Section 2.8 11.2(d) Company Disclosure Schedule Article IV Certificate of Merger ‎Section 2.2(d) Company Expenses Schedule Section 2.13 Equity Interests ‎Section 4.3(a) Company Indemnified Parties Section 8.2(a)(iiMerger ‎Section 2.2(a) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Company Merger Closing Section 2.2 ERISA Section 4.13(a(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Merger Section 2.1 Merger Certificate Section 2.2 Company Merger Sub Preamble Parent Company Optionholder Letter of Transmittal ‎Section 3.4(a) Company Unitholder Letter of Transmittal ‎Section 3.4(a) Competing Buyer ‎Section 8.23 Contribution Common Units Section 3.2(e)(i)(A) Control ‎Section 1.1 D&O Provisions ‎Section 8.14(a) Data Room ‎Section 13.5 Debt Financing Section 8.13(a)(i) Debt Financing Sources Section 8.13(a)(i) Debt Payoff Amount ‎Section 3.2(e)(i)(A) DGCL Recital Disclosing Party ‎Section 1.1 Dispute Notice ‎Section 3.5(b) DLLCA Recitals Domestication Recitals E2open Intermediate ‎Section 4.4(e) Effective Date Preamble Parent Disclosure Schedule Article V Parent Effective Time ‎Section 2.2(d) EALP Section 1.1 EIP ‎Section 8.4 EILP Section 1.1 ▇▇▇▇▇▇▇ Catch-Up Amount 3.2(e)(i)(E) ▇▇▇▇▇▇▇ Eagle Blocker Preamble ▇▇▇▇▇▇▇ Merger Recitals ▇▇▇▇▇▇▇ Note Transfer Section 3.2(f) ▇▇▇▇▇▇▇ Reorganization Transferee Section 8.26 Environmental Permits ‎Section 4.17 Equity Financing ‎Section 1.1 Equityholder Materials ‎Section 3.4(b) Equityholder Representative Preamble Estimated Closing Blocker Indebtedness Section 3.2(b)(i) Estimated Closing Statement ‎Section 3.2(b)(ii) Estimated Merger Consideration ‎Section 3.2(b)(ii) Final Allocation ‎Section 10.1(e) Final Closing Blocker Indebtedness Section 3.5(a) Final Closing Company Indebtedness ‎Section 3.5(a) Final Tax Basis Balance Sheet ‎Section 10.1(e) Financial Statements ‎Section 4.4(a) Foreign Plan ‎Section 4.15(f) Forward Purchase Agreement Recitals Forward Purchase Amount Recitals ▇▇▇▇▇ Payoff Letter ‎Section 3.2(e)(ii)(D) Indemnified Parties Persons ‎Section 8.14(a) Insight Agreement Section 8.2(a)(i3.6(m) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Insight Catch-Up Amount Section 2.10(f3.2(e)(i)(E) Stockholder Consent Insight Cayman Blocker Preamble Insight Cayman Merger Recitals Stockholder Representative Insight Delaware Blocker Preamble Super Majority Insight Delaware Merger Recitals Insight GBCF Cayman Blocker Preamble Insight GBCF Cayman Merger Preamble Insight GBCF Delaware Blocker Preamble Insight GBCF Delaware Merger Recitals Insight Blocker Letter Agreement Section 2.12(b3.7(f) Insight Letter Agreement Section 3.6(m) Insurance Policies ‎Section 4.15(b) Intended Tax Treatment Section 10.1(e) Internal Controls ‎Section 4.4(c) Investor Rights Agreement Recitals IRS ‎Section 4.15(a) LLCA Amendment and Restatement Section 3.1(e) Lock-Up Agreement Recitals Material Contract ‎Section 4.9(b) Material Customer ‎Section 4.9(c) Material Leases ‎Section 4.7 Maximum Payable Amount Section 8.15(d) Merger Consideration ‎Section 3.2(a) Mergers Recitals NBOKS Recitals NBOKS Side Letter Recitals New Commitment Letter Section 8.13(a)(iv) Non-Party Affiliate ‎Section 13.14 Outside Date ‎Section 12.1(c) Parties Preamble Party Preamble PCAOB Financial Statements ‎Section 8.10(h) PDI Blocker Preamble PDI Merger Recitals Permits ‎Section 4.17(b) Permitted Equity Financing Proceeds Section 8.15(c) PIPE Investment Recitals PIPE Investors Recitals Pre-Closing Period ‎Section 7.1 Pre-Closing Reorganization Section 8.26 Premium Cap ‎Section 8.14(b)(ii) Recipient ‎Section 1.1 Resolution Period ‎Section 3.5(b) Review Period ‎Section 3.5(b) Sale ‎Section 10.1(e) Sellers Prepared Returns ‎Section 10.1(a) Signing Form 8-K ‎Section 8.10(b) Signing Press Release ‎Section 8.10(b) Sponsor Side Letter Recitals Subscription Agreements Recitals Support Agreement Section 8.12 Surviving Blocker Section 2.1(g) Surviving Corporation Section 2.1 Third Milestone Section 2.10(gBlocker Interests ‎Section 3.1(a)(i) Third Milestone Payment Surviving Buyer ‎Section 2.1(h) Surviving Company ‎Section 2.1(i) Surviving ▇▇▇▇▇▇▇ Eagle Blocker ‎Section 2.1(f) Surviving Insight Cayman Blocker ‎Section 2.1(a) Surviving Insight Delaware Blocker ‎Section 2.1(c) Surviving Insight GBCF Cayman Blocker ‎Section 2.1(d) Surviving Insight GBCF Delaware Blocker ‎Section 2.1(e) Surviving PDI Blocker ‎Section 2.1(g) SVB Payoff Amount Section 2.10(g)3.2(e)(i)(B) SVB Payoff Letter ‎Section 3.2(e)(i)(A) Tail Policy ‎Section 8.14(b)(ii) Tax Accounting Firm ‎Section 10.1(e) Tax Basis Balance Sheet ‎Section 10.1(e) Tax Contest Section 10.1(i) Tax Positions ‎Section 10.1(g) Tax Receivable Agreement Recitals Total Individual Blocker Merger Consideration Section 3.1(a)(ii) Total Individual Company Optionholder Merger Consideration Section 3.1(c)(iii) Total Individual Company Class A Unitholder Merger Consideration ‎Section 3.1(c)(ii) Total Individual Company Class B Unitholder Merger Consideration Section 3.1(c)(iii) Trade Controls ‎Section 4.21(a) Transaction Expenses Amount ‎Section 3.2(e)(i)(B) Trust Amount ‎Section 6.7 Trust Distributions ‎Section 13.9 Unaudited Balance Sheet ‎Section 4.4(a)(ii) Unaudited Financial Statements ‎Section 4.4(a)(ii) Valuation Firm ‎Section 3.5(b) Waived 280G Benefits ‎Section 8.17

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: Acquisition Proposal Section hereof in which such term is defined: 5.3(g)(i) Agreement Preamble Biogen Idec License Agreement Board Recitals Board Recommendation Section 4.7 Biogen Idec Supply Agreement 3.3(b) Change of Board Recommendation Section 4.7 Books and Records 5.3(a) China JV Section 2.12(f)(2) Claim Notice Section 8.3(a) 5.12 Closing Section 2.3 2.2(a) Closing Date Section 2.3 2.2(a) Closing Date Payment Section 2.2(b) Company Preamble Company Benefit Plan Section 3.14(a) Company Bylaws Section 3.1 Company Charter Section 3.1 Company Common Stock Section 2.8 3.2(a) Company Designees Section 5.18(a) Company Disclosure Schedule Article IV 3 Company Expenses Schedule Financial Statements Section 2.13 3.7(c) Company Indemnified Parties Leased Real Property Section 8.2(a)(ii3.17(a) Contracts Company Material Contract Section 4.8(a3.19 Company Meeting Section 5.4(b) Covered Party (PartiesCompany Options Section 3.2(a) Company Owned Real Property Section 8.2(a)(ii3.17(a) Damages Company Preferred Stock Section 8.2(a)(i3.2(a) Company Real Property Section 3.17(a) Company RSUs Section 3.2(a) Company SEC Documents Section 3.7(a) Company Termination Fee Section 7.3(a) Competing China JV Proposal Section 5.3(h) Confidentiality Agreement Section 5.2(b) DGCL Section 2.1 Document Retention Period 4.7 Dispute Section 2.12(f)(28.8(b) Drug Regulatory Agency ECL Claims Section 4.25 Effective Time 7.4(c) Escrow Agent Section 2.2 ERISA 5.21 Escrow Agreement Section 4.13(a5.21 FCPA Section 3.26 Guarantor Recitals Guarantee Recitals ICDR Section 8.8(b) ERISA Affiliate Intervening Event Section 4.13(a5.3(g)(v) Finally Determined Investor Preamble Investor Designees Section 8.5(b5.18(a) First Milestone Investor Sub Section 2.10(e5.22 Investor Termination Fee Release Event Section 7.4(a) First Milestone Payment Amount Letter of Credit Section 2.10(e5.23 Minority Transaction Termination Fee Section 7.3(a) Indemnifying Party OFAC Section 8.3(a3.27 Outside Date Section 7.1(d) Instrument Section 2.12(c) Merger Per Share Price Section 2.1 Merger Certificate Proposed Changed Terms Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i5.3(d)(ii) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Purchase Price Section 2.1 Third Milestone Service Provider Section 2.10(g3.14(a) Third Milestone Payment Amount Shares Section 2.10(g2.1 Superior Majority Proposal Section 5.3(g)(ii) Superior Minority Proposal Section 5.3(g)(iii) Superior Proposal Section 5.3(g)(iv)

Terms Defined Elsewhere. The For purposes of this Agreement, each of the following is a list of additional terms (as capitalized below) when used in this Agreement and a reference will have the meaning ascribed to such term in the Section hereof in which set forth opposite such term is definedterm: Action Section 5.10(b) Agreement Preamble Biogen Idec License Agreement Alternative Financing Section 4.7 Biogen Idec Supply Agreement 5.16(c) Alternative Proposal Section 4.7 Books and Records 5.4(g) Appraisal Rights Section 2.12(f)(22.1(b) Claim Notice Book-Entry Shares Section 8.3(a2.2(a) Burdensome Condition Section 5.7(c) Cancelled Shares Section 2.1(a)(ii) Certificate of Merger ‎Section 1.3 Certificates Section 2.2(a) Change of Recommendation Section 5.4(c) Closing Section 2.3 1.2 Closing Date Section 2.3 1.2 Code Section 2.2(b)(iii) Commitment Letter Section 4.6(a) Common Stock Section 2.1(a)(i) Company Preamble Company Common Stock Section 2.8 Board Recitals Company Disclosure Schedule Letter Article IV 3 Company Expenses Schedule PSU Consideration Section 2.13 2.3(c) Company Indemnified Recommendation Section 3.3 Company Registered IP Section 3.10(a) Company Related Parties ‎Section 7.3(d) Company RSU Consideration Section 8.2(a)(ii2.3(a) Contracts Company SEC Reports Section 4.8(a3.5(a) Covered Party (PartiesCompany Stockholder Approval Section 3.20 Company Stockholders’ Meeting ‎Section 5.5(b) Company Termination Fee Section 8.2(a)(ii7.3(a) Damages Confidentiality Agreement Section 8.2(a)(i5.3(b) Continuation Period Section 5.6(a) Data Breach Section 3.10(f) Data Protection Requirements Section 3.10(a) Definitive Agreements Section 5.16(a) DGCL Recitals Dissenting Shares Section 2.1 Document Retention Period Section 2.12(f)(22.1(b) Drug Regulatory Agency Section 4.25 ▇▇▇▇▇ Article 3 Effective Time Section 2.2 ERISA 1.3 Employee Census ‎Section 3.15(g) End Date ‎Section 7.1(b) Filed SEC Reports Article 3 Financing Section 4.13(a4.6(a) ERISA Affiliate Financing Amounts Section 4.13(a4.6(d) Finally Determined Indemnified Party Section 8.5(b5.10(b) First Milestone Intervening Event Section 2.10(e5.4(i) First Milestone Payment Intervening Event Notice Section 5.4(e) Intervening Event Notice Period Section 5.4(e) Leases Section 3.9(a) Legal Restraint ‎Section 6.1(b) Lenders Section 4.6(a) Made Available to Parent Section 8.12 Material Contract Section 3.11(a) Maximum Amount Section 2.10(e5.10(c) Indemnifying Party Measurement Time Section 8.3(a) Instrument Section 2.12(c3.2(a) Merger Recitals Merger Consideration Section 2.1 Merger Certificate Section 2.2 2.1(a)(i) Merger Sub Preamble New Plans Section 5.6(b) Old Plans Section 5.6(b) Owned Real Property Section 3.9(a) Parent Preamble Parent Approvals Section 4.2(b) Parent Disclosure Schedule Letter Article V 4 Parent Indemnified Material Adverse Effect ‎Section 4.1 Parent Related Parties ‎Section 7.3(d) Parent RSU Section 8.2(a)(i2.3(b) parties Preamble Payee Parent Termination Fee Section 8.5 Payor 7.3(b)(i) Paying Agent Section 8.5 Per Diem Taxes 2.2(a) Payment Fund Section 8.7(a2.2(a) Proceeding Permitted Change of Recommendation Section 4.17 Royalties 5.4(e) Permitted Termination Section 2.10(h5.16(b) Second Milestone Prohibited Modifications Section 2.10(f5.16(b) Second Milestone Payment Amount Proposed Dissenting Shares Section 2.10(f2.1(b) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Representatives Section 2.12(b5.3(a) Share Section 2.1(a)(i) Subsidiary Shares Section 2.1(a)(i) Superior Proposal ‎Section 5.4(h) Superior Proposal Notice Section 5.4(d) Superior Proposal Notice Period ‎Section 5.4(c) Surviving Corporation Section 2.1 Third Milestone 1.1 Takeover Statute Section 2.10(g3.19 Tax Incentive ‎Section 3.15(g) Third Milestone Payment Amount Terminating Company PSU Section 2.10(g2.3(c) Terminating Company RSU Section 2.3(a) Termination Date Section 5.1(a)

Terms Defined Elsewhere. The following is a list of additional terms used in this Agreement and a reference to the Section hereof in which such term is defined: Acquisition Proposal Section 5.04(a) Agreement Preamble Biogen Idec License Agreement Audited Financial Statements Section 4.7 Biogen Idec Supply Agreement 3.06 Articles of Merger Section 4.7 Books and Records 2.05 Balance Sheet Section 2.12(f)(23.06 Balance Sheet Date Section 3.06 Basket Section 8.04(a) Claim Notice Benefit Plan Section 8.3(a3.18(a) Cap Section 8.04(a) Closing Section 2.3 2.03 Closing Date Section 2.3 2.03 Closing Statement Section 2.02 Common Stock Section 3.04(a) Company Preamble Company Common Stock Board Recitals Company Board Recommendation Section 2.8 3.02(b) Company Disclosure Schedule Article IV Charter Documents Section 3.01(a) Company Expenses Schedule Counsel Section 2.13 10.14(a) Company Special Meeting Section 5.05 Company Subsidiary Charter Documents Section 3.01(b) Confidentiality Agreement Section 5.03(c) Continuing Employees Section 5.12(a) Direct Claim Section 8.05(c) Disputed Amounts Section 2.16(b)(iii) Dissenting Shares Section 2.10 D&O Indemnified Parties Party Section 8.2(a)(ii5.11(a) Contracts D&O Tail Policy Section 4.8(a5.11(b) Covered Party (PartiesEarn-out Calculation Section 2.17(b)(i) Earn-out Calculation Objection Notice Section 8.2(a)(ii2.17(b)(iii) Damages Earn-out Calculation Statement Section 8.2(a)(i2.17(b)(i) DGCL Section 2.1 Document Retention Earn-out Review Period Section 2.12(f)(22.17(b)(ii) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA 2.05 End Date Section 4.13(a9.01 Escrow Funds Section 2.12(b) ERISA Affiliate Excess Working Capital Section 4.13(a2.16(c)(ii) Finally Determined Financial Statements Section 8.5(b3.06 FIRPTA Statement Section 6.07 Government Contracts Section 3.09(a)(v) First Milestone Indemnification Escrow Fund Section 2.10(e2.12(a)(i) First Milestone Payment Amount Independent Accountant Section 2.10(e2.16(b)(iii) Indemnifying Party Insurance Policies Section 8.3(a3.14 Interim Balance Sheet Section 3.06 Interim Balance Sheet Date Section 3.06 Interim Financial Statements Section 3.06 iSun Residential Preamble iSun Residential Board Recitals Letter of Transmittal Section 2.11(c) Instrument Liabilities Section 2.12(c3.07 Lockup Period Section 5.15 Majority Holders Section 10.01(e) Material Contracts Section 3.09(a) Material Customers Section 3.13(a) Material Suppliers Section 3.13(b) Merger Section 2.1 Merger Certificate Section 2.2 Recitals Merger Sub Preamble Merger Sub Board Recitals Parent Preamble Parent Disclosure Schedule Article V Board Recitals Parent Indemnified Equity Awards Section 4.11(b)(i) Parent Indemnitees Section 8.02 Parent Preferred Stock Section 4.11(a) Parent Restricted Share Section 4.11(b)(i) Parent SEC Documents Section 4.01 Parent Securities Section 4.11(b)(ii) Parent Stock Plans Section 4.11(b)(i) Parent Stock Option Section 4.11(b)(i) Parent Subsidiaries Preamble Parent Subsidiary Securities Section 4.11(d) Parent Voting Debt Section 4.11(c) Party Preamble Parties Preamble Permitted Encumbrances Section 8.2(a)(i3.10(a) parties Preamble Payee Post-Closing Adjustment Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a2.16(c) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority PPP Escrow Fund Section 2.12(b) Preferred Stock Section 3.04(a) Privileged Communications Section 10.14(d) Registrable Shares Section 5.14(a) Registration Statement Section 5.14(a) Representative Losses Section 10.01(f) Requisite Company Vote Section 3.02(a) Resolution Period Section 2.16(b)(ii) Review Period Section 2.16(b)(ii) Revised Closing Statement Section 2.16(b)(i) Termination Fee Section 9.02(a) Third Party Claim Section 8.05(a) SEC Section 4.01 Series A Preferred Stock Section 3.04(a) Series B Preferred Stock Section 3.04(a) Series C Preferred Stock Section 3.04(a) Shareholder Representative Group Preamble Shareholder Indemnitees Section 8.03 Shares Section 2.09(a) Signing Date Preamble Statement of Objections Section 2.16(b)(ii) Straddle Period Section 6.04 Surviving Corporation Section 2.1 Third Milestone 2.01 Tax Claim Section 2.10(g6.05 Undisputed Amounts Section 2.16(b)(iii) Third Milestone Payment Amount Union Section 2.10(g3.19(b) VBCA Recitals Working Capital Escrow Fund Section 2.12(a)(ii) Working Capital Shortfall Section 2.16(c)(iii)

Terms Defined Elsewhere. The For purposes of this Agreement, the following is a list of additional terms (as capitalized below) will have the following meanings when used in this Agreement and a reference to the Agreement: Action Section hereof in which such term is defined: 5.10(b) Agreement Preamble Biogen Idec License Agreement Appraisal Rights Section 4.7 Biogen Idec Supply Agreement 2.1(b) Board of Directors Recitals Book-Entry Shares Section 4.7 Books and Records 2.2(a) Cancelled Shares Section 2.12(f)(22.1(a)(ii) Claim Notice Certificate of Merger Section 8.3(a1.3 Certificates Section 2.2(a) Change of Recommendation Section 5.4(e) Closing Section 2.3 1.2 Closing Date Section 2.3 1.2 Code Section 2.2(b)(iii) Common Stock Section 2.1(a)(i) Company Preamble Company Common Stock Disclosure Letter Article 3 Company Employees Section 2.8 5.6(a) Company Disclosure Schedule Article IV Post-Signing RSU Award Section 2.3(c) Company Expenses Schedule Section 2.13 Company Indemnified Related Parties Section 8.2(a)(ii7.3(a) Contracts Company SEC Reports Section 4.8(a3.5(a) Covered Party (PartiesCompany Stockholders’ Meeting Section 5.5(b) Company Termination Fee Section 8.2(a)(ii7.3(a) Damages Confidentiality Agreement Section 8.2(a)(i5.3(b) Development Real Property Section 3.9(e) DFARS Section 3.20(c) DGCL Recitals Dissenting Shares Section 2.1 Document Retention Period 2.1(b) EAR Section 2.12(f)(23.15(d) Drug Regulatory Agency Section 4.25 ▇▇▇▇▇ Article 3 Effective Time Section 2.2 ERISA 1.3 End Date Section 4.13(a7.1(b) ERISA Affiliate ESPP Section 4.13(a3.2(b)(i) Finally Determined Exchange Fund Section 8.5(b2.2(a) First Milestone Filed SEC Reports Article 3 Financing Amounts Section 2.10(e4.12 HSR Act Section 3.4 Indemnified Party Section 5.10(b) First Milestone Payment Intervening Event Notice Section 5.4(f) Leases Section 3.9(a) Legal Restraint Section 6.1(b) Major Customer Section 3.13(a) Major Supplier Section 3.13(b) Material Contract Section 3.11(a) Maximum Amount Section 2.10(e5.10(c) Indemnifying Party Measurement Time Section 8.3(a) Instrument Section 2.12(c3.2(a) Merger Recitals Merger Consideration Section 2.1 Merger Certificate Section 2.2 2.1(a)(i) Merger Sub Preamble New Plans Section 5.6(b) Old Plans Section 5.6(b) Owned Real Property Section 3.9(a) Parent Preamble Parent Approvals Section 4.2(b) Parent Disclosure Schedule Letter Article V 4 Parent Indemnified Material Adverse Effect Section 4.1 Parent Related Parties Section 8.2(a)(i7.3(a) parties Preamble Payee Parent RSU Award Section 8.5 Payor 2.3(c)(i) Paying Agent Section 8.5 Per Diem Taxes 2.2(a) Proposed Dissenting Shares Section 8.7(a2.1(b) Proceeding Recommendation Section 4.17 Royalties 3.3 Remedial Action Section 2.10(h5.7(b) Second Milestone Representatives Section 2.10(f5.3(a) Second Milestone Payment Amount Required Company Stockholder Vote Section 2.10(f3.23 Sexual Misconduct Allegation Section 3.18(c) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Share Section 2.12(b2.1(a)(i) Specified Approvals Section 3.4 Standards Organization Section 3.10(b) Superior Proposal Notice Section 5.4(e) Surviving Corporation Section 2.1 Third Milestone 1.1 Takeover Statute Section 2.10(g3.22 Termination Date Section 5.1(a) Third Milestone Payment Amount WARN Act Section 2.10(g3.18(a)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: Action Section hereof in which such term is defined: 3.11 Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 5.2(c)(ii) Anti-Takeover Statute Section 4.7 Books and Records 3.3(c) Antitrust Order Section 2.12(f)(25.5(d) Claim Notice Antitrust Proceeding Section 8.3(a5.5(d) Certificates Section 2.2(b) Closing Section 2.3 1.2 Closing Date Section 2.3 1.2 Company Preamble Company Adverse Recommendation Change Section 5.2(c)(i) Company Board Recitals Company Board Recommendation Section 3.2(c) Company Common Stock Section 2.8 2.1(a)(i) Company Disclosure Schedule Article IV Financial Advisor Section 3.2(d) Company Expenses Schedule Financial Statements Section 2.13 3.5(b) Company Indemnified Parties Material Contract Section 8.2(a)(ii3.10(a) Contracts Section 4.8(a) Covered Party (PartiesCompany Plan(s) Section 8.2(a)(ii3.12(a) Damages Company Preferred Stock Section 8.2(a)(i3.4(a) DGCL Company Registered Intellectual Property Section 2.1 Document Retention Period 3.14(a) Company Representatives Section 2.12(f)(25.4(a) Drug Regulatory Agency Company SEC Filings Section 4.25 3.5(a) Company Shareholders Recitals Company Shareholders’ Meeting Section 5.3(a) Company Shareholder Approval Section 3.2(b) Company Subsidiary Section 2.7 D&O Insurance Section 5.9(c) Deferred Share Cash Balance Section 2.4(d) Department of State Section 1.3 Determination Notice Section 5.2(d)(i)(A) Effective Time Section 2.2 1.3 End Date Section 7.1(b) Enforceability Exception Section 3.10(b) ERISA Section 4.13(a3.12(a) ERISA Affiliate Section 4.13(a3.12(a) Finally Determined Event Section 8.5(b8.1(p) First Milestone Exchange Fund Section 2.10(e2.2(a) First Milestone Payment FCPA Section 3.21 Final Exercise Date Section 2.5 Indemnified Parties Section 5.9(a) Investments Section 3.4(f) Material Leased Real Property Section 3.17(b) Material Real Property Leases Section 3.17(b) Maximum Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c5.9(c) Merger Section 2.1 1.1 Merger Certificate Consideration Section 2.2 2.1(a)(i) Merger Sub Preamble Notice Period Section 5.2(d)(i)(A) Owned Real Property Section 3.17(a) Parent Preamble Parent Disclosure Schedule Article V Benefit Plans Section 5.8(c) Parent Indemnified Parties Representatives Section 8.2(a)(i5.4(a) parties Party Preamble Payee Paying Agent Section 8.5 Payor 2.2(a) PBCL Recitals Proxy Date Section 8.5 Per Diem Taxes 5.3(a) Proxy Statement Section 8.7(a5.3(b) Proceeding Shares Section 4.17 Royalties 2.1(a)(i) Statement of Merger Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) 1.3 Surviving Corporation Section 2.1 Third Milestone 1.1 Tail Period Section 2.10(g) Third Milestone Payment Amount Section 2.10(g5.9(c)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: Action Section hereof in which such term is defined: 5.15 Acceptance Time Section 2.4(a) Acquisition Proposal Termination Fee Section 9.4(b)(iii) Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 7.5(c)(ii) Articles of Merger Section 4.7 Books and Records 3.3 Board Appointment Date Section 2.12(f)(22.4(a) Claim Notice Certificates Section 8.3(a4.2(b) Closing Section 2.3 3.2 Closing Date Section 2.3 3.2 Company Preamble Company Adverse Recommendation Change Section 7.5(c)(i) Company Board Recitals Company Board Recommendation Section 2.3(a)(iii) Company Common Stock Recitals Company Disclosure Documents Section 5.10(a) Company Financial Advisor Section 5.3(c) Company Financial Statements Section 5.7(b) Company Intellectual Property Section 5.17(b) Company Material Contract Section 5.13(a) Company Non-Voting Common Stock Section 2.8 5.2(a) Company Disclosure Schedule Article IV Company Expenses Schedule Section 2.13 Company Indemnified Parties Section 8.2(a)(ii) Contracts Section 4.8(a) Covered Party (PartiesPlan(s) Section 8.2(a)(ii5.11(a) Damages Company Preferred Stock Section 8.2(a)(i5.2(a) DGCL Company Representatives Section 2.1 Document 7.4(a) Company Retention Period and Severance Plan Section 2.12(f)(27.17(b)(ii) Drug Regulatory Agency Company SEC Filings Section 4.25 5.7(a) Company Shareholders Recitals Company Shareholders’ Meeting Section 7.2(a) Company Shareholder Approval Section 5.3(b) Company Subsidiary Section 5.1 Company Systems Section 5.17(f) Compensation Committee Section 5.24 Continuing Directors Section 2.4(a) D&O Insurance Policies Section 7.12(c) Determination Notice Section 7.5(d) Dissenting Shares Section 4.3 Dissenting Shareholder Section 4.3 Effective Time Section 2.2 3.3 EMEA Section 5.6(a) Employment Compensation Arrangement Section 5.24 End Date Section 9.1(b) Enforceability Exception Section 5.13(b) ERISA Section 4.13(a5.11(a) ERISA Affiliate Section 4.13(a5.11(a) Finally Determined Event Section 8.5(b1.1(l) First Milestone Exchange Fund Section 2.10(e4.2(a) First Milestone Payment Amount FDA Section 2.10(e5.6(e) Indemnifying Party Follow-On Period Section 8.3(a9.4(b)(iii) Instrument Indemnified Parties Section 2.12(c7.12(a) Independent Directors Section 2.4(b) Intervening Event Change of Recommendation Section 7.5(d)(ii) Intervening Event Termination Fee Section 9.4(b)(iv) Investments Section 5.2(e) IRS Section 5.11(b) Merger Recitals Merger Consideration Section 2.1 Merger Certificate Section 2.2 4.1(a) Merger Sub Preamble Minimum Condition Section 2.1(b) Notice Period Section 7.5(d) Offer Recitals Offer Documents Section 2.1(g) Offer Price Recitals Offer to Purchase Section 2.1(g) Parent Preamble Parent Disclosure Schedule Insiders Section 2.4(a) Parent Representatives Section 7.4(a) Party Preamble Paying Agent Section 4.2(a) Plan of Merger Section 3.3 Proxy Statement Section 7.2(b) Recent SEC Reports Article V Parent Indemnified Parties Schedule TO Section 8.2(a)(i2.1(g) parties Preamble Payee Schedule 14D-9 Section 8.5 Payor 2.3(b) Short-Form Election Section 8.5 Per Diem Taxes 7.3 Short-Form Threshold Section 8.7(a7.3 Social Security Act Section 5.6(b) Proceeding Specified Contracts Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent 5.14 Support Agreements Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone 3.1 Tail Period Section 2.10(g7.12(c) Third Milestone Payment Amount Takeover Provisions Section 2.10(g)5.22(a) Top-Up Option Section 2.2(a) Transaction Litigation Section 7.8 Transition Committee Section 7.1(c) Transferred Employee Section 7.17(a)(ii) Transitioned Employees Section 7.17(a)(ii) WARN Act Section 5.12

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Acquired Assets Acquired Assets Permits Acquired Assets Regulatory Filings Aggregate Threshold Agreed Amount Agreement and a reference to the Antitrust Approvals Assigned Contracts Assigned IP Contracts Assumed Liabilities Assumption Agreements Bill of Sale Burdensome Term or Condition Section hereof in which such term is defined: Agreement 1.01(a) Section 2.12(a) Section 2.12(a) Section 6.05(b)(ii) Section 6.04 (b) Preamble Biogen Idec License Agreement Section 4.7 Biogen Idec Supply Agreement 4 .03(b) Section 4.7 Books and Records 1.01(a)(iv) Section 2.12(f)(21.01(a)(iv) Section 1.01(d) Section 1.01(d) Section 1.03(b)(iii) Section 4 .03(f) 49 Ame ric as 9 2 4 2 5 1 0 0 Buyer Preamble Buyer FDA Letter Section 5.03(e) Buyer Group Section 1.01(a) Buyer Indemnified Parties Section 6.02 Buyer Orphan Designation Letter Section 5.03(e) Cap Section 6.05(b)(i) CF Enterprise Recitals Claim Notice Section 8.3(a6.04 (b) Claimed Amount Section 6.04 (b) Closing Section 2.3 1.03(a) Closing Date Section 2.3 Company 1.03(a) Confidentiality Agreement Section 4 .02 Contingent Payment Section 1.02(b) CTAs Section 2.10(a)(viii) DOJ Section 4 .03(a) Electronic Delivery Section 10.07 Excluded Assets Section 1.01(b) Excluded Liabilities Section 1.01(e) FDA Section 2.12(a) FDCA Section 2.12(a) FTC Section 4 .03(a) Fundamental Representations Section 6.01(a) Guarantor Preamble Company Common Stock HSR Act Section 2.8 Company Disclosure Schedule Article IV Company Expenses Schedule 2.05(c) Indemnified Party Section 2.13 Company Indemnified Parties Section 8.2(a)(ii) Contracts Section 4.8(a) Covered Party 6.04 (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(ea) Indemnifying Party Section 8.3(a6.04 (a) Instrument IP Assignment Agreements Section 2.12(c1.03(b)(iv) Merger Material Contract Section 2.1 Merger Certificate 2.10(a) MTAs Section 2.2 Merger Sub 2.10(a)(viii) NDAs Section 2.10(a)(viii) Non‑Compete Period Section 9.05(a) Outside Date Section 7.01(f)(ii) Parties Preamble Parent Party Preamble Parent PHSA Section 2.12(a) Pre‑Closing Period Section 4 .01(a) Research and Testing Agreement Recitals Registered Business IP Section 2.09(a) Regulatory Authority Section 2.12(a) Regulatory Filings Section 4 .03(a) Related Agreements Section 2.03 Restricted Names Section 9.02 Safety Notice Section 2.12(d) Ame ric as 9 2 4 2 5 1 0 0 Seller Preamble Seller Board Section 2.03 Seller Board Approval Section 2.20 Seller Change of Recommendation Section 4 .07(c) Seller Disclosure Schedule Letter Article V Parent II Seller FDA Letter Section 5.02(f) Seller Indemnified Parties Section 8.2(a)(i6.03 Seller Orphan Designation Letter Section 5.02(f) parties Preamble Payee Supplement Section 8.5 Payor 4 .04 Termination Fee Section 8.5 Per Diem 7.02(b) Third Party Claim Section 6.04 (a) Third Party IP Section 2.09(f) Transfer Taxes Section 8.7(a8.01(a) Proceeding Transferred IP Section 4.17 Royalties 1.01(a)(ii) Transferred IP Documentation Section 2.10(h1.01(a)(iii) Second Milestone Transferred Permits Section 2.10(f1.01(a)(vi) Second Milestone Payment Amount Transition Services Agreement Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g1.03(b)(vii)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Section hereof in which such term is definedAgreement, as indicated below: Action ‎Section 4.14(a) Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement Section 4.7 Books and Records Section 2.12(f)(2‎Section 6.4(c)(ii) Claim Notice Section 8.3(aArticles of Merger ‎Section 2.3 Bankruptcy Exception ‎Section 4.3(a) Certificates ‎Section 3.2(b) Closing Section 2.3 ‎Section 2.2 Closing Date Section 2.3 ‎Section 2.2 Company Preamble Company Common Stock Section 2.8 Adverse Recommendation Change ‎Section 6.4(c)(i) Company Board Recommendation ‎Section 4.3(d) Company Disclosure Schedule Article IV Documents ‎Section 4.10(a) Company Expenses Schedule Section 2.13 Financial Advisor ‎Section 4.3(c) Company Indemnified Parties Section 8.2(a)(iiFinancial Statements ‎Section 4.7(b) Contracts Section 4.8(aCompany Intellectual Property ‎Section 4.16(a) Covered Party (PartiesCompany Material Contract ‎Section 4.13(a) Section 8.2(a)(iiCompany Plan(s) Damages Section 8.2(a)(i‎Section 4.11(a) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2Company Preferred Stock ‎Section 4.2(a) Drug Regulatory Agency Section 4.25 Company Representatives ‎Section 6.3(a) Company SEC Filings ‎Section 4.7(a) Company Shareholder Approval ‎Section 4.3(b) Company Shareholders Recitals Company Shareholders’ Meeting ‎Section 6.2(c) Company Subsidiary ‎Section 4.1 Determination Notice ‎Section 6.4(d)(i)(C) Effective Time Section 2.2 ‎Section 2.3 End Date ‎Section 8.1(b)(i) ERISA Section 4.13(a‎Section 4.11(a) ERISA Affiliate Section 4.13(a‎Section 4.11(a) Finally Determined Section 8.5(bExchange Fund ‎Section 3.2(a) First Milestone Section 2.10(eImprovements ‎Section 4.19(c) First Milestone Payment Amount Section 2.10(eIndemnified Parties ‎Section 6.11(a) Indemnifying Party Section 8.3(aIntervening Event Change of Recommendation ‎Section 6.4(d)(ii) Instrument Section 2.12(cInvestments ‎Section 4.2(d) IRS ‎Section 4.11(b) Measurement Date ‎Section 4.2(a) Merger Section 2.1 Recitals Merger Certificate Section 2.2 Consideration ‎Section 3.1(a) Merger Sub Preamble Multiemployer Plan ‎Section 4.11(c) Notice Period ‎Section 6.4(d)(i)(C) OFAC ‎Section 1.1(v) Parent Preamble Parent Disclosure Schedule Article V Expenses ‎Section 8.2(c) Parent Indemnified Parties Section 8.2(a)(iRepresentatives ‎Section 6.3(a) parties Party Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(aPaying Agent ‎Section 3.2(a) Proceeding Section 4.17 Royalties Section 2.10(hPerformance Awards ‎Section 3.5(d) Second Milestone Section 2.10(fProxy Statement ‎Section 6.2(a) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(bRecent SEC Reports ‎Article IV Rollover Option ‎Section 3.5(b) Surviving Corporation Section ‎Section 2.1 Third Milestone Section 2.10(gTail Period ‎Section 6.11(c) Third Milestone Payment Amount Section 2.10(g)Takeover Provisions ‎Section 4.21(a) TBCA Recitals Transaction Litigation ‎Section 6.6 WARN Act ‎Section 4.12

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: Acquired Assets Section hereof in which such term is defined: 1.01(a) Acquired Assets Permits Section 2.12(a) Acquired Assets Regulatory Filings Section 2.12(a) Aggregate Threshold Section 6.05(b)(ii) Agreed Amount Section 6.04(b) Agreement Preamble Biogen Idec License Agreement Antitrust Approvals Section 4.7 Biogen Idec Supply Agreement 4.03(b) Assigned Contracts Section 4.7 Books and Records 1.01(a)(iv) Assigned IP Contracts Section 2.12(f)(21.01(a)(iv) Assumed Liabilities Section 1.01(d) Assumption Agreements Section 1.01(d) ▇▇▇▇ of Sale Section 1.03(b)(iii) Burdensome Term or Condition Section 4.03(f) Americas 92425100 Buyer Preamble Buyer FDA Letter Section 5.03(e) Buyer Group Section 1.01(a) Buyer Indemnified Parties Section 6.02 Buyer Orphan Designation Letter Section 5.03(e) Cap Section 6.05(b)(i) CF Enterprise Recitals Claim Notice Section 8.3(a6.04(b) Claimed Amount Section 6.04(b) Closing Section 2.3 1.03(a) Closing Date Section 2.3 Company 1.03(a) Confidentiality Agreement Section 4.02 Contingent Payment Section 1.02(b) CTAs Section 2.10(a)(viii) DOJ Section 4.03(a) Electronic Delivery Section 10.07 Excluded Assets Section 1.01(b) Excluded Liabilities Section 1.01(e) FDA Section 2.12(a) FDCA Section 2.12(a) FTC Section 4.03(a) Fundamental Representations Section 6.01(a) Guarantor Preamble Company Common Stock HSR Act Section 2.8 Company Disclosure Schedule Article IV Company Expenses Schedule 2.05(c) Indemnified Party Section 2.13 Company Indemnified Parties Section 8.2(a)(ii) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e6.04(a) Indemnifying Party Section 8.3(a6.04(a) Instrument IP Assignment Agreements Section 2.12(c1.03(b)(iv) Merger Material Contract Section 2.1 Merger Certificate 2.10(a) MTAs Section 2.2 Merger Sub 2.10(a)(viii) NDAs Section 2.10(a)(viii) Non‑Compete Period Section 9.05(a) Outside Date Section 7.01(f)(ii) Parties Preamble Parent Party Preamble Parent PHSA Section 2.12(a) Pre‑Closing Period Section 4.01(a) Research and Testing Agreement Recitals Registered Business IP Section 2.09(a) Regulatory Authority Section 2.12(a) Regulatory Filings Section 4.03(a) Related Agreements Section 2.03 Restricted Names Section 9.02 Safety Notice Section 2.12(d) Americas 92425100 Seller Preamble Seller Board Section 2.03 Seller Board Approval Section 2.20 Seller Change of Recommendation Section 4.07(c) Seller Disclosure Schedule Letter Article V Parent II Seller FDA Letter Section 5.02(f) Seller Indemnified Parties Section 8.2(a)(i6.03 Seller Orphan Designation Letter Section 5.02(f) parties Preamble Payee Supplement Section 8.5 Payor 4.04 Termination Fee Section 8.5 Per Diem 7.02(b) Third Party Claim Section 6.04(a) Third Party IP Section 2.09(f) Transfer Taxes Section 8.7(a8.01(a) Proceeding Transferred IP Section 4.17 Royalties 1.01(a)(ii) Transferred IP Documentation Section 2.10(h1.01(a)(iii) Second Milestone Transferred Permits Section 2.10(f1.01(a)(vi) Second Milestone Payment Amount Transition Services Agreement Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g1.03(b)(vii)

Terms Defined Elsewhere. The Each of the following is a list of additional terms used in this Agreement and a reference has the meaning ascribed to the Section hereof in which such term is definedin the Article or Section set forth opposite such term: 2023 45X Credit Section 2.9(a) 2024 45X Credit Section 2.9(a) 2025 45X Credit Section 2.9(a) 401(k) Plan Section 7.3(b) Accounting Firm Section 2.4(b) Active Job Section 3.5(i) Affiliate Arrangements Section 3.22 Agreement Preamble Biogen Idec License Allocation Schedule Section 7.2(e) Antitrust Laws Section 7.12(c) Benefits Transition Period Section 7.3(a) Benefits Transition Services Section 7.3(a) Binder Agreement Section 4.7 Biogen Idec Supply Agreement 7.11 Buyer Preamble CBA Section 4.7 Books and Records 3.7(d) Claims Section 2.12(f)(2) Claim Notice Section 8.3(a) 7.8 Closing Section 2.3 2.7(a) Closing Date Section 2.3 2.7(a) Closing Item Section 2.4(a) Closing Payment Section 2.7(d)(vi) Closing Statement Section 2.4(a) Company Preamble Company Common Employee Benefit Plan Section 3.15(a) Company Interests Recitals Company Licenses Section 3.17(b) Company Proprietary Rights Section 3.12(a) Company Transaction Section 7.1(d) Confidential Information Section 7.13(a) Customer Assets Section 3.28 Deferred Consideration Section 2.6(a) Deferred Consideration Anniversary Section 2.6(a) Deferred Consideration Installment Section 2.6(a) Deferred Consideration Shares Section 2.6(a) Dispute Notice Section 2.4(b) Earnout Stock Section 2.8 Company Disclosure Schedule Article IV Company 2.5 Effective Date Preamble Employed Guarantor Section 2.6(c) End Date Section 8.1(d) Estimated Cash Section 2.3(a)(i) Estimated Closing Statement Section 2.3(a) Estimated Indebtedness Section 2.3(a)(i) Estimated Transaction Expenses Schedule Section 2.13 Company Indemnified Parties 2.3(a)(i) Estimated Working Capital Section 8.2(a)(ii2.3(a)(i) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Excess Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g2.4(d)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: 280G Stockholder Approval Section hereof in which such term is defined: 5.6(b) 401(k) Plan Section 1.4(b)(i) Adjustment Resolution Period Section 1.15(b) Adjustment Review Period Section 1.15(b) Agreement Preamble Biogen Idec License Agreement Date Preamble Allocation Schedule Section 4.7 Biogen Idec Supply Agreement 4.3(a) Anti-Corruption Laws Section 4.7 2.24 Balance Sheet Date Section 2.7(b) Behavioral Data Section 2.12(a)(i) Board Recitals Books and Records Section 2.12(f)(22.17(b) Cancelled Shares Section 1.7(e) Cash Portion Section 4.2(f) CCPA Section 2.12(a)(xiv) Certificate of Incorporation Section 2.1(d) Certificate of Merger Section 1.2(a) Certificates of Merger Section 1.2(b) Charter Documents Section 2.1(d) Closing Section 1.4(a) Closing Date Section 1.4(a) Company Preamble Company Authorizations Section 2.15 Company Board Resolutions Section 2.4(a) Company Data Section 2.12(a)(ii) Company Indemnitees Section 4.5(a) Company IP Section 2.12(a)(iii) Company Owned IP Section 2.12(a)(iv) Company Prepared Returns Section 4.2(a)(i) Company Privacy Policy Section 2.12(a)(v) Company Products Section 2.12(a)(vi) Company Products Data Section 2.12(a)(vii) Company Registered IP Section 2.12(b) Company Software Section 2.12(a)(viii) Company Source Code Section 2.12(a)(ix) Company Stockholder Approval Recitals Company Voting Debt Section 2.2(f) Confidentiality Agreement Section 5.7 Contaminant Section 2.12(a)(x) Continuing Claim Section 7.4(f) Converted Option Section 1.7(b)(ii) Converted Option Exercise Price Section 1.7(b)(ii) Current Balance Sheet Section 2.7(b) D&O Indemnifiable Matters Section 4.5(a) D&O Tail Policy Section 4.5(b) Deductible Amount Section 7.3(a) Delaware LLC Act Section 1.1(b) Determination Date Section 1.15(c) DGCL Section 1.1(a) Director and Officer Resignation Letters Section 1.4(b)(iv) Disclosure Schedule Article II Dissenting Shares Section 1.11(a) Effective Time Section 1.2(a) Eligible Continuing Employee Section 5.19 Embargoed Countries Section 2.23 End Date Section 8.1(b) Engagement Letter Section 7.6(b) ePrivacy Directive Section 2.12(a)(xiv) Escrow Agreement Section 1.4(b)(xi) Escrow Fund Section 1.10(a) Estimated Closing Cash Amount Section 1.15(a) Estimated Closing Indebtedness Amount Section 1.15(a) Estimated Closing Statement Section 1.15(a) Estimated Closing Third Party Expenses Section 1.15(a) Estimated Closing Working Capital Adjustment Amount Section 1.15(a) Exchange Documents Section 1.9(b) Expense Fund Section 7.6(c) Expense Fund Account Section 7.6(c) Export Approvals Section 2.23 FCPA Section 2.24 Final Closing Statement Section 1.15(c) Financials Section 2.7(a) FIRPTA Compliance Certificate Section 1.4(b)(x) First Merger Recitals GDPR Section 2.12(a)(xiv) HSR Act Section 2.6(b) HIPAA Section 2.12(a)(xiv) Inbound Licenses Section 2.12(d)(i) Indemnification Claim Notice Section 8.3(a7.4(a) Closing Indemnification Claim Objection Notice Section 2.3 Closing Date 7.4(b) Independent Accountant Section 2.3 Company Preamble Company Common Stock 1.15(b) Intellectual Property Rights Section 2.8 Company Disclosure Schedule Article IV Company Expenses Schedule 2.12(a)(xi) Interested Party Section 2.13 Company Indemnified Parties 2.14(a) Invoice Section 8.2(a)(ii1.4(b)(vi) Contracts Lease Agreements Section 4.8(a2.11(b) Covered Party (PartiesLeased Real Property Section 2.11(b) Letter of Transmittal Section 1.9(a) Material Contract(s) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c2.13(b) Merger Section 2.1 Merger Certificate Section 2.2 Sub I Preamble Merger Sub II Preamble Merger Subs Preamble Mergers Recitals Notice of Adjustment Disagreement Section 1.15(b) Notices Section 5.11(c) OFAC Section 2.23 Open Source Material Section 2.12(a)(xii) Open Source Licenses Section 2.12(a)(xii) Outbound Licenses Section 2.12(d)(ii) Parent Preamble Parent Disclosure Schedule Article V Arrangement Section 2.9(b) Parent Certificate Section 6.3(c) Parent Financial Statements Section 3.5(b) Parent Indemnified Parties Section 8.2(a)(i7.2(a) parties Preamble Payee Parent Prepared Returns Section 8.5 Payor 4.2(a)(ii) Parent SEC Documents Section 8.5 Per Diem Taxes 3.5(a) Parent Stock Issuance Recitals Patent Rights Section 8.7(a2.12(a)(xi) Proceeding Paying Agent Agreement Section 4.17 Royalties 1.4(b)(xv) Payoff Letter Section 2.10(h1.4(b)(vi) Permitted Transferee Section 4.4(b) Personal Data Section 2.12(a)(xiii) Personnel Agreements Section 2.12(f)(i) PNO Section 2.6(b) Post-Closing Deficit Amount Section 1.15(d) Post-Closing Excess Amount Section 1.15(e) Post-Closing Statement Section 1.15(b) Privacy Requirements Section 2.12(a)(xiv) Prohibited Party Lists Section 2.23 PTO Section 2.12(b) Recovered Fraud Amounts Section 7.3(b) Registered IP Section 2.12(a)(xv) Reorg Threshold Section 4.2(f) Representative Losses Section 7.6(b) Resolved Matters Section 1.15(b) Restricted Shares Section 2.2(a) Retained Escrow Amount Section 7.4(f) Retention Pool Section 4.6 Second Certificate of Merger Section 1.2(b) Second Milestone Effective Time Section 2.10(f1.2(b) Second Milestone Payment Amount Merger Recitals Secretary Certificate Section 2.10(f1.4(b)(v) Section 280G Payments Section 5.6(b) Securityholder Representative Preamble Shrink-Wrap Software Section 2.12(a)(xvi) Standard Form Agreements Section 2.12(d)(iii) Stock Portion Section 4.2(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Notice Section 2.12(b4.1(b) Surviving Corporation Section 2.1 1.1(a) Surviving Entity Section 1.1(b) Systems Section 2.12(p) Tax Attribute Section 7.2(c) Technology Section 2.12(a)(xvii) Terminated Agreements Section 5.12 Third Milestone Party Claim Section 2.10(g7.5 Third Party Notice Section 7.5 Top Customers Section 2.25(a) Third Milestone Payment Amount Top Resellers Section 2.10(g2.25(a) Top Suppliers Section 2.25(a) Total Stockholder Consideration Section 4.2(f) Trade Laws ▇▇▇▇▇▇▇ ▇.▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇ Real Property Holding Corporation Section 2.9(a)(viii) Unresolved Matters Section 1.15(b) Warrant Cancellation Agreement Section 1.4(b)(xii)

Terms Defined Elsewhere. The Each of the following is a list of additional terms used in this Agreement and a reference has the meaning ascribed to the Section hereof in which such term is definedin the Article or Section set forth opposite such term: Accounts Receivable Section 3.23(a) Additional Parent Filing Section 6.7(f) Aggregate Consideration Section 6.6(f) Agreement Preamble Biogen Idec License Altenative Acquisition Section 6.1(g) Alternative Financing Section 6.17(d) Antitrust Laws Section 6.2(c) Applicable Limitation Date Section 6.4(c) A&R LLC Agreement Section 4.7 Biogen Idec Supply 2.6(b) Bid Section 3.19(a) Binder Agreement Section 4.7 Books and Records 6.3(a) Buyer Preamble Buyer Arrangements Section 2.12(f)(26.21 CapEx Reimbursement Section 6.6(f) Claim Notice Change in Recommendation Section 8.3(a6.7(f) Class A Common Stock Section 5.4 Closing Section 2.3 2.5 Closing Date Section 2.3 2.5 Closing Form 8-K Section 6.7(g) Closing Item Section 2.4(a) Closing Press Release Section 6.7(g) Closing Statement Section 2.4(a) Committed Financing Section 5.15 Communication Policy Section 6.1(i) Company Preamble Company Common Stock Employee Benefit Plan Section 2.8 3.14(a) Company Disclosure Schedule Article IV Government Contract Section 3.19(a) Company Government Subcontract Section 3.19(a) Continuing Employees Section 6.14 Control Section 1.1 Customer Assets Section 3.22 D&O Provisions Section 6.11(a) Data Room Section 8.5 Debt Commitment Letters Section 5.15 Definitive Debt Agreement Section 6.17(b) Dispute Notice Section 2.4(b) Environmental Permits Section 3.17 Estimated Cash Section 2.3(a) Estimated Closing Statement Section 2.3(a) Estimated Indebtedness Section 2.3(a) Estimated Transaction Expenses Section 2.3(a) Estimated Working Capital Section 2.3(a) Excess Amount Section 2.4(d) Fee Letter Section 5.15 Final Allocation Section 6.6(f) Final CapEx Schedule Section 2.13 Company 6.6(f) Final Cash Section 2.4(a) Final Indebtedness Section 2.4(a) Final Transaction Expenses Section 2.4(a) Final Working Capital Section 2.4(a) Financial Statements Section 3.4(a) Holdings Preamble Indemnified Parties Persons Section 8.2(a)(ii6.11(a) Contracts Indemnitee Section 4.8(a6.5(f) Covered Indemnitor Section 6.5(f) Intended Tax Treatment Section 6.6(f) Interim Financial Statement Section 3.4(a) Internal Controls Section 3.4(b) IRS Section 3.14(a) K&E Section 8.12 Latest Balance Sheet Section 3.4(a) LTIP Section 6.1(f) Material Contract Section 3.9(b) Material Customer Section 3.9(c) New Plans Section 6.14 Non-Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a6.16 Ordinary Course of Business Section 8.5 Outside Date Section 7.1(c) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Public Securities Section 5.9 Parent Prepared Returns Section 6.6(a) Parent SEC Documents Section 5.5(a) Parent Tax Contest Section 6.6(c) Party Preamble Permits Section 3.16(b) Post-Closing Representation Section 8.12 Pre-Closing Period Section 6.1(a) Proposed Allocation Section 6.6(f) Proposed CapEx Schedule Article V Parent Indemnified Section 6.6(f) Remedial Actions Section 6.2(c) Resolution Period Section 2.4(b) Registration Rights Agreement Section 2.6(b) Review Period Section 2.4(b) R&W Insurance Policy Section 6.3(a) Seller Preamble Seller Holdings Units Section 2.1 Seller Prepared Returns Section 6.6(a) Seller Tax Contest Section 6.6(c) Shortfall Amount Section 2.4(e) Signing Form 8-K Section 6.7(b) Signing Press Release Section 6.7(b) Tail Policy Section 6.11(b) Tax Contest Section 6.6(c) Third-Party Recovery Proceeds Section 6.5(d)(i) Trade Controls Section 3.24(a) Transfer Taxes Section 6.6(e) Trust Amount Section 5.4 Units Recitals Valuation Firm Section 2.4(b) Waiving Parties Section 8.2(a)(i) parties Preamble Payee 8.12 Warrants Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g5.2(b)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement, as indicated below: Action Section 4.13 Agreement and a reference to the Section hereof in which such term is defined: Agreement Preamble Biogen Idec License Introduction Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 6.4(b)(iii) Alternative Financing Section 4.7 Books and Records 6.6(b) Alternative Financing Commitment Section 2.12(f)(26.6(b) Claim Antitrust Laws Section 4.4(b) Capped Damages Section 8.2(a)(ii) Certificate of Merger Section 2.3 Certificates Section 3.2(b), Section 3.2(b) CFIUS Section 4.4(b) Change of Recommendation Notice Section 8.3(a6.4(e)(i) Closing Section 2.3 2.2 Closing Date Section 2.3 2.2 COBRA Section 4.10(i) Company Preamble Introduction Company Common Adverse Recommendation Change Section 6.4(d)(i) Company Financial Advisor Section 4.21 Company Financial Statements Section 4.6(b) Company Group Section 8.2(b)(v) Company Insurance Policies Section 4.17 Company Material Contract Section 4.12(a) Company Preferred Stock Section 2.8 4.2(a) Company Disclosure Schedule Article IV Recommendation Section 4.3(b) Company Expenses Schedule Representatives Section 2.13 6.3(a) Company Indemnified Parties SEC Filings Section 8.2(a)(ii4.6(a) Contracts Company Stock Rights Section 4.8(a4.2(c) Covered Party (PartiesCompany Stockholders Meeting Section 6.2(d) Company Subsidiary Section 8.2(a)(ii4.1(a) Damages Condemnation Actions Section 8.2(a)(i4.18(d) Cut-Off Date Section 6.4(b)(vi) D&O Insurance Section 6.12(b) Debt Commitment Letters Section 5.6(a) Debt Financing Section 5.6(a) DGCL Recitals Dissenting Shares Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 3.3 Effective Time Section 2.2 ERISA 2.3 End Date Section 4.13(a8.1(b)(i) ERISA Affiliate Enforcement Exceptions Section 4.13(a4.3(a) Finally Determined Equity Commitment Letter Section 8.5(b5.6(a) First Milestone Equity Financing Section 2.10(e5.6(a) First Milestone Payment Amount Exchange Fund Section 2.10(e3.2(a) Indemnifying Party Existing Debt Section 8.3(a4.2(h) Instrument Exon-▇▇▇▇▇▇ Section 2.12(c4.4(b) FCPA Section 4.27 Financing Section 5.6(a) Financing Commitments Section 5.6(a) Guarantee Recitals Guarantor Recitals Leased Real Property Section 4.18(a) Liability Section 4.7 Merger Recitals Merger Consideration Section 3.1(a) Merger Sub Introduction NDA Consent Section 2.1 Merger Certificate 6.5(e) New Plans Section 2.2 Merger Sub Preamble 6.10(c) NRC Consents Section 4.4(b) Option Cash Payment Section 3.5(b) Original Date Section 6.2(e) Owned Real Property Section 4.18(a) Parent Preamble Introduction Parent Disclosure Schedule Article V Group Section 8.2(c)(iii) Parent Indemnified Representatives Section 6.3(a) Parties Introduction Party Introduction Paying Agent Section 8.2(a)(i3.2(a) parties Preamble Payee Performance-Based Company Phantom Share Award Section 8.5 Payor 3.5(d) Present Fair Salable Value Section 8.5 Per Diem Taxes 5.11 Proxy Statement Section 8.7(a4.20 Real Property Section 4.18(a) Proceeding Real Property Leases Section 4.17 Royalties 4.18(a) Required Financial Information Section 2.10(h6.7(a) Second Milestone Restricted Stock Payment Section 2.10(f3.5(c) Second Milestone Payment Amount Solicitation Period End Date Section 2.10(f6.4(a) Solvent Section 5.11 Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Approval Section 2.12(b) 4.23 Surviving Corporation Section 2.1 Third Milestone Takeover Statute Section 2.10(g) Third Milestone Payment Amount 4.19 Transaction Litigation Section 2.10(g)6.8

Terms Defined Elsewhere. The Solely for convenience, the following is a list of additional terms used that are defined in the section of this Agreement and a reference to the Section hereof in which set forth after each such term is definedbelow: Accounting Firm Section 3.2 Accounts Receivable Section 2.1(j) Agreement Preamble Biogen Idec License Agreement Allocation Schedule Section 4.7 Biogen Idec Supply Agreement 3.2 Alternate Debt Financing Section 4.7 7.18(c) Alternative Financing Commitment Section 7.18(c) Assumed Liabilities Section 2.3 Balance Sheet Date Section 5.6 ▇▇▇▇ of Sale Section 4.2(a) Books and Records Section 2.12(f)(22.1(e) Business Related Software Section 5.14(b) Cash Purchase Price Section 3.1 Claim Notice Section 8.3(a10.4(a) Closing Section 2.3 4.1 Closing Date Section 2.3 4.1 Code Section 3.2 Company Cash Section 2.1(q) Comprint Preamble Company Common Stock Confidentiality Agreement Section 2.8 Company 7.4 Consents Section 5.5 Contract Section 2.1(g) Controversy Section 11.10 Disclosure Schedule Letter Article IV Company Expenses Schedule V Domain Name Assignment Section 2.13 Company Indemnified Parties Section 8.2(a)(ii4.2(c) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Exchange Act Article V Excluded Assets Section 2.2 ERISA Financial Statements Section 4.13(a5.6 Financing Section 6.4 Financing Commitment Section 6.4 Flex Plan Section 7.16(f) ERISA Affiliate Form 8594 Section 4.13(a3.2 Grant Deed Section 4.2(b) Finally Determined Guarantor Preamble ▇▇▇▇▇-▇▇▇▇▇ ▇▇▇▇ and Logo Section 8.5(b2.2(f) First Milestone HH Shoppers Preamble Indemnified Party Section 2.10(e) First Milestone Payment Amount Section 2.10(e10.4(a) Indemnifying Party Section 8.3(a10.4(a) Instrument of Assignment and ▇▇▇▇ of Sale Section 2.12(c4.2(a) Merger Inventory Section 2.1 Merger Certificate 2.1(i) Lease Assignment Section 2.2 Merger Sub Preamble 4.2(e) Leased Real Property Section 2.1(a)(ii) Licensed Software Section 5.14(b) Licenses and Permits Section 2.1(h) Machinery Section 2.1(c) Material Agreement Section 5.9(a) Natural Hazard Areas Section 11.20 Notice Section 11.10 Notice Period Section 10.4(c) Owned Real Property Section 2.1(a)(i) Parent Preamble Parent Disclosure Schedule Article V Benefit Plans Section 5.12 Parent Deductible Section 10.2(b)(i) Parent Indemnified Parties Section 8.2(a)(i10.3(a) parties Personal Property Leases Section 2.1(b) Party Preamble Payee Proprietary Software Section 8.5 Payor 5.14(b) Purchase Price Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation 3.1 Purchased Assets Section 2.1 Third Milestone Purchasers Preamble Purchasers Deductible Section 2.10(g10.3(b)(i) Third Milestone Payment Amount Purchasers Indemnified Parties Section 2.10(g10.2(a) Purchasers Plan Section 7.16(c) Purchasers Savings Plan Section 7.16(d) RE Purchaser Preamble Response Section 11.10 Retained Liabilities Section 2.4 Reverse Termination Fee Section 9.2 SEC Article V Sellers Preamble Software Section 5.14(b) Tax Refunds Section 2.2(b) Trademark Assignment Section 4.2(c) Transfer Tax Returns Section 7.8(a) Transferred Employees Section 7.16(a) Transferred Intellectual Property Section 2.1(d) Transition Services Agreement Section 4.2(d)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement, as indicated below: 2005 Balance Sheet Section 3.5(c) Acquisition Agreement and a reference to the Section hereof in which such term is defined: 5.5(b) Agreement Preamble Biogen Idec License Agreement Buyer Preamble Certificate of Merger Section 4.7 Biogen Idec Supply Agreement 1.2 Certificates Section 4.7 Books and Records Section 2.12(f)(22.2(b) Claim Notice Section 8.3(a) Closing Section 2.3 Closing Date Section 2.3 1.2 Common Stock Consideration Section 2.1(c) Communications Licenses Section 3.12(c) Company Preamble Company Common Stock Adverse Recommendation Change Section 2.8 5.5(b) Company Board Section 3.2(b) Company Expense Reimbursement Amount Section 7.3(b) Company Registered Copyrights Section 3.13(a) Company Registered IP Section 3.13(a) Company Registered Marks Section 3.13(a) Company Registered Patents Section 3.13(a) Company SEC Reports Section 3.5(a) Company Stockholders’ Meeting Section 5.4 Copyrights Section 9.1(r) Covered Persons Section 5.8(a) D&O Insurance Section 5.6(b) Department of Labor Section 5.14(d) Disclosure Schedule Letter Article IV Company Expenses Schedule 3 Dissenting Shares Section 2.13 Company 2.4(a) Effective Time Section 1.2 Exchange Act Section 3.5(a) FCC Consents Section 5.6(a) HSR Act Section 3.4(b) Inbound License Agreements Section 3.13(d) Indemnified Parties Section 8.2(a)(ii5.8(a) Contracts June 30 Balance Sheet Section 4.8(a3.5(c) Covered Party (PartiesMarks Section 9.1(r) Material Contract Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c3.9(a) Merger Section 2.1 Merger Certificate Section 2.2 Introduction Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Misrepresentation Notice Section 8.2(a)(i6.2(a)(i) parties Preamble Payee Municipal Franchising Authority Consents Section 8.5 Payor 5.6(a) NQDC Plan Section 8.5 Per Diem Taxes 3.15(j) Outbound License Agreements Section 8.7(a3.13(d) Proceeding Patents Section 4.17 Royalties 9.1(r) Permits Section 2.10(h3.12(b) Second Milestone Preferred Stock Section 2.10(f3.3(a) Second Milestone Payment Amount Proxy Statement Section 2.10(f5.3(a) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Representatives Section 2.12(b5.5(a) Required Company Stockholders Section 3.2(c) Sarbanes-Oxley Act Section 3.5(d) Series A Preferred ▇▇▇▇▇ ▇▇▇▇▇on 3.3(c) Software Section 9.1(r) State PUC Consents Section 5.6(a) Surviving Corporation Section 2.1 Third Milestone 1.1 Termination Date Section 2.10(g7.1(b)(ii) Third Milestone Payment Amount Termination Fee Section 2.10(g7.3(a)(ii) Trade Secrets Section 9.1(r)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: Action Section hereof in which such term is defined: 4.12 Agreement Preamble Biogen Idec License Agreement Anti-Corruption Laws Section 4.7 Biogen Idec Supply Agreement 4.5(b) Bankruptcy and Equity Exception Section 4.7 Books and Records 4.3(a) Cayman Companies Act Preamble Certificates Section 2.12(f)(2) Claim Notice Section 8.3(a3.2(c)(i) Closing Section 2.3 2.2 Closing Date Section 2.3 2.2 Company Preamble Company Common Stock Adverse Recommendation Change Section 2.8 6.4(c)(i) Company Disclosure Schedule Article IV Board Preamble Company Expenses Schedule Financial Advisor Section 2.13 4.3(b) Company Financial Statements Section 4.6(b) Company Group Section 8.2(e)(i) Company Material Contract Section 4.11(b) Company Plan(s) Section 4.9(a) Company Recommendation Section 4.3(b) Company Representatives Section 6.3(a) Company SEC Filings Section 4.6(a) Company Shareholders Meeting Section 6.2(e)(i) Company Subsidiary Section 4.1 Company Workers Section 4.14(d) Dissenter Rights Section 3.1(e) Dissenting Shareholders Section 3.1(e) Dissenting Shares Section 3.1(e) Effective Time Section 2.3 End Date Section 8.1(b)(i) Equity Financing Section 5.6(a) Equity Commitment Letter Section 5.6(a) Exchange Fund Section 3.2(b) Guarantor Preamble HKIAC Section 9.7(b) Indemnified Parties Section 8.2(a)(ii6.12(a) Contracts Investments Section 4.8(a4.2(d) Covered Party (PartiesLeased Real Property Section 4.17(b) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Limited Guarantee Preamble Merger Section 2.1 Merger Certificate Section 2.2 Preamble Merger Sub Preamble Notice Period Section 6.4(d)(i) Owned Real Property Section 4.17(a) Parent Preamble Parent Disclosure Group Section 8.2(e)(i) Parent Representatives Section 6.3(a) Party Preamble Paying Agent Section 3.2(a) Per ADS Merger Consideration Section 3.1(b) Per Share Merger Consideration Section 3.1(b) Plan of Merger Section 2.3 PRC VIEs Section 4.21(b) Proxy Statement Section 6.2(a) Registrar of Companies Section 2.3 Rollover Securities Preamble Rollover SecurityHolder Preamble SAFE Rules and Regulations Section 4.5(c) Schedule Article V Parent Indemnified Parties 13E-3 Section 8.2(a)(i4.4(b) parties Services Provider Section 4.14(e) Special Committee Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Support Agreement Preamble Super Majority Section 2.12(b) Surviving Corporation Company Section 2.1 Third Milestone Transaction Litigation Section 2.10(g6.8 Uncertificated Shares Section 3.2(c)(i) Third Milestone Payment Amount VIE Contracts Section 2.10(g4.21(b)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Section hereof in which such term is definedAgreement, as indicated below: Adverse Recommendation Change Section6.02(c) Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement Section 4.7 Books and Records Section 2.12(f)(2Section6.02(c) Claim Notice Section 8.3(aArbitrator Section10.08(b) Assumed Option Section3.03(b) Base Premium Section7.05(d) Benefit Plan Section4.15(b) BlueCity Holdings Limited Section2.06 Closing Section 2.3 Section2.02 Closing Date Section 2.3 Section2.02 Company Preamble Company Common Stock Section 2.8 Board Recitals Company Disclosure Schedule Article IV Board Recommendation Recitals Company Expenses Schedule Section 2.13 Equity Interests Section4.02(b) Company Indemnified Parties Section 8.2(a)(iiGroup Section9.02(h) Contracts Section 4.8(aCompany Termination Fee Section9.02(e) Competing Proposal Section6.02(g) Covered Party (PartiesPersons Section7.05(a) Section 8.2(a)(iiDeposit Agreement Section3.05 Depositary Section3.05 Dissenting Shareholders Section3.06(a) Damages Section 8.2(a)(iDissenting Shares Section3.06(a) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(aSection2.03 Enforceability Exceptions Section4.03 Equity Commitment Letter Section5.05(a) ERISA Affiliate Section 4.13(aEquity Financing Section5.05(a) Finally Determined Section 8.5(bExchange Ratio Section3.03(b) First Milestone Section 2.10(eFinancial Statements Section4.06(b) First Milestone Payment Amount Section 2.10(eHKIAC Section10.08(b) Indemnifying Party Section 8.3(aHKIAC Rules Section10.08(b) Instrument Section 2.12(cIndemnification Agreements Section7.05(a) Insurance Policies Section4.18 Intervening Event Section6.02(e) Legal Proceeding Section5.08 Limited Guarantee Recitals Material Contracts Section4.16(a)(xiv) Merger Section 2.1 Recitals Merger Certificate Section 2.2 Consideration Section3.02(a) Merger Consideration Fund Section3.02(a) Merger Sub Preamble Nasdaq Section4.02(c) Non-Required Remedy Section7.02(d) Operating Subsidiary Section4.16(a)(xi) Parent Preamble Parent Disclosure Group Section9.02(h) Parent Termination Fee Section9.02(f) Parties Preamble Party Preamble Paying Agent Section3.02(a) Per ADS Merger Consideration Section3.01(b) Per Share Merger Consideration Section3.01(a) Plan of Merger Section2.03 PRC Subsidiaries Section4.09(a) Proxy Statement Section4.05 Record ADS Holders Section6.04(a) Record Date Section6.04(a) Registrar of Companies Section2.03 Rollover Shareholders Recitals ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section4.06(a) Schedule Article V Parent Indemnified Parties Section 8.2(a)(i13E-3 Section6.03(a) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(aSEC Documents Section4.06(a) Proceeding Section 4.17 Royalties Section 2.10(hSecurities Act Section4.06(a) Second Milestone Section 2.10(fShare Certificates Section3.02(b)(i) Second Milestone Payment Amount Section 2.10(fSocial Insurance Section4.15(k) Stockholder Consent Special Committee Recitals Stockholder Representative Preamble Super Majority Section 2.12(bSuperior Proposal Section6.02(h) Support Agreement Recitals Surviving Corporation Section 2.1 Third Milestone Section 2.10(gCompany Section2.01 Takeover Statute Section4.23 Tax Returns Section4.13(a) Third Milestone Payment Amount Section 2.10(gTransaction Litigation Section7.08 Transactions Recitals U.S. GAAP Section4.06(b) Uncertificated Shares Section3.02(b)(i) VIE Contracts Section4.09(c)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: Acceptance Time Section hereof in which such term is defined: 2.4(a) Action Section 5.14 Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 7.5(c)(ii) Articles of Merger Section 4.7 Books and Records 3.3 Bankruptcy Exception Section 2.12(f)(25.12(b) Claim Notice Board Appointment Date Section 8.3(a2.4(a) Certificates Section 4.2(b) Closing Section 2.3 3.2 Closing Date Section 2.3 3.2 COI Section 5.13(a)(vi) Company Preamble Company Adverse Recommendation Change Section 7.5(c)(i) Company Board Recommendation Section 2.3(a)(iv) Company Common Stock Recitals Company Disclosing Party Section 2.8 1.1(cc) Company Disclosure Schedule Article IV Documents Section 7.20(a) Company Expenses Schedule Financial Advisor Section 2.13 5.3(c) Company Indemnified Parties Financial Statements Section 8.2(a)(ii5.6(b) Contracts Company Intellectual Property Section 4.8(a5.16(b) Covered Party (PartiesCompany Material Contract Section 5.12(a) Company Plan(s) Section 8.2(a)(ii5.10(a) Damages Company Preferred Stock Section 8.2(a)(i5.2(a) DGCL Company Representatives Section 2.1 Document Retention Period 7.4(a) Company SEC Filings Section 2.12(f)(25.6(a) Drug Regulatory Agency Company Stockholder Approval Section 4.25 5.3(b) Company Stockholders’ Meeting Section 7.2(a) Company Subsidiary Section 5.1 Compensation Committee Section 5.25 Continuing Directors Section 2.4(a) Effective Time Section 2.2 3.3 Employment Compensation Arrangement Section 5.25 End Date Section 9.1(b) ERISA Section 4.13(a5.10(a) ERISA Affiliate Section 4.13(a5.10(a) Finally Determined Exchange Fund Section 8.5(b4.2(a) First Milestone Indemnified Parties Section 2.10(e7.12(a) First Milestone Payment Amount Independent Directors Section 2.10(e2.4(b) Indemnifying Party Investments Section 8.3(a5.2(d) Instrument IRS Section 2.12(c5.10(b) JV Partner Section 1.1(o) Merger Recitals Merger Consideration Section 2.1 Merger Certificate Section 2.2 4.1(a) Merger Sub Preamble Minimum Condition Section 2.1(b) Notice Period Section 7.5(d)(iii) Offer Recitals Offer Documents Section 2.1(g) Offer Price Recitals Parent Preamble Parent Disclosure Expenses Section 9.4(c) Parent Plans Section 7.18(a) Parent Representatives Section 7.4(a) Party Preamble Paying Agent Section 4.2(a) Proxy Statement Section 7.2(b) Purchaser Welfare Benefit Plans Section 7.18(c) Reimbursable Expenses Section 9.4(c) SCC Section 3.3 Schedule Article V Parent Indemnified Parties TO Section 8.2(a)(i2.1(g) parties Preamble Payee Schedule 14D-9 Section 8.5 Payor 2.3(b) Software Section 8.5 Per Diem Taxes Section 8.7(a1.1(kk) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Support Agreement Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone 3.1 Tail Period Section 2.10(g7.12(c) Third Milestone Payment Amount Takeover Provisions Section 2.10(g2.3(a)(iii) Top-Up Option Section 2.2(a) Top-Up Option Shares Section 2.2(d) VSCA Section 2.2(a)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: Action Section hereof in which such term is defined: 4.15 Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 6.4(a)(ii)(E) Bankruptcy and Equity Exception Section 4.7 Books and Records 4.3(a) Capitalization Date Section 2.12(f)(24.2(a) Claim Notice Cash Equity. Section 8.3(a5.6(b) Certificate of Merger Section 2.3 Certificates Section 3.2(b) Closing Section 2.3 2.2 Closing Date Date. Section 2.3 2.2 Company Preamble Company Common Adverse Recommendation Change Section 6.4(c)(v) Company Board Recommendation Recitals Company Financial Advisor Section 4.3(b) Company Financial Statements Section 4.7(b) Company Material Contract. Section 4.14(a) Company Plans Section 4.10(a) Company Preferred Stock Section 2.8 4.2(a) Company Disclosure Schedule Article IV Recommendation Section 4.3(b) Company Expenses Schedule Registered Intellectual Property Section 2.13 4.17(a) Company Representatives Section 6.3 Company SEC Filings Section 4.7(a) Company Stockholders Recitals Company Stockholders Meeting Section 6.2(d)(i) Company Subsidiary Section 4.1 Continuing Employee Section 6.10(a) Current Premium Amount Section 6.12(b) Debt Financing Commitments. Section 5.6(a) Debt Financing Sources Section 9.9 Debt Financing. Section 5.6(a) Determination Notice Section 6.4(d)(i)(D) DGCL Recitals Dissenting Shares Section 3.1(a) Dissenting Stockholders Section 3.1(a) Effective Time Section 2.3 End Date Section 8.1(b)(i) Equity Financing Commitments Section 5.6(b) ERISA Section 4.10(a) Exchange Fund Section 3.2(a) FCPA Section 4.5(d) FDA Section 1.1(ee) Fee Letters. Section 5.6(a) Financing Commitments Section 5.6(b) Governmental Plan Section 4.10(a) Health Care Permits Section 4.6(c) HIPAA Section 1.1(dd) Improvements Section 4.20(d) Incremental Debt Financing Cooperation Section 2.3 Indemnified Parties Section 8.2(a)(ii6.12(a) Contracts Intervening Event Change of Recommendation Section 4.8(a6.4(d)(ii) Covered Party (PartiesInvestments Section 4.2(d) IRS Section 8.2(a)(ii4.10(b) Damages Lenders Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c5.6(a) Merger Recitals Merger Consideration Section 2.1 Merger Certificate Section 2.2 3.1(a) Merger Sub Preamble Notice Period Section 6.4(d)(i)(D) Parent Preamble Parent Disclosure Schedule Article V Expenses Section 8.2(b)(iv) Parent Indemnified Parties Representatives Section 8.2(a)(i6.3 Parties. Preamble Party Preamble Paying Agent Section 3.2(a) parties Preamble Payee Proxy Statement Section 8.5 Payor 6.2(a) Purchaser Plans Section 8.5 Per Diem Taxes 6.10(c) Record Date Section 8.7(a6.2(d)(ii) Proceeding Replacement Financing Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment 2.3 Required Amount Section 2.10(f5.6(d) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Approval Section 2.12(b4.3(a) Surviving Corporation Section 2.1 Third Milestone Tail Period Section 2.10(g6.12(a) Third Milestone Payment Amount Takeover Provision Section 2.10(g)4.22(a) Top Customers Section 4.12 Top Suppliers Section 4.12 Transaction Litigation Section 6.7

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement, as indicated below: Action Section 4.12 Acceptable Confidentiality Agreement and a reference to the Section hereof in which such term is defined: 6.4(b) Alternative Acquisition Agreement Section 6.4(c)(2) Alternative Financing Section 6.6 Agreement Preamble Biogen Idec License Agreement Anti-Corruption Laws Section 4.7 Biogen Idec Supply Agreement 4.5(b) Bankruptcy and Equity Exception Section 4.7 Books and Records 4.3(a) Cashed-Out Option Section 2.12(f)(23.1(f)(ii) Claim Notice Cayman Companies Law Preamble Certificates Section 8.3(a3.2(c) Closing Section 2.3 2.2 Closing Date Section 2.3 2.2 Company Preamble Company Common Stock Adverse Recommendation Change Section 2.8 6.4(b)(i) Company Disclosure Schedule Article IV Board Preamble Company Expenses Schedule Financial Advisor Section 2.13 4.3(b) Company Financial Statements Section 4.6(b) Company Group Section 8.2(e)(i) Company Intellectual Property Section 4.14(b) Company Material Contract Section 4.11(b) Company Plan(s) Section 4.9(a) Company Recommendation Section 4.3(b) Company SEC Filings Section 4.6(a) Company Shareholders Meeting Section 6.2(e)(i) Company Subsidiary Section 4.1 Company Workers Section 4.14(f) D&O Insurance Section 6.12(b) Dissenter Rights Section 3.1(e) Dissenting Shares Section 3.1(e) Dissenting Shareholders Section 3.1(e) Effective Time Section 2.3 Equity Commitment Letters Section 5.6 Equity Financing Section 5.6 Equity Financing Commitments Section 5.6 End Date Section 8.1(b)(i) Exchange Fund Financing Financing Commitments Section 3.2(b) Section 5.6(a) Section 5.6(a) Guarantor Preamble HKIAC Section 9.7(c) Indemnified Parties Section 8.2(a)(ii6.12(a) Contracts Independent Committee Preamble Investments Section 4.8(a4.2(d) Covered Party (PartiesLeased Real Property Section 4.17(b) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Limited Guarantee Preamble Merger Section 2.1 Merger Certificate Section 2.2 Preamble Merger Sub Preamble Notice Period Section 6.4(d)(iii) Owned Real Property Section 4.17(a) Parent Preamble Parent Disclosure Group Parent Material Adverse Effect Section 8.2(e)(i) Section 5.4(a) Party Preamble Paying Agent Section 3.2(a) Per ADS Merger Consideration Section 3.1(b) Per Share Merger Consideration Section 3.1(b) Plan of Merger Section 2.3 Proxy Statement Section 6.2(a) Registrar of Companies Section 2.3 Rollover Securities Preamble SAFE Rules and Regulations Section 4.5(c) Schedule Article V Parent Indemnified Parties 13E-3 Section 8.2(a)(i4.4(b) parties Services Provider Section 4.14(g) Support Agreement Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Company Transactions Section 2.1 Third Milestone Preamble Transaction Litigation Section 2.10(g) Third Milestone Payment Amount 6.8 Uncertificated Shares Section 2.10(g3.2(c)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Section hereof in which such term is definedAgreement, as indicated below: Agreement Preamble Biogen Idec License Agreement of Merger Section 4.7 Biogen Idec Supply Agreement 1.2 Audited Financial Statements Section 4.7 Books and Records 3.7(a) Cashed-Out Shares Section 2.12(f)(28.5(a) Certificates Section 2.3(a) CGCL Recitals Claim Notice Section 8.3(a8.4(a) Closing Section 2.3 1.2 Closing Date Section 2.3 1.2 Company Preamble Company Benefit Plan Section 3.9(a) Company Common Stock Section 2.8 2.1(a) Company Customers Section 3.21 Company Disclosure Schedule Article IV III Company Expenses Schedule Financial Statements Section 2.13 3.7(a) Company Material Contracts Section 3.11(a) Company Material Intellectual Property Section 3.15 Company Permits Section 3.6 Company Subsidiary Section 5.14 Confidentiality Agreement Section 5.5 Consents Section 3.5(c) DNS Korea Financial Statements Section 3.7(a) Effective Time Section 1.2 Escrowed Shares Section 2.2 FCPA Section 3.6(d) Financial Statements Section 3.7(a) Indemnified Parties Section 8.2(a)(ii) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e8.3(c) Indemnifying Party Section 8.3(a8.4(a) Instrument Losses Section 2.12(c8.2 Merger Recitals Merger Consideration Section 2.1(a) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Multiemployer Plan Section 3.9(c) Outside Date Section 7.1(b) Parent Preamble Parent Balance Sheet Section 4.8(c) Parent Benefit Plan Section 4.10(a) Parent Board Section 1.7 Parent Customers Section 4.19 Parent Disclosure Schedule Article V IV Parent Financial Advisor Section 4.23 Parent Indemnified Parties Section 8.2(a)(i8.2(a) parties Parent Material Contract Section 4.12 Parent Material Intellectual Property Section 4.16 Parent Options Section 4.3(a) Parent Permits Section 4.7(a) Parent Preferred Stock Section 4.3(a) Parent SEC Filings Section 4.8(a) Parent Recommendation Section 5.6(d) Parent Stockholder Approval Section 4.5 Parent Stockholders’ Meeting Section 5.6(c) Parties Preamble Payee Pending Claim Section 8.5 Payor 8.5(b) Proxy Statement Section 8.5 Per Diem Taxes 5.6(a) Remedies Exception Section 8.7(a3.4(a) Proceeding Restructuring Plan Section 4.17 Royalties 5.13 ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 2.10(h4.8(d) Second Milestone Special Committee Section 2.10(f) Second Milestone Payment Amount Section 2.10(f8.8(a) Stockholder Consent Recitals Preamble Stockholder Representative Preamble Super Majority Indemnified Parties Section 2.12(b8.2(b) Surviving Corporation Section 2.1 Third Milestone 1.1 Tax Matter Section 2.10(g5.11(d) Termination Fee Section 7.2(d) Third Milestone Payment Amount Party Claim Section 2.10(g8.4(a) Transfer Taxes Section 5.11(f)

Terms Defined Elsewhere. The following is a list of additional terms used in this Agreement and a reference to the Section hereof in which such term is defined: Agreement Acquisition Proposal Section 7.7(a) ARRA Section 4.11(g) Audited Financial Statements Section 6.13 Auditor’s Consent Section 6.13 Bankruptcy and Equity Exception Section 4.2(a) Buyer Preamble Biogen Idec License Agreement Business Software Section 4.7 Biogen Idec Supply Agreement 4.13(i) Buyer Indemnitees Section 4.7 Books and Records 12.2(a) Cap Section 2.12(f)(212.3(c)(i) Calculation Notice Section 3.2(b) Change In Control Customer Contracts Section 4.14(d) Closing Section 9.1 Closing Date Section 9.1 Closing Date Interest Rate Section 3.2(d) CMS Preamble CMS Group Charter Documents Section 4.1(b) CMS Group Release Section 7.8 COBRA Section 4.11(g) Coventry Preamble Cure Period Section 11.1(b) Deductible Section 12.3(a) Disputed Items Section 3.2(b) D&O Obligations Section 6.12 D&O Released Parties Section 12.6 Excluded Assets Section 2.2(a) FHC Recitals FHC Stock Recitals FHS Recitals FHS Closing Date Balance Sheet Section 3.2(a) FHS Closing Date Payment Section 2.4(a) FHS Estimated Working Capital Section 3.1(a) FHS Financial Statements Section 4.5(a) FHS Initial Calculation Section 3.2(a) FHS Interim Financial Statements Section 4.5(a) FHS Material Permits Section 4.17 FHS Negative Estimated Working Capital Adjustment Section 3.1(a) FHS Positive Estimated Working Capital Adjustment Section 3.1(a) FHS Restricted Business Section 7.3(a) FHS Stock Recitals FHS Working Capital Adjustment Amount Section 3.2(d) FHS Year End Financial Statements Section 4.5(a) Final FHS Working Capital Section 3.2(d) FIRPTA Affidavit Section 9.2(l) First Health Group Preamble Foreign Plans Section 4.11(h) Fundamental Representations Section 12.1(a) Governmental Damages Section 10.2(e) Governmental Investigation Section 10.2(e) HIPAA Section 4.11(g) Hired Employees Section 7.2(b)(i) HSR Filing Section 6.5(b) Indemnifiable Losses Section 12.2(b) Indemnification Notice Section 12.5(a) Indemnified Party Section 12.2(c) Infringes Section 4.13(b) Injunctions Section 10.1(b) Labor Union Section 4.12(a) Legal Actions Section 10.1(c) Loss of Profits Section 12.3(f) Material Contract Section 4.14(b) Party or Parties Preamble Policies Section 4.15 Property Taxes Section 8.2(b)(i) Provider Synergies Recitals Provider Synergies Interests Recitals Purchase Price Section 2.4(a) Re-Calculated FHS Working Capital Section 3.2(e) Re-Calculated FHS Working Capital Adjustment Amount Section 3.2(e) Registered IP Section 4.13(a) Related Persons Section 4.19 Releasing Parties Section 12.6 Restraints Section 10.1(c) Seller Indemnifiable Losses Section 12.2(b) Seller Indemnitees Section 12.2(b) Settlement Firm Section 3.2(c) Shares Recitals Tax Claim Notice Section 8.3(a) Closing Tax Return Notice Section 2.3 Closing 8.1(b)(i) Tax Settlement Firm Section 8.1(b)(i) Termination Date Section 2.3 Company Preamble Company Common Stock 11.1(e)(i) Third Party Claim Section 2.8 Company Disclosure Schedule Article IV Company Expenses Schedule Section 2.13 Company Indemnified Parties Section 8.2(a)(ii12.4(a) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Transfer Taxes Section 8.7(a8.2(a) Proceeding Unsold Securities Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g)7.9

Terms Defined Elsewhere. The following is a list of additional terms used in this Agreement and a reference to the Section hereof in which such term is defined: Aggregate Outstanding Claims Section 2.9(b) Agreement Preamble Biogen Idec License Agreement Basket Amount Section 4.7 Biogen Idec Supply Agreement 8.5(a) Benefit Plan(s) Section 4.7 Books and Records 4.14(a) CERCLA Section 2.12(f)(2) 4.13 Claim Notice Section 8.3(a) Closing Section 2.3 Closing Amount Section 2.10(a) Closing Date Section 2.3 Company Preamble Company Common Stock Section 2.8 2.8(a) Company Preamble Company Disclosure Schedule Article IV Company Expenses Schedule Dissenting Shares Section 2.13 2.11 Company Indemnified Parties Partner Section 8.2(a)(ii) Contracts Section 4.8(a) 4.27 Covered Party (Parties) Section 8.2(a)(ii8.2(a) Damages Section 8.2(a)(i8.2(a) DGCL Section 2.1 Document Retention Period Dispute Notice Section 2.12(f)(22.13(h) Drug Regulatory Agency Section 4.25 4.27 Effective Time Section 2.2 Employee Loans Section 4.8(a) Environmental Laws Section 4.13 Equityholder Representative Preamble ERISA Section 4.13(a4.14(a) ERISA Affiliate Section 4.13(a4.14(a) Finally Determined Escrow Account Section 8.5(b2.9(a) Escrow Agent Section 2.9(a) Escrow Agreement Section 2.9(a) Escrow Amount Section 2.9(a) Escrow Earnings Section 2.9(c) First Milestone Section 2.10(e) First Milestone MAA Subsequent Payment Amount Section 2.10(e) Indemnifying Party First NDA Subsequent Payment Amount Section 8.3(a2.10(f) Hazardous Materials Section 4.13 HSR Act Section 4.17 Instrument Section 2.12(c2.13(c) IRS Section 4.14(d) Majority Section 2.13(b) Material Contracts Section 4.8(a) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Net Cash Section 4.10(b) Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Parent-Prepared Tax Return Section 8.2(a)(i6.2(a) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Preferred Stock Section 2.8(a) Proceeding Section 4.17 Royalties 4.18 Real Property Section 4.5(c) Required Company Stockholder Vote Section 4.3 Retained Escrow Amount Section 2.9(b) Rules Section 4.28 Second MAA Subsequent Payment Amount Section 2.10(g) Second NDA Subsequent Payment Amount Section 2.10(h) Second Milestone Series A Preferred Stock Section 2.10(f2.8(a) Second Milestone Payment Amount Section 2.10(fStockholder(s) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Tax Consent Section 2.10(g6.2(c) Third Milestone Payment Amount Transaction Fee Schedule Section 2.10(g)2.14

Terms Defined Elsewhere. The Each of the following terms is a list of additional terms used defined in this Agreement and a reference to the Section hereof in which set forth opposite such term is definedterm: Agreement Preamble Biogen Idec License Agreement Book-Entry Shares Section 4.7 Biogen Idec Supply Agreement Section 4.7 Books and Records Section 2.12(f)(22.2(a)(ii) Claim Notice Section 8.3(a) Closing Section 2.3 Closing Date Section 2.3 Company Buyer Preamble Company Common Stock Section 2.8 Company Buyer Disclosure Schedule Article IV Buyer Related Parties Section 8.2(e) Certificates Section 2.2(a)(ii) Closing Section 1.2 Closing Date Section 1.2 Company Expenses Schedule Preamble Company Alternative Acquisition Agreement Section 2.13 5.2(b)(iv) Company Balance Sheet Date Section 3.6 Company Capitalization Date Section 3.2(a) Company Change of Recommendation Section 5.2(d)(viii) Company Competing Proposal Section 8.2(b) Company Disclosure Documents Section 3.17(a) Company Governing Documents Section 3.1 Company Intellectual Property Section 3.16(a) Company Leased Real Property Section 3.17(a) Company Material Adverse Effect Section 7.2(a)(iv) Company Material Contracts Section 3.19(a) Company Permits Section 3.9(b) Company Permitted Lien Section 3.17(a) Company Related Parties Section 8.2(e) Company SEC Documents Section 3.4(a) Company Termination Fee Section 8.2(b) Continuing Employees Section 6.5(a) Controllers Section 7.1(f) Counsel Section 5.3(b)(xxi) Court Section 1.3 Court Documentation Section 5.3(b)(vii) Court Order Section 1.3 Debt Financing Section 6.10(a) Effective Time Section 1.3 Enforceability Exceptions Section 4.2(b) Forms of Proxy Section 5.3(b)(vii) Indemnification Agreements Section 6.4(a) Indemnified Parties Section 8.2(a)(ii6.4 International Employee Plan Section 3.11(i) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Irrevocable Undertakings Recitals Maximum Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c6.4(c) Merger Section 2.1 Merger Certificate 6.13(a) New Company Plans Section 2.2 Merger Sub 6.5(c) Offer Section 6.12(a) Offer Document Section 6.12(b) Owned Intellectual Property Section 3.16(a) Owned Software Section 3.16(c) Parties Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Paying Agent Section 8.2(a)(i2.2(a)(i) parties Preamble Payee Paying Agent Agreement Section 8.5 Payor 2.2(a)(i) Payment Section 8.5 Per Diem Taxes Section 8.7(a8.2(d) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Payoff Amount Section 2.10(f6.10(e) Stockholder Consent Payoff Letters Section 6.10(e) Per Share Consideration Section 1.1 Pre-Closing Period Section 5.1(a) Proceedings Section 3.14 Repaid Indebtedness Section 6.10(e) Scheme Document Section 5.3(b)(i) Scheme Supplemental Document Section 5.3(b)(vii) Transaction Recitals Stockholder Representative Preamble Super Majority Transaction Litigation Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g)6.7